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Abstract

Throughout the 1990s, the incidence of methicillin-resistant Staphylococcus
aureus has increased in many health care areas including acute and chronic
care facilities, outpatient clinics and in the community. Once introduced into a
health care environment, this nosocomial pathogen can spread rapidly and as
MRSA are resistant to multiple antibiotics, treatment is often difficult. Therefore
effective infection control measures are required to prevent cross-infection and
further spread of endemic strains.
In this study, a sensitive and specific triplex-PCR assay was designed for
MRSA detection, wherein three genes, the methicillin resistance gene (mecA).
femA and the extracellular thermonuclease gene (rmc) were simultaneously
amplified. The products of this triplex-PCR were analysed using a number of
detection formats (including conventional agarose gel electrophoresis, “dot blot”
analysis, colour amplified PCR detection system (CAPS) and fluorescent
GeneScan technology).
Such PCR detection assays do not investigate the complex epidemiology
of this pathogen. Rapid and accurate epidemiological typing methods are
required to identify the source and track the spread of different MRSA clinical
isolates. To this end, the genetic relationship(s) among two Cork University
Hospital (CUH) MRSA outbreaks was successfully analysed using rep-PCR with
a single RW3A primer, together with agarose gel electrophoresis and
fluorescent GeneScan analysis.
The fluorescent triplex-PCR and RW3A fingerprinting strategies were
multiplexed and this permitted the development of a combined detection and
typing scheme termed COGEDET for MRSA strains.
In addition, a number of conserved RW3A-generated amplicons were
characterised by cloning and sequencing to determine their genomic origins.
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Section 1
Introduction

1.1 Methicillin-resistant Staphylococcus aureus
Staphylococcus aureus has persisted as a devastating human pathogen since its
earliest description by Alexander Ogsten in the late 1880s. S. aureus is a
versatile human pathogen, with many virulence factor and an ability to survive a
wide range of environmental conditions. The organism can colonise quickly and
invade through breaks in the skin and mucous membranes. The organism can
protect itself against many of the host defences and therefore frequently reaches
the bloodstream causing severe infections (Sheagren

1984).

The emergence of strains with multiple antibiotic resistance, MRSA
(methicillin-resistant Staphylococcus aureus) has caused much concern in the
medical field. The ease of transmission of the organism has allowed MRSA to
become a common cause of nosocomial infection with limited therapeutic options
available. Today, much research is focused on the mechanism of resistance of
the organism, effective detection and typing strategies, control measures and the
development of alternative antimicrobial agents.

1.1.1: General Characteristics of Staphylococcus aureus
1.1.1.1: The genus staphylococci
Staphylococcus aureus is a member of the Micrococcaceae family. This family is
divided into two clinically important genera, the micorcocci and the staphylococci.
The staphylococci encompass approximately 31 different species, the majority of
which are common inhabitants of skin and mucous membranes of man, other
mammals and birds. Staphylococcus aureus is an especially virulent species and is
the commonest staphylococcal agent of disease.

Staphylococcus aureus are non-motile, non-spore forming, Gram-positive
cocci that generally appear as grape-like clusters under the microscope. S. aureus
grow as large round opaque colonies at an optimum temperature of 37°C (with a
reported temperature range of 10 to 46°C). The organism is a facultative anaerobe
that is easily cultivated on most routine laboratory media (Talero et al.. 1993).
S.aureus colonisation of an infant begins within hours of birth and continues
throughout life. The principal sites of S.aureus colonisation are the anterior nares
and in some individuals the perineum. Nasal carriage of S.aureus occurs in almost
all children and about 40% of adults but tends to be intermittent and transient (Morita,
1993).

1.1.1.2: Virulence factors
S. aureus, both sensitive and resistant to antibiotics produce an impressive range of
virulence factors that facilitate invasion of tissues, affecting it protection from host
defence mechanisms. These factors are divided into two categories:
i.

Enzymes

ii.

Exotoxins

i. Enzymes:
A wide variety of enzymes are produced by S. aureus, including coagulase which
promotes plasma and blood coagulation, this possibly serves a protective function,
eliciting clot formation around the organism thereby shielding the pathogen from the
hosts defence systems (Gould ^aj., 1995). Staphylococcus aureus alone produces
the enzyme coagulase, a factor that distinguishes that organism from the other

staphylococci (collectively referred to as the coagulase-negative staphylococci or
CNS).
Hyaluronidase or ‘spreading factor’ digests the ground substance (hyaluronic
acid) around the hosts cells hence facilitating invasiveness (Kaplan etM-, 1982).
Other enzymes include staphylokinase (which digests blood clots), DNase
and lipases. The precise functions of each of these enzymes in the pathogenesis of
disease is unclear.

ii. Exotoxins:
Most of the toxic proteins produced by S. aureus are specific for a particular tissue or
cell type. The toxins can be grouped as follows
- blood cell toxins
- intestinal toxins
- epithelial toxins
The blood cell toxins incorporate the haemolysins and staphylococcal leukocidin.
The a-, p-, 6 - and y- toxins are haemolysins which effect lysis of the red blood cells by
disrupting the cell’s membrane. The a-toxin is a potent extracellular protein that can
lyse the erythrocytes of various mammals and damages leukocytes, skeletal muscle,
heart and renal tissue. Leukocidin effects cell lysis of neutrophils and macrophages
by altering the permeability of the cell membrane to potassium. This action
constitutes another defence mechanism of pathogenic S. aureus.
Staphylococcal enterotoxins are well recognised agents of staphylococcal
food poisoning. They may also be responible for other types of infection in humans
and animals. Serologically five groups have been identified and designated SEA,

SEB, SEC, SED, and SEE. These enterotoxins are relatively heat resistant and may
survive in partially cooked foods.
Two types of exfoliative toxins (ETA and ETB) are recognised. These are
produced by only a few strains of S. aureus and cause splitting of the desmosome in
stratum granulosum of skin, which ultimately causes the skin to peel away. This
exfoliation is characteristic of staphylococcal scalded-skin syndrome, which most
frequently affects infants.
The most recently identified toxin is the toxic-shock-syndrome toxin I (TSST-1).
This toxin can elicit severe and sometimes fatal systemic symptoms including fever,
vomiting, rash, renal, liver and muscle damage (Talero ^ a}., 1993).
Currrently opinions vary, but is most likely that MRSA is no more virulent than
MSSA. MRSA represents a heterogeneous group of antibiotic resistant strains of S.
aureus. It is this multiple antibiotic resistance that makes this pathogen the serious
global problem it is today.

1.1.1.3: Clinical syndromes
Diseases caused by S. aureus can be localised or systemic depending upon the
degree of invasion or whether a toxin is produced by the particular strain. S.
aureus can colonise quickly and then invade through breaks in the skin or mucous
membrane rapidly causing a localised disease which can then lead to widespread
dissemination of the organism to body organs (Shreagren MM-,1984).
Localised cutaneous infections are caused when the organism invades
through wounds, hair follicles or breaks in the skin. These include folliculitis,
furuncles, carbuncles and impetigo. The symptoms of these vary from a mild

superficial hair follicle infection (folliculitis) to a less confined epidermal bubbling
that may break and peel away (impetigo).
Systemic staphylococcal infections usually begin as localised infections
that seed the blood and are transported to other sites. In osteomyelitis, the
pathogen can become established in the end arteries of long bone in children.
Abscess formation results in necrosis of bone tissue and symptoms of the disease
include fever, chills, pain and muscle spasm.
S. aureus is the most common cause of secondary pneumonia associated
with influenza. Another form of pneumonia, which most frequently effects infants
and children with cystic fibrosis and measles, occurs when S. aureus that colonise
the anterior nares are aspirated into the lungs and cause pneumonia that is
associated with multiple lung abscesses. Although rare, this pneumonia is
important as the fatality rate is about 50%.
Staphylococcal bacteremia is a severe infection whereby S. aureus
circulating in the bloodstream is transported to the kidney (causing perinephric
abscess), liver, spleen and muscles and can cause serious toxaemia. A fatal form
of endocarditis can result from infection of the heart lining leading to subsequent
cardiac abnormalities and destruction of heart valves. Endocarditis can lead to
the development of septic emboli which can spread to other sites.
Toxigenic staphylococcal diseases include the enterotoxin induced food
intoxications, the exfoliative scalded skin syndrome and toxic shock syndrome
(Talero ^aj., ; Shreagren

1984; Kaplan Maj., 1982).

1.1.2: Methicillin-resistant Staphylococcus aureus
1.1.2.1: Emergence of MRSA:

Staphylococcus aureus is one of the most versatile human pathogens known,
and has acquired resistance to virtually all available antibiotics.
Prior to the antibiotic era, S. aureus infections were responsible for
numerous deaths. In the early 1940s, the introduction of benzyl-penicillin
(penicillin G) dramatically changed this situation. However, resistant strains that
produced penillinase (|3-lactamase) emerged. The increased use of antibiotics in
the 1950s allowed S. aur^s strains to develop resistance to antimicrobial agents
such as erythromycin, streptomycin and the tetracyclines.
Semi-synthetic penicillins such as methicillin, oxacillin, naficillin,
dicloxacillin and floxacillin which were not inactivated by p-lactamases, became
available in the 1960s (Brumfitt ^^.,1989). In 1961, shortly after the introduction
of methicillin into clinical practice, the first methicillin-resistant strain of S. aureus
was reported in the United Kingdom. By the late 1960s, the incidence of MRSA in
Europe was on the increase. Naturally acquired resistance to p-lactamaseresistant penicillins by S. aureus was documented in countries where these
agents were not available (Poland, India and Turkey). Although MRSA infections
were described in the United States in the 1960s MRSA did not become a
significant problem there until the following decade.
In the 1970s, much attention was turned towards antibiotic resistance in
gram-negative micro-organisms with the introduction of aminogicosides. There
was a decrease in the incidence of MRSA possibly due to the introduction of
gentamicin and improvements in infection control programs. Therefore during the
1970s MRSA were less of a concern until the first reports of gentamicin-resistance

in MRSA (GMRSA) in Australia and Ireland in 1976 (Crossley

1979). The

1980s brought renewed interest in the organism with the re-emergence of MRSA
strains now resistant to some or many of the aminoglycosides. Resistance of
MRSA to the fluoroquinolone ciprofloxacin emerged rapidly in 90% of strains
following the introduction of this antibiotic in the late 1980s (Ayliffe et al.,1997).
Today, MRSA represents a heterogeneous group of staphylococci with
multiple antibiotic resistance. These organisms are a persistent cause of
nosocomial infection and are an established risk upon hospital admission (Gould
^ ai., 1995).

MRSA is no longer restricted to the larger teaching hospitals, with

reports of outbreaks in smaller hospitals, long-term care facilities and nursing
homes becoming increasingly common.

1.1.2.2: Prevalence of MRSA
A number of studies have attempted to estimate the prevalence of MRSA in
different settings (Voss^aj., 1994; Doebbeling

1995; Panililio M aj., 1992).

A European study to elucidate the frequency of MRSA in different countries
revealed a north-south gradient (see Figure 1.1 taken from Voss ^aj., 1994).
Less than 0.5% of S. aureus isolates in Scandinavian countries were resistant to
methicillin compared with 30% in France, Spain and Italy. The reason for such low
incidences of colonisation and infection in Scandinavian countries is unclear.
This may be a consequence of the restricted use of antibiotics and/or the rapid
detection and isolation of MRSA infected patients. In contrast, exceptionally high
prevalence has been observed in Japan (60%) and Brazil (56%).
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Figure 1.1: Bar chart representation of the proportion
of S.. aurcug strains exhibiting methicillin resistance
in the 10 countries that participated in the European
study performed by Voss ejai., 1994.

A one-day prevalence study, the European Prevalence of Infection in
Intensive Care (EPIC), performed in 1,472 ICUs in 17 countries, showed that
MRSA were significant pathogens. Approximately 45% of the patients sampled
had an infection, of which ^ aureus accounted for one-third and 60% of these
isolates were resistant to methicillin.
It has been reported that MRSA accounts for 30% of all bacteraemias in the
USA and that 44% of these infections are fatal. The frequency of MRSA in the
United States, between 1975 and 1991, was estimated in the National
Nosocomial Infection Surveillance Study (Panlilio et al.. 1992). Among 16,132 S.
isolates examined, the incidence of methicillin-resistance increased from
2.4% in 1975 to 29% in 1991. The greatest increases were seen in the largest
hospitals. In the smallest hospitals (< 200 beds) during 1991, 14.9% of a. aureus
isolates were MRSA. In the medium-sized hospitals (200-499 beds), 20.3% were

MRSA with 38.3% MRSA in the largest hospitals. (Doebbeling, 1995). Similar
results were described in Europe and elsewhere.
In the Republic of Ireland in 1995, a national survey was performed to
determine the extent of the MRSA problem before the introduction of national
guidelines on MRSA control (Johnson et^., 1997). Forty-five laboratories
participated in this study and within a two week period, the total number of patients
from whom MRSA was isolated was 448. The period prevalence rate of MRSA
infection and colonisation for the study duration was estimated at 15.9 / 100,000 of
the Irish population. Thus, MRSA is clearly a problem in Irish hospitals as a
substantial number of isolates were recorded during a short survey period.
Microbiology laboratories collaborating in the INFOSCAN network, which
covers a population of 1.25 million in the southern part of Ireland, have noted an
increase in new isolates since 1992. The statistics have shown a progressive
increase in the MRSA monthly isolation rate in Munster (see Table 1.1). Figure
1.2 is a graphical representation showing the steady increase in the number of
cases of MRSA reported in Cork University Hospital (CUH) between 1992 and
1996.

Table 1.1: INFOSCAN statisitcs of monthly
isolation raten of MRSA in Munster
Year
Monthly Isolation Rate
1992

15-45

1993

45-98

1994

90-110

1994-1998

>100

Cases of MRSA

Figure 1.2: Incidence of reported cases of MRSA
at Cork University Hospital (CUri; from 1992-1996.

In the past decade in the United Kingdom, many hospitals have experienced
outbreaks of patient colonisation and infection with epidemic MRSA (EMRSA). An
EMRSA has been defined as an MRSA strain affecting more than one hospital.
Sixteen UK EMRSA have now been described. EMRSA strains spread readily
and are difficult to contain. The most recently described, EMRSA-16, caused a
large outbreak in Northamptonshire in 1991 where 21% of the 400 affected
patients were infected over a 20 month period. EMRSA-16 initially spread locally,
then to areas west and south of London. There were 132 hospitals affected in
1995, most had small outbreaks (<50 patients) but in about 30 of these facilities
there was a large MRSA problem (Cookson et al., 1995). One hospital reported

10

that 39% of all their wounds colonised with EMRSA-16 subsequently became
infected.
These investigations illustrate that the incidence of MRSA colonisation and
infection varies from country to country, city to city and from ward to ward within a
health care facility. It is evident that MRSA remains a persistent cause of
nosocomial infection, the frequency of which is continually increasing in many
different areas of the health sector.

1.1.3: Mechanism of methicillin resistance, and the genes involved
1.1.3.1: Cell wall synthesis in Staphylococcus aureus
A knowledge of the cell wall structure and the mechanism of peptidoglycan
synthesis (as elucidated so far) are essential to fully comprehend the process of
methicillin-resistance in staphylococcal strains.
The cell wall of S. aureus is composed of unbranched |3(1^4) linked glycan
chains consisting of 10-12 alternating subunits of N-acetylmuramic acid (Mur) and
N-acetylglucosamine (N-AceGlu). Pentapeptide side chains are linked to the
muramic acid molecules. These side chains are cross-linked yja pentaglycine
bridges in S. aureus, attached to the L-lysine on one pentapeptide and the Dalanine on the other. This complex structure is the cell wall peptidoglycan
(Kaplan,

1982) (see Figure 1.3.).

Peptidoglycan synthesis begins in the cytoplasm with the conversion of
uridine diphosphate N-acetylglucosamine to uridine diphosphate Nacetylmuramic acid. The synthesis of the pentapeptide side chains begins with
the sequential addition of three amino acids- alanine, iso-glutamine and lysine to
the muramic acid residue. Each of these additions is catalysed by separate

11

enzymes. The final 2 amino acids of the pentapeptide are connected as a
dipeptide, D-alanyl-D-alanine. This muramic acid pentapeptide precursor is
moved to the cell membrane where an acetylglucosamine Is attached. In a series
of separate enzyme-catalysed reactions, five glycines are added to the lysine of
the pentapeptide. The disaccharide-pentapeptide with its pentaglycine bridge is
moved to the cell wall, where it is attached to the growing peptidoglycan chain by
transpeptidation. The cross-linking of the pentapeptide chains yja the
pentaglycine bridges is catalysed by transpeptidase enzymes known as penicillin
binding proteins (PBPs). Connection of the pentapeptide side chains occurs
when the terminal glycine of the pentaglycine bridge is joined to the fourth amino
acid (alanine) with the concomitant release of the terminal D-alanine residue
(Baron, 1995).

Fig. 1.3: Structure of the peptidoglycan cell wall of Staphylococcus aureus.
Mur (N-acetylmuramic acid) and NAcGlu (N-acetyl glucosamine) are the
peptidoglycan sugar moieties. To each Mur is attached a peptide side chain
comprised of the amino acids Ala (alanine), GIU-NH2 (glutamine) and Lys
(lysine). Gly5 represents the pentaglycine bridges which crosslink peptide
side chains.
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1.1.3.2: Penicillin-binding protein 2a (PBP 2a)
Penicillin-susceptible staphylococci have five constitutively expressed PBPs
designated PBP 1, PBP 2, PBP 3, PBP 3’ and PBP 4. PBPs are surface located
proteins that function as peptidglycan transpeptidases (Brakstad ^aj., 1997). The
PBPs have high affinity for p-lactam antibiotics which inhibit transpeptidation by
binding to the active sites of PBPs causing the synthesis of defective, poorly
crosslinked cell wall which ultimately results in cell lysis and death.
In MRSA, an additional PBP termed PBP 2a or PBP 2’ may be expressed
upon induction by methicillin. The latter is a transpeptidase with a low binding
affinity for p-lactam antibiotics. Identical penicillin binding motifs found in the
penicillin binding domains of the high affinity PBPs are also present in PBP 2a.
However, the precise reason for PBP 2a’s observed low affinity is unknown.
Affinity studies between methicillin and PBPs have shown that methicillin
concentrations greater than 250 }ig/ml saturated only 50% of PBP 2a
transpeptidase activity (Dominguez ^aj., 1997).
When the concentration of (3-lactam antibiotic increases in the environment
of the cell, the antibiotic penetrates the cell and inactivates the normal set of PBPs.
It is assumed that the low affinity and therefore unsaturated PBP 2a continues cell
wall transpeptidation conferring a resistant phenotype on the organism.

1.1.3.3: mec DMA
Methcillin resistant staphylococci possess a 30-50 kb DMA element of nonstaphylococcal origin, mec , that is absent in susceptible strains (Chambers,
1997). This mecDNA integrates at a specific site on the S. aureus chromosome
near the pur-nov-his gene cluster.
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The mecDNA gene locus consists of the following::
-mecA: the structural gene for PBP 2a
-meci and mecR1: putative regulatory genes controlling mecA transcription
- 20-45 kb of mec associated DNA (including plasmids and insertion
sequences which tend to cluster at this locus), (see Figure 1.4)

femA3

feme

Tn554

IS

•

IS

pueiio

Figure 1.4: Molecular organisation of the approximately
50 kb mecDNA. The location of this mecDNA is shown
relative to the fern genes (see Section 1.1.3.6) and the
pur-nov-his operon. IS represents the insertion sequence
IS 431 which flanks the tobramycin resistance plasmid
pUBIIO. The transposon Tn 554 contains the ermA gene
that codes for erythromycin resistance.

An important feature of mecDNA is its propensity for carrying additional antibiotic
resistance determinants. Within this genetic element, there are many transposons
and insertion sequences that confer on the host several resistance determinants
Including resistance to erythromycin, tetracycline, mercury and cadmium. The
ability of insertion sequences such as IS431 to trap and cluster many resistance
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determinants may explain the characteristic multiple drug resistance phenotype of
MRS.

1.1.3.4: The mecA gene, and its genetic regulation
The mecA gene (2.1-kb) codes for the novel PBP 2a of MRS. mecA is proposed
to be a combination of sequences from a staphylococcal (3-lactamase and an
Escherchia coli PBP gene (Baron, 1995).
The origins of the mecA gene are disputed. One study of European isolates
of MRSA suggests the early introduction of mecA into one or a few S. aureus from
a coagulase negative Staphylococcus species. Evidence suggests there was little
or no subsequent horizontal transfer within the species. All MRSA isolates are
thought to be clonal descendants of these few ancestral strains (Kreisworth ^ aj.,
1993). This hypothesis is currently disputed by several authors based on
evidence obtained from multilocus enzyme electrophoresis (MLEE) results, these
demonstrated clonal diversity of MRSA consistent with continuous horizontal
acquisition of mec sequences by S. aureus (Musser et a]., 1992). Further studies
are required to determine the true origin of the mecA gene in MRSA strains.
Transcription of mec A is regulated by the meci and mecRI genes located
immediately upstream of the mecA promoter. These regulator genes are similar in
structure, function and mechanism of regulation as the j3-lactamase regulatory
elements ^1 and blaRI (Chambers, 1997). Amino acid sequence analysis for
mecI and mecRI show 61% and 34% homology respectively with sequences of
blal and blaRI.
The products of the mecRI and meci gene are a putative transmembrane
signalling protein and a putative repressor. These elements are expected to
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regulate mecA gene transcription just as Na regulators do on bIaZ gene
(Dominguez

1997)

The Mai gene encodes a repressor protein that acts at an operator site
upstream of the (3-lactamase gene (blaZV The MaRI gene encodes a
transmembrane protein with an extracellular penicillin-binding domain and an
intracellular signalling mechanism. The blaRI product, the trasmembrane protein
BlaRI, senses the presence of (3-iactam antibiotics on the cell surface and
induces derepression of bIaZ by releasing the Mai repressor from the operator site
(Brakstad Maj., 1997). (see Figure 1.5).

B-lactaiii antibiotic

Figure 1.5: Putative role of the mecRI and meci regulatory
elements on mecA expression In MRSA . (Figure modified
from Brakstrad
1997)

Prior to 1970, clinical isolates of MRS were identified which contained deletions of
the mecI gene, resulting in constitutuve expression of PBP 2a. Studies have
shown that the presence of an inducible p-lactamase, leads to PBP 2a expression.
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This occurs due to the presence of plasmid-encoded (3-lactamase regulatory
genes that can also regulate PBP 2a production. Currently it is believed that PBP
2a is under the control of both the mec and p-lactamase regulatory genes.
However, the bja regulatory system is thought to play a critical role in PBP 2a
expression whereas the mec R1-mecl system appears to be an important but not
vital component in the regulation of PBP 2a expression (Chambers, 1997;
Brakstad^^., 1997).

1.1.3.5: Phenotypic expression of methiciiiin resistance
The resistance level to methiciiiin can vary greatly from one strain to another
(Dominguez

1997). Phenotypic expression of methiciiiin resistance can be

homogeneous or heterogeneous. With homogeneous resistance, a uniformity of
high level resistance is displayed by all cells in the population (i.e. cells can grow
in the presence of methiciiiin concentrations >100 |xg/ml). However, the majority of
MRSA strains are heterogeneously resistant, that is, most of the cells are
susceptible to low concentrations of methiciiiin (1-5 ^ig/ml) while a minor
subpopulation are resistant to higher concentrations of methiciiiin (Morita, 1993).
Heterogeneous strains can appear homogeneous under certain growth
conditions, such as growth in hypertonic culture medium supplemented with NaCI
or sucrose or incubation at 30°C. Addition of EDTA or incubation at 37 to 43°C
favours a heterogeneous resistance pattern (Chambers, 1997).
The heterogeneous nature of methiciiiin resistance exhibited by most
clinical MRSA isolates make it difficult to detect MRSA.
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1.1.3.6: Other genes that affect methicillin-resistance levels
Comparable amounts of PBP 2a are produced by all MRSA isolates. However,
the minimum inhibitory concentration (MIC) level and mode (homogeneous or
heterogeneous) of expression of methicilin resistance is highly variable.
This observation has led to the identification of a number of other genes
that play a vital role in determining the expression of resistance to p-lactam
antibiotics (De Lencestre et a]., 1994). These genes are located outside the mec
locus on the S. aureus chromosome, and include fern (for factors enhancing
methicillin resistance) or aux (auxiliary) factors.
Insertional inactivation studies using the transposon Tn551 led to the
discovery of at least six fern genes that participate in the expression of methicillinresistance. Transposon inactivated fern elements have increased susceptibility to
methicillin. These fern genes are present both in sensitive and resistant strains of
S. aureus and have been mapped to several sites throughout the staphylococcal
genome (Chambers, 1997) (see Figure 1.4).
These fem:Tn551 mutants have altered peptidoglycan composition.
Therefore, it is evident that the fern genes identified thus far femA. femB. femC.
femD. femEand femF genes (with the exception of femE which is of unknown
function) play roles in the synthesis of peptidogican precursors for cell wall
synthesis. Figure 1.6 shows the functions of the fern genes involved in the
synthesis of peptidoglycan precursors and the sites of synthesis that are blocked
by mutations in these fern genes.
Recent data has suggested the involvement of 10-12 additional genes
necessary to support the maximal expression of methicillin-resistance.
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Figure 1.6: Functions proposed for the fern gene products in the biosynthesis
of peptidoglycan. Also illustrates the blockage in cell wall synthesis resulting
from fern gene mutations.(NAM =N-acetylmuramic acid, ala= alanine, lys=lysine,
glu=glutamate, glU‘NH2= glutamine and gly=glycine)
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Studies have shown that in a drug-free medium, the ceil wall composition
consists of >60% trimers or higher oligomers. The introduction of methicillin into
the bacteriums environment alters the cell wall components so that the complex
cell wall structure is replaced by a simpler peptidoglycan composed of monomers
and dimers and <15% oligomers. It appears that PBP 2a is a transpeptidase
capable of linking only two monomers (De Jonge M ai.,1993). De Lencestre et af.
(1994) proposed a role for the interplay of PBP 2a and these recently identified
auxiliary genes. It is assumed that the PBP 2a requires a supply of structurally
correct cell wall precursors. These precursors can compete with methicillin for the
binding site of the PBP 2a transpeptidase and augment the methicillin MIC.
Precursors of 'modified' structure (e.g. fern mutants) are unable to compete
effectively with methicillin and thereby decrease methicillin MICs and cell wall
synthesis continues (see Figure 1.7).

Cultures of heteroresistant MRSA have a highly resistant subpopulation of cells
but most of the cells have a lower resistance to methicillin. Studies have shown
that introduction of mecA into susceptible strains of S. aureus produced a small
number of highly resistant cells. Ryffel ^aj. (1994) suggested that high level
resistance may be due to the presence of chromosomal mutation(s) (chr *) distinct
from the mecA and fern gene mutations of undetermined chromosomal sites. The
chr * mutations have no effect on susceptible S. aureus strains but become
apparent only in the presence of mecA (Ryffel
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1994).
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Figure 1.7: Competition for the active site of PBP 2a by cell wall
precursors and |3-lactam antibiotics.
a. Structurally normal precursors are effective competitors driving the
MIC value up.
b. Precursors with abnormal structure are ineffective competitors of
methicillin resulting in reduced MIC values.

Autolysins are peptidoglycan hydrolases, These enzymes function in cell wall
turnover and cell division. Experiments indicate that autolysins are involved in the
expression of methicillin-resistance by MRSA. Several genes determine autolysis
including Um and Mi- It has been suggested that the acquisition of the mecDNA
element increases the autolytic rate of staphylococci. However, further studies are

oV’

■

/,

21

-

required to confirm the role of the autolysins in the expression of methicillin
resistance (Brakstad

1997).

The acquisition of the mecA gene is the prerequisite for methicillin
resistance. However the genetic background of the S. aureus strain determines
the level and mode of resistance expressed. Further investigations are required to
fully understand the molecular basis of methicillin resistance and these studies
may provide new targets for antimicrobial therapies.

1.1.3.7: Borderline resistant Staphylococcus aureus (BORSA)
Low-level methicillin resistance has been observed in staphylococci that do not
possess the mecA. Several theories have been proposed to account for this mec
-independent methicillin-resistance. Some clinical S. aureus isolates produce
elevated quantities of p-lactamase. The increased enzymatic activity may permit
the slow hydrolysis of the p-lactamase stable p-lactam antibiotics such as
methicillin and oxacillin producing borderline MICs for these strains (Brakstad et
al., 1997).
A plasmid encoded methicillinase enzyme distinct from p-lactamase has
also been reported in borderline-resistant S. aureus strains (Barg ^aj., 1991;
Chambers, 1997). This enzyme is produced in addition to p-lactamase and may
be responsible for borderline resistance.
Another possible mechanism of borderline resistance in S. aureus is
chromosomal gene modifications of PBP genes. These alter the structure of the
PBPs causing decreased affinity for p-lactam antibiotics or changes in the amount
of PBP produced. This may occur due to the accumulation of multiple mutations in
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PBP genes, however further investigations are required to elucidate the exact
genetic basis of these PBP structural alterations (Dominguez Mai-, 1997).
The importance of the mec-independent methicillin-resistance is unclear
however there is no clinical evidence that the level of resistance expressed is
sufficient to lead to failure of treatment.

1.1.3.8: Susceptibility testing for methicillin-resistance
Laboratory detection of MRSA requires modified culture conditions to improve the
accuracy of testing. These experimental steps enhance the expression of
resistance especially in strains that exhibit heterogeneous resistance.
Modifications include the use of oxacillin (instead of methicillin), incubation at 3035 °C (instead of 37 °C) and incubation for 24 h (as opposed to 16-18 h)
(Chambers, 1997).
Agar screen methods are considered preferable to disc diffusion methods.
The sensitivity of the oxacillin disc diffusion test is estimated at around 80%.
However, an agar screen test using Mueller-Hinton agar supplemented with 4%
NaCI and containing 6 ug/ml of oxacillin has almost 100% sensitivity for MRSA.
MIC determinations are performed by microdilution or agar dilution test. E test
strips are a convenient and reliable means of MIC estimation. Automated systems
are now available for methicillin resistance testing, these have excellent specificity
but lack sensitivity and therefore a second confirmatory test should be performed
(Baron, 1995). Not all mecA containing strains will be detected by any one of
these laboratory tests.
An ideal approach would focus directly on the presence of the mecA gene.
The advent of DNA technology has facilitated the development of such strategies.

23

Polymerase chain reaction (PCR) based techniques and DNA probe hybridisation
assays have been developed that can accurately detect the presence of the mecA
gene (Kobayashi etaj., 1994; Ligozzi^al., 1991; Shimaoka ^ a]., 1994). A
comparative study performed by Tokue MM- (1992) identified 28 mecA positive
strains of S. aureus by PCR from a total of 58 S. aureus strains tested (mecA
positivity represented 60% of the population tested). Six of these strains showed
susceptibility to methicillin by conventional microbiological assay. Further
analysis of these six strains included culturing the organism in the presence of
ceftizoxime which increased the phenotypic level of resistance indicating that
these strains should have been classified as methicillin-resistant.
Multiplex polymerase chain reactions have been described that permit
simultaneous identification of mecA and an S. aureus specific gene, thereby
allowing discrimination between MRSA, MSSA (methicillin-sensitive S, aureus)
and CNS (coagulase negative staphylococci) strains (Cotter etM-, 1997;
Salisbury MM-, 1997; SchimitzMM-, 1997). (These PCR apporaches are
discussed in more detail in Section 1.4)
It is evident that these DNA-based procedures will correctly identify even
the most heterogeneous of strains as they do not rely on the in vitro expression of
resistance but detect the gene involved (mecAl directly. Such approaches are not
limited by variable gene expression. However currently these methods are
confined to research facilities. mecA detection by genetic strategies provides
definitive confirmation of the resistance status of S. aureus strains, therefore in the
future it is highly probably that these methods will be adopted for the routine
determination of methicillin resistance.
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1.1.4: Control of MRSA
The incidence of MRSA colonisation and infection has increased in many areas
including acute and chronic care facilities, outpatient clinics and in the community.
Prevention of infection is possible and therefore essential as the options for
treatment are very limited. A large number of studies have evaluated various
control regimens (Boyce, 1995; Harstein M^.,1995; Humphreys ^a]-, 1997;
Mulligan ^aj., 1993) to determine the best possible approach.
Control schemes vary depending upon:
1. the type of hospital setting e.g. ICU, burns unit, or other,
2. the virulence of the organism involved,
3. the degree of endemic MRSA present in the facility, and
4. facilities and resources at the disposal of the infection control team.
Boyce described the various strategies employed to control MRSA in different
countries. The methods used in the Netherlands and in Western Australia are
aggressive strategies that are only feasible in areas where MRSA prevalence is
still low (Boyce, 1995).

No single control programme is likely to be achievable

and cost effective in all institutions and so the method used should be tailored to
meet the requirements of the individual institution. Complete eradication of
endemic MRSA from a health care facility is unlikely. Thompson ^aj. (1982)
tracked outbreaks of MRSA in 18 hospitals and observed that only 2 of these
facilities achieved complete eradication of MRSA. Therefore the ideal goals of
any infection control program should be the prevention of outbreaks and the
limitation of intra- and inter- facility transmission.
Prevention of MRSA transmission is the cornerstone of any infection control
policy. This can be accomplished by identifying the (potential) reservoirs of
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infection. It is well recognised that the major reservoir of MRSA is colonised or
infected patients. The organism can then be spread from patient to patient yja the
contaminated hands of medical personnel (Martin, 1994). This has been
confirmed by a number of studies. Thompson

(1982) inoculated MRSA onto

the hands of health care workers and demonstrated that the organism can persist
for greater than three hours without handwashing and this creates an opportunity
for direct transmission following contact with an infected or colonised patient.
Cookson ^aj. (1995) demonstrated that direct contact between nurses and
heavily colonised patients was associated with the acquisition of finger and nasal
carriage by these staff members. Airborne transmission is another potential
means for transmission although this has not been well documented and may only
be important in burns units where patients have heavily colonised exposed
wounds. Controversy exists when evaluating the role of the environment in the
transmission of MRSA. However Boyce (1995) sampled the environmental
surfaces in the rooms of MRSA patients and recovered MRSA by culture from 23%
of the surfaces. Contamination was higher (34%) in the rooms of patients with
MRSA in a wound or urine when compared with the surfaces of the rooms of
individuals with MRSA in other body sites (2%). Most significantly MRSA was
recovered from the gloves of nurses who did not have direct contact with the
patients but had touched contaminated objects in the patient’s room.
Strategies for controlling transmission of MRSA differ but most recommend
the isolation of infected and colonised patients to prevent spread. Where single
rooms are unavailable, cohorting has been used (2 or more MRSA positive
patients in the same room). The care of these patients should be performed by
nurses that are limited to treating only MRSA positive patients. Evidence has
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shown that handwashing is a critical component of infection control, it interrupts
the direct contact transmission. The use of barrier precautions, such as gloves,
gowns and masks are variably implicated but it is largely recommended that
gloves be used when medical staff are dealing with infectious bodily secretions.
Infection control is also dependent on surveillance and staff education.
Thompson Mai- (1982) concluded that a combination of surveillance approaches
were necessary to identify all MRSA cases. Clinical laboratory testing, monthly
prospective microbiological surveillance of high-risk patients and the compilation
of a registry of previously positive patients, when adopted by these authors
resulted in a marked decrease in the incidence of MRSA infections over a 12month period.
Strain typing is now used as a supplement to routine surveillance methods
to determine the relatedness of isolates in an outbreak and thereby differentiate
epidemic from endemic strains. These typing strategies allow the identification of
the potential sources of different strains and the evaluation of the role of the
human carrier in transmission. A number of studies have reported that
approximately 50% of hospitalised MRSA cases were colonised or infected prior
to admission. These newly introduced community acquired cases may complicate
the interpretation of genuine nosocomial outbreaks. The implementation of typing
methods should help infection control teams to unravel the epidemiology of this
pathogen (Mulligan MM-, 1993; Harstein M aj., 1995).
Most patients in hospitals today have one or more risk factors for acquisition
of MRSA and with inadequate resources, MRSA persists despite intensive control
policies. Humphreys Mai- (1997) have advocated a targeted approach where
resources are stretched or limited. A directed effort would control MRSA in key
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clinical areas in the hospital where the impact of MRSA is likely to be greatest (e.g.
ITU and orthopaedic/trauma units) while maintaining a general infection control
policy in other hospital areas. Hopefully such strategies will relieve pressure on
infection control teams, limit the disruption of routine medical procedures and
focus resources on the most vulnerable areas.

1.1.5: Antimicrobial Agents for MRSA
1.1.5.1: Eradication of the carrier state
In certain circumstances elimination of MRSA carriage may be necessary, such as
during an epidemic or when epidemiological data implicates one carrier
disseminating MRSA in a health care setting. Topical mupirocin is the agent of
choice for treatment of nasal carriage. This antibiotic is unsuitable for systemic
use due to its rapid hydrolysis in plasma. Mupirocin is an inhibitor of bacterial
isoleucyl tRNA synthetase and therefore inhibits protein synthesis. Recent data
has shown a considerable increase in the numbers of cases of mupirocin
resistance (both low-level and high-level being reported). Low-level resistance is
unlikely to present a major problem but high-level resistance due to the
acquisition of the mupA gene may lead to widespread resistance. Alternatives to
mupirocin are limited and therefore careful discriminatory use of this agent is
essential in maintaining its role as an effective treatment option (Cookson, 1998;
Eltringam, 1995). Chlorhexidine is another important agent for treatment of MRSA
carriage, however reports of resistance to this agent have been documented
(Irizarry ^al., 1996).
The essential oil of Melaleuca alternifolia. or tea-tree oil, has a broad
spectrum of antimicrobial activity. Carson et aj. (1995) investigated the
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susceptibility of 66 Staphylococcus aureus isolates (64 methicillin-resistant and
33 mupirocin-resistant strains) to tea-tree oil using disc diffusion and modified
broth microdilution methods. Results of these testes showed the minimum
inhibitory concentration (MIC) for these S. aureus isolates was 0.25%. This
suggests that tea-tree oil may be useful in the treatment of MRSA carriage (Carson
et al., 1995). However the efficacy of this agent in a clinical environment remains
to be assessed and reports of dermal irritation (although rare) require further study
(Apted, 1991).

1.1.5.2: Treatment of MRSA infections
All strains of MRSA are regarded as resistant to all p-lactam antibiotics although
several new p-lactam antibiotics with high binding affinity for PBP 2a have now
been developed. These have shown excellent activity in animals models but
none as yet have been assessed by clinical trials (Chambers, 1997).
The glycopeptide vancomycin remains the treatment of choice for MRSA
infections. Despite many limitations including toxicity, difficulty in administration
and expense, no comparable alternative has been developed. Teicoplanin is
another glycopeptide active against Gram-positive organisms however early
studies suggested the success rate of MRSA treatment with this drug was <50%
(Galanakis ^aj., 1988; Glupezinski et^., 1996). Other studies have shown the
clinical efficacy of teicoplanin to be >90% (Dagan et al., 1991), however the
definitive role of this agent in MRSA infection remains unclear as the optimum
dosage remains to be established. A number of other agents including the
fluoroquinolones, rifampicin, trimethoprim-sulfamethoxazole and the
aminoglycosides must be used in combination therapy to elicit a beneficial effect
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as resistance to most of these agents had been clearly demonstrated (Martin,
1994; Brumfitt et

1989). The identification of a vancomycin-resistant strain of

S. haemolytiocus and the emergence of vancomycin resistant enterococci (VRE)
may lead to the selection of a vancomycin-resistant MRSA which would pose a
serious medical problem. A clinical isolate of MRSA (designated Mu50) with
reduced resistance to vancomycin (MIC=8|ig/ml) has been reported in 2% of all
MRSA strains in the Juntendo Hospital, Japan (Hiramatsu et^., 1997). The exact
mechanism of this organisms reduced susceptibility to vancomycin remains to be
determined. PCR amplification demonstrated that Mu50 does not carry the vanA
and vanB genes of VRE. It is postulated that the intrinsic mechanism of this
reduced vancomycin susceptibility results from augmented cell-wall synthesis.

It is obvious from the limited amount of antimicrobial therapy available for the
treatment of MRSA colonisation and infection that the development and synthesis
of newer agents is urgently required. The oxazolidinones, streptogramins, and
LY333328 have shown promising results but are currently in clinical trials. A
clearer understanding of the pathology and mechanism of resistance of this
pathogen may facilitate the development of novel therapies.
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1.2: Strategies for typing methicillin-resistant Staphylococcus aureus
MRSA strains need to be distinguished for epidemiological purposes. The clinical
goals of an MRSA typing system are to
1.

outline the baseline prevalence of MRSA strain types in the
community

2.

aid interpretation of epidemiological data

3.

define the means of transmission of MRSA in a health care facility

4.

identify outbreaks

5.

influence the development and monitoring of preventative strategies

Correct interpretation of the results of such schemes should permit the
implementation of directed and cost-effective control measures during MRSA
outbreaks (Mulligan et aj., 1993). The high degree of genetic relatedness among
strains of MRSA has complicated the establishment of a universal typing strategy.
Any acceptable laboratory procedure should reliably differentiate
epidemiologically related isolates from random unrelated isolates of the same
species. However, despite intensive investigations no definitive ‘universal’ system
for typing MRSA has emerged (Fang et

1993).

1.2.1: Characteristics of an ideal typing strategy:
The three most important criteria for evaluating the clinical utility of any MRSA
typing scheme are:
• Typeability
• Reproducibility
• Discriminatory power
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• Typeability: All strains should be typed by the method. An approach that yields a
significant percentage of negative results (i.e. non-typeable strains) should be
deemed unsuitable as a universal system.

• Reproducibility: The assay should consistently give the same result each time a
particular isolate is examined. Reproducibility should be maintained over long
period of time and be achievable in different laboratories. This criterion dictates
the necessity to base the ‘universal’ typing strategy on a stable characteristic of
the organism.

• Discriminatory power: An ideal typing system should have the ability to
recognise a reasonable number of strain types. Unrelated strains must be
distinguished by the assay and isolates that are designated to be of the same
type must be reliably judged as epidemiologically related (Mulligan et aj., 1991;
Towner

1995).

In addition to these features the ideal typing strategy should be:
• Simple,
• Rapid,
• Inexpensive,
• Readily available, and
• Have the potential to be automated.
Traditional MRSA typing methods were based on the detection of phenotypic
characteristics. However advances in molecular biology have seen the
development of novel molecular biology approaches that directly the assess
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bacterial genome. The following table (modified from Mulligan et aj., 1991)
reviews the characteristics of many of the currently available MRSA typing
schemes:

Table 1.2: Characteristics of MRSA typing strategies
Proportion of

Discriminatory

Laboratory

strains typeable

Reproducibility

power

Availability

All

Good

Poor

Clinical

Variable

Fair

Poor

Service

Whole cell electrophoresis

All

Fair

Good

Research

Immunoblots

All

Fair

good

Research

Plasmid Profile Analysis

Variable

Fair

Fair

Service

Plasmid REA

Variable

Good

Good

Service

Chromosomal REA

All

Excellent

Excellent

Research

Ribotyping

All

Excellent

Good

Research

Most

Excellent

Fair

Research

Pulsed Field Gel Electrophoresis

All

Excellent

Excellent

Service

Random Amplified Polymorphic DNA

All

Good

Excellent

Research

Typing System
Phenotypic Method
Antimicrobial Susceptibility Testing
Bacteriophage Typing

Genotvoic Methods

Gene Polymorphism-RFLP Analysis

(Note: REA = restriction enzyme analysis. Laboratory availability: Clinical = available in routine microbiology
laboratories, Service = available from reference centre, Research = presently confined to research facilities)

1.2.2: Phenotypic Techniques:
Classical methods of MRSA strain differentiation used in epidemiological studies
are based on phenotypic characteristics of the organism. These approaches
include antimicrobial susceptibility testing (Cookson Mai-, 1986; HoefnagelsSchuermans eta]., 1997), bacteriophage typing (Cookson etaf., 1986; Gaston^
a]-, 1988; van Belkum M al-, 1993) and electrophoretic methods such as whole cell
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polypeptide analysis (Gaston et aj., 1988) and immunoblotting (Coia et al.. 1990;
Gaston et^., 1988).
Determination of the antibiogram of a strain (resistance to a variety of
antibiotics), while easy to perform, rapid and readily available, is frequently
inadequate for differentiating MRSA. Many resistance determinants are plasmidborne and the pattern may vary due to the loss or gain of these mobile elements
during an outbreak. Antibiograms usually reflect antibiotic usage in a community
however with MRSA isolates the profiles tend to be poorly discriminated, as many
strains are similarly resistant to multiple antibiotics (i.e. strains have similar
antibiograms).
Phage typing MRSA has long been the standard method of strain
differentiation. However in more recent times non-typeable strains (i.e: strains
resistant to the current set of phages) have emerged. To overcome this problem
supplementary (often experimental) phages and/or altered assay conditions are
being utilised. The poor reproducibility and limited availability of the standard
phage typing procedure (only available in references centres), together with the
difficulties associated with maintenance of phage stocks has highlighted the
necessity for alternative, effective typing schemes.
Whole cell polypeptide electrophoresis and immunoblotting have been
advocated in a number of studies as effective typing schemes (Coia ^ a}., 1990;
Gaston ^^.,1988). All strains are typeable but the applicability of these
approaches has been limited because of the difficulty in interpreting the complex
patterns resolved, the high technical expertise required and the lack of
reproducibility.
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It is evident that the conventional phenotypic-based strategies have
inherent limitations. The capacity of micro-organisms to alter (unpredictably)
phenotypic expression and the ever increasing number of non-typeable strains
has led to the development of DNA-based typing procedures for MRSA.

1.2.3: DNA-based techniques:
Recent advances in molecular biology have resulted in the availability of a wide
variety of genotypic typing strategies for MRSA. Some of the genotypic strateiges
available for MRSA typing are shown in table 1.3.

Table 1.3: DNA-based typing strategies utilised for MRSA strain differentiation
Typing Strategy

Reference(s)

Plasmid profiles

Cookson et al-, 1986; Fang ^al-, 1993; Gaston ^al.,
1988

Restriction fragment length polymorphism
(RFLP) of:
i plasmid DNA
ii chromosomal DNA
iii PCR amplified MRSA genes:
- protein A gene

Coiaetal-, 1990
El-adhami ^al., 1991
Frenay etal-,1994: Hoefnagels- Schuermans elal-, 1997

- coagulase gene

Kobayashi ^al.,1995: Nada etal.,1996

- mec hypervariable region

Nishietal.,1995

DNA hybridisation assays
i. ribotyping
ii. IS 256 probing
Pulsed-field gel electrophoresis (PFGE)

Prevost etal., 1992; YoshidaetM-, 1997
Morvanet^., 1997
Ichytyamaetal., 1991; Stewart etal.,1993; Struelens et
al., 1992

Random amplified polymorphic DNA assays

Saulnier et al.,1993; Iambic et al., 1997; van Belkum et
al., 1993

In general, genotypic approaches have improved the ability to differentiate strains
of MRSA. However plasmid profiles and RFLP analysis of plasmid DNA have
significant limitations. Results can be variably interpreted due to the existence of
plasmid DNA in different forms. Plasmids are mobile genetic elements that can be
lost or gained during the course of an outbreak. Some pathogens have few if any
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plasmids and therefore a certain percentage of strains are non-typeable.
Restriction endonuclease digestion of plasmid DNA provides greater
reproducibility and discriminatory power than plasmid profiles alone, although the
tendency of plasmids to be gained or lost can also adversely affect the results
obtained using this procedure (Mulligan MaJ-, 1991).
All bacterial strains are typeable using restriction enzyme analysis (REA) of
chromosomal DNA. Reproducibility of results is improved when compared with
those of REA on plasmid DNA. The major limitations of this procedure is the
complexity of the patterns resolved which hinder accurate comparisons of strain
similarities and differences. PFGE analysis of chromosomal DNA is a much used
tool for MRSA strain differentiation. Restriction endonucleases are selected that
target DNA with low frequency generating large fragments to be resolved by
PFGE. Many investigations have shown that the typeability, reproducibility and
discriminatory power of PFGE is excellent (Ichytyama
1992; Stewart

1991; Struelens

1993; Kumari et aj., 1997). Although this method meets the

major requirements of an ideal typing system, its application is limited by the
costly, time-consuming, labour intensive nature of the assay.
The advent of PCR technology has led to the development of an array of
new typing schemes. PCR amplification of gene segments (that contain variable
numbers of a particular repeat sequence) followed by RFLP analysis have been
utilised. Gene targets for such approaches include the coagulase (Kobayashi et
^., 1995; Nada^aj., 1996) and protein A genes (Frenay et al.. 1994; HoefnagelsSchuermans Mai-, 1997) and also the hypervariable region of the mec DNA
(Nishi MM-, 1995). The disadvantage of such strategies is that typing focuses on
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a single locus and there are some reports of lack of discriminatory ability
(Hoefnagels-Schuermans

1997).

Random amplified polymorphic DNA (RAPD), arbitrarily primed PCR (APPCR) and DNA amplification fingerprinting (DAF) were originally reported by
separate groups (RAPD - Welsh and McClelland, 1990; AP-PCR - Williams ^aj.,
1991; DAF - Gaetano- Anolles ^a]., 1991). These procedures have become
increasingly popular for bacterial typing. Selection of an appropriate primer is a
key factor in determining the clinical utility of RAPD. Once optimised for a
particular organism the assay provides a simple and easy to perform test that has
excellent discriminatory capacity, typeability and reproducibility (van Belkum
1993).
In summary, the typing method adopted should be guided by the
circumstances at the individual centres i.e. the available facilities, the technical
expertise and the resource constraints (Coia ^aj., 1990). Although antibiotic
susceptibility patterns have low discrimination, they are readily available and may
indicate the emergence of a particular source of infection (Mulligan et a}., 1993).
Therefore, it is evident that traditional typing methods such as antibiograms and
phage typing will retain an important role in hospital epidemiology. However
modern molecular approaches can enhance the ability of infection control teams
to analyse and interpret epidemiological data, and help eliminate hospital
epidemics (Fang

1993).
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1.3: The Polymerase Chain Reaction (PCR):
The polymerase chain reaction (PCR) was devised by Kary Mullis in the mid
1980s (Mullis and Faloona, 1987). This powerful tool has greatly accelerated the
progress towards a more complete understanding of genomic structure.
Numerous novel applications of PCR have been developed, thus PCR has
become an invaluable tool in scientific research. The principles and protocols of
PCR have been extensively reviewed in Mullis

1994. The purpose of the

following section is to provide a rapid review of the essential features of PCR and
to demonstrate some of the microbiological and epidemiological applications of
this method that can be used in a clinical setting.

1.3.1: Principle of PCR:
PCR allows the selective in vitro amplification of a specific DNA region by
exploiting certain feature of in vivo enzyme-mediated DNA replication. DNA
polymerase uses single-stranded DNA as a template for the synthesis of new
strands.
The specificity of the PCR reaction is dependent on the design of the
oligonucleotide primers used. These primers specify the starting point of DNA
synthesis by binding to the DNA template at complementary sequences. The
primers chosen for PCR should flank the DNA region of interest and in this way
DNA polymerase can be directed to selectively synthesise a stringently selected
DNA sequence.
Both strands of DNA can serve as templates for the synthesis, provided an
appropriate primer is supplied for each strand. Amplification of the DNA starts at
each primer and extends beyond the position of the primer on the opposite strand
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and therefore new primer binding sites are generated on each newly synthesised
DNA strand, (see Figure 1.8)

PCR consists of three reiterated steps constituting one cycle:
1. Denaturation; In this step the double stranded DNA templates are separated,
typically at temperatures between 92 and 96 °C.

2. Annealing: A lower reaction temperature (between 45 and 72 °C) permits
primer binding to complementary sites of the DNA template. The temperature
chosen should be as high as possible to allow selective hybridisation of the
primers, thereby maintaining specific binding and amplification. The temperature
and length of time required for this annealing is dependent upon the base
sequence, length and concentration of the primers used for amplification.

3. Extension: This step involves the synthesis of the new DNA strands and
comprises the successive addition of dNTPs at the 3’- OH termini of the primers.
Extensions are typically performed at 72 °C (the temperature selected depends on
the enzyme used) and the time required depends upon the length of the sequence
to be amplified.

The number of repetitions of this cycle of reiterated steps depends upon the
starting material and the subsequent use of the PCR product (e.g. 25 repeated
cycles should be sufficient to permit visualisation of an ethidium-bromide stained
band on an agarose gel from a single copy gene in 0.5 |ig of genomic DNA).
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Figure 1.8: Diagrammatic representation of the polymerase chain reaction (PCR).
In the first cycle, the DNA template is denatured and oligonucleotides anneal to
the single stranded DNA. These primers serve as starting points for polymerasemediated addition of nucleotides to beyond the opposing primer. After the first
cycle, twice as many DNA sequences exist, which in turn can serve as templates
for DNA synthesis. Initially the amplification products are heterogeneous in size
but the segment of DNA between the two primers is preferentially amplified and
therefore becomes the predominant product of the reaction.
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The net result of this protocol is that by the end of n cycles, the reaction contains 2^
double stranded DNA molecules that are copies of the DNA sequence located
between the chosen primers. Table 1.4 shows the expected number of PCR
amplified products after 30 amplification cycles.

Table 1.4: PCR amplification of a DNA fragment
Cycle Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Number of double-stranded
target molecules
0
0
2
4
8
16
32
64
128
256
512
1024
2048
4096
8192
16,384
32,768
65,536
131,072
262,144
524,288
1,048,576
2,097,152
4,194,304
8,388,608
16,777,216
33,544,432
67,108,864
134,217,728
268,435,456

1.3.2: Requirements for PCR:
A number of physical and chemical components can be varied to improve the
results obtained using a PCR assay. These factors include:
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1.3.2.1: Sample DNA:
The PCR is quite tolerant of poor quality DNA, both in terms of the degree to which
it is degraded and the presence of contaminating materials. The sensitivity of PCR
is such that a single DNA molecule has been amplified.

1.3.2.2: Oligonucleotide primers:
The design of the primers for PCR is critical as they determine the specificity and
efficiency of the amplification. The primers should correspond to unique DNA
sequences and thus avoid non-specific amplification. The optimal annealing
temperature of both primers should be similar to avoid differences in melting
characteristics. The potential for hybridisation between the primers (i.e. primerdimers) should be minimal. A set of guidelines for primer design can be found in
Fanning

(1997).

1.3.2.3:

polymerase:

Originally E. coil DNA polymerase was used in PCR but this enzyme was heatsensitive and therefore destroyed at temperatures required to denature doublestranded DNA. The introduction of the heat stable Taq polymerase (originally
isolated from Thermus aquaticus. a bacterium found inhabiting hot springs) has
led to significant improvements in PCR and permitted automation of PCR
protocols. (Saiki M aj., 1988)
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1.3.2.4: Magnesium ion concentration:
Magnesium ions are essential cofactors for the enzymatic activity of Tag
polymerase. The concentration of Mg

2+

ions in the reaction must be optimised as

it may have an effect on primer annealing, strand dissociation temperatures,
product specificity, formation of primer-dimer artefacts, enzyme activity and fidelity.

1.3.2.5: Concentration of dNTPs:
The four dNTPs should be at equal concentration in the PCR mixture.
Concentration of between 20 and 200 ^iM appear to provide the optimal balance
between yield, specificity and fidelity.

PCR is a powerful technique that has revolutionised molecular biology. It is widely
used for an ever increasing number of applications. Clinical diagnosis is one area
in which the use of PCR is becoming more important. The application of in vitro
enzyme-mediated DNA amplification procedures, such as PCR, to the detect the
presence or absence of microbial pathogens in clinical specimens has been
clearly demonstrated (van Belkum et a}., 1995). A number of PCR-based typing
strategies including RAPD (Williams ^aj., 1990; Welsh et^-, 1990; CaetanoAnolles

1991), and PCR-RFLPs such as those described for MRSA in

Frenay etal., 1994 and Hoefnaqels-Schuermans et al..1997. have provided
epidemiological tools that are technically easy to perform, rapid and relatively
inexpensive for epidemiological assessment of important micro-organisms.
The following sections concentrate on providing the experimental
background leading to the development of PCR methods aimed at specifically
detecting and typing MRSA.
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1.4: PCR detection of MRSA:
1.4.1: Detection of methicillin-resistance by PCR:
The methods of choice for detection of methicillin resistance in Staphylococcus
aureus are the traditional antibiotic susceptibility tests, such as agar diffusion and
microdilution (Schimitz et aj., 1997). In certain instances, this conventional
laboratory detection has been problematic. The heterogeneous nature of
4

6

expression of methicillin resistance, with only a few cells (1 in 10 or 10 )
expressing the phenotype, can lead to inaccurate test results. Assay variables,
such as incubation temperature and time, pH, and NaCI concentration, can also
influence the phenotypic expression of methicillin resistance and therefore these
tests may provide unreliable results (Salisbury ^aj., 1997; Schimitz ^ a]., 1997).
Many authors have advocated the direct detection of the methicillinresistance gene (mecA) by PCR as a substitute for or supplement to the traditional
microbiological tests (Brakstad et aj., 1993; Kizaki ^^.,1994; Kobayashi et a}.,
1994; Salisbury ^aj., 1997; Schimitz

1997). It has been suggested that the

genotypic detection of mecA would provide a more definitive determination of
methicillin resistance by avoiding the phenotypic variables of the traditional tests
and the heterogeneous expression of methicillin resistance. PCR detection of
mecA will improve the reliability of the results obtained especially in borderline
resistance cases where conventional methods are unreliable. Also it is only
strains that possess the mecA gene that preclude the use of flucloxacillin for
treatment or require patient isolation, therefore correct identification of strains that
contain mecA allows the restricted use of glycopeptides by reserving their
administration for truly methicillin-resistant organisms.
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The sensitivity of PCR is such that in a study performed by Kizaki ^aj.
(1994) all strains proved to be positive in a mecA PCR amplification assay.
Similar results have been attained in a number of studies (Ashimoto
Kobayashi

1995;

1994; Cotter ^ai. unpublished data).

Epidemiological studies have revealed that the mecA gene is also present
in the genomes of coagulase-negative staphylococci (Kizaki

1994;

Kobayashi MaJ., 1994). Therefore, to distinguish between methicillin-resistant
Staphylococcus aureus and the other methicillin-resistant staphylococci, the
detection of an additional marker which is specific for S. aureus should be used in
addition to mecA detection. Detection of the mecA and S. aureus specific genes
can be performed in two separate PCR reactions or in a multiplex PCR (mPCR).
In mPCR primers targeting the required genetic determinants are combined
in the same PCR reaction mixture allowing multi-target simultaneous amplification.
The primer sets used should have similar thermal profiles and MgCl2
concentration requirements. For discrimination of MRSA from other methicillinresistant staphylococci, a multiplex PCR can be performed that allows combined
detection of the mecA gene and a S. aureus specific gene.
Brakstad

(1993) combined detection of the mecA gene with that of a

portion of the thermonuclease gene, nuc (which is specific for S. aureus). A total
of 219 staphylococcal strains were tested using this mPCR. There was 100%
agreement between coagulase test results and nuc amplification. Amplification of
mecA was compared with oxacillin resistance testing and showed 97.7%, 96.8%
and 97.3% correlation with MIC determination, disk diffusion and agar screen test
respectively. Discrepant results were due to non-S. aureus isolates with
borderline MICs of oxacillin (ranging from 1-8 |ig/ml). Results of the assay
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confirmed that the mPCR is a rapid and effective means of MRSA identification.
Other investigations have reported the use of different mPCR assays for MRSA
detection, Cotter^a]. (1997) combined mecA amplification with femA and
thermonuclease detection (see Section 1.4.2 below), Salisbury

(1997)

combined mecA d^ection with amplification of a 16S rRNA gene (used as a
positive internal PCR amplification control), and SchimitzMM- (1997) detected
mecA in association with a portion of the coagulase (coa) gene and 16S rRNA.
The sensitivity and specificity of PCR permits an accurate result to be
obtained directly from bacterial colonies (Schimitz et a]., 1997) and clinical
samples such as blood cultures (Brakstad et a]., 1993). This significantly improves
the speed of MRSA detection providing a result within 4 hours.

1.4.2: Thermonuclease testing:
Rapid and accurate tests are necessary to identify S. aureus strains and to enable
(as quickly as possible) eradication of this pathogen. Current methods used to
rapidly identify MRSA involve the isolation of the bacterium from patient samples
and characterisation of S. aureus using tests for staphylocoagulase, thermostable
nuclease or the presence of clumping factor. These properties can be shared by
other species and therefore methods are required that specifically discriminate S.
aureus from other staphylococci (Chesneau ^aj., 1993). Also, in some cases,
access to a focus of infection may be difficult or dangerous or cultural confirmation
may be hampered by ongoing antibiotic therapy (Brakstad ^aj., 1992). PCR
amplification of the thermonuclease gene has been described by Brakstad et aj.
(1992) and this test provides a rapid, sensitive and specific approach for diagnosis
of S. aureus infection.
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The extracellular thermonuclease (TNase) is produced by strains of S.
aureus with a frequency similar to that at which they produce coagulase. The
TNase enzyme is an endonuclease that degrades both DNA and RNA, it is feature
that forms the basis of many of the tests used for its detection (Madison ^ a]..,
1983). Studies have demonstrated that TNase activity is not specific to S. aureus.
However the TNase-evcoding gene nuc does contains sequences that are
species-specific and can be used to design S. aureus specifc primers (Gudding,
1983; LiebI Maj., 1987).
Brakstad ^ ai. (1992) described a PCR reaction which amplifies a 267 bp
portion of the nuc gene specfic to S. aureus. This PCR identified the 90 isolates of
S. aureus tested. Amplification did not occur when 80 strains representing other
staphylococcal species and 20 strains representing non-staphylococcal species
were tested. All patients swabs which contained S. aureus directly tested with this
nuc-PCR amplified the expected 267 bp product. These results indicate that a
rapid diagnosis of S. aureus is possible with a thermonuclease PCR assay.

1.4.3: Detection of S. aureus toxin genes:
S. aureus strains can produce a wide variety of toxins which are believed to
contribute to the pathogenicity of the organism. These toxins can be detected
immunologically but these assays tend to have variable sensitivities and can lack
reproducibility.
Staphylococcal food poisoning is associated with five staphylococcal
enterotoxins designated Staphylococcal Enterotoxin A (SEA), SEB, SEC, SED,
and SEE. The genes coding for SEB and SEC are chromosomally located, the
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gene for SEA is located on a bacteriophage vector and the gene for SED is
plasmid-borne. The exact location of the SEE gene is unknown (landolo, 1989).
Strains of S. aureus which contain the chromosomal tM gene which
encodes the toxic shock syndrome toxin-1 (TSST-1) are associated with the toxic
shock syndrome.
Two exfoliative toxins are associated with certain toxigenic S. aureus
strains (ETA and ETB). The gene coding for ETA is chromosomal whereas the
gene coding for ETB is plasmid-linked.
Johnson ^ai. (1991) described a number of PCR protocols which
permitted the rapid and sensitive detection of the different S. aureus toxins (the
five enterotxins A-E, the exfoliative toxins and the toxic shock syndrome toxins
described above). These toxin-PCR assays can be applied directly to whole
bacterial cells and thereby increase assay speed. The sensitivity of the toxin-PCR
assays provides a definitive determination of the presence of toxin genes and
therefore can be used as a supplementary test to confirm the results obtained by
the sometimes inaccurate conventional immunological approaches. The
possibility of multiplexing PCR primers provides opportunities for the development
of methods that can simultaneously detect a number of toxin genes, or allow
combination of toxin gene detection with other genetic determinants (such as
antibiotic resistance genes or S. aureus specific genes).
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1.5: Random amplified polymorphic DNA (RAPP):

RAPD represents a recently developed and now widely used DNA-based typing
strategy. Several studies have demonstrated the successful application of this
technique for typing multiple species of bacteria, fungi, protozoan parasites and
even human cell lines. (Bassam ^ aj., 1992; van Belkum A, 1994; Kohno ^ aj.,
1998). Table 1.5 shows a representative sample of typing studies that have been
performed successfully on various microbial species utilising RAPD technology.
Widespread application of RAPD confirms the importance and acceptance of this
approach as an epidemiological typing tool.

Table 1.5: Examples of RAPD fingerprinting studies
Organism

Reference

Mvcobacterium tuberculosis

Matsiota-Bernard

Burkolderia cepacia

Darling et^.,1998

Hameophilus influenzae

van Belkum £t al., 1997

Mvcobacterium avium

Matsiota-Bernard et al.,1997

Salmonella enteritidis

Lin et al.,1996

Acinetobacter baumannii

Sheehan at3l.,1996

Streotococcus ovooenes

Osterlund et al.,1995

Listeria monocvtoaenes

O’ Donoghue et al.,1995

Staohvlococcus haemoivticus

Young et al.,1994

Klebsiella oneumoniae

Wong et al.,1994

Camovlobacterieiuni

Fayos^ al.,1993

Candida albicans

Bostock el al.,1993

Helicobacter Dviori

Akopyanz et ai., 1992

Brucella strains

Fekete et al.,1992

1998

1.5.1: Nomenclature:
This novel PCR amplification fingerprinting strategy was described independently
by three groups and acquired three different names:
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• Arbitrarily grimed PCR (AP-PCR) (Welsh and McClelland, 1990),
• Random amplified piolymorphic DNA (RAPD) (Williams

1991), and

• DNA amplification fingerprinting (DAF) (Gaetano- Anolles ^aj., 1991).
It has been suggested that the application of these titles to DNA fingerprinting with
arbitrary oligonucleotides should be dependent on the length of the primer
employed to generate the DNA profiles (Gaetano- Anolles Mid-, 1992b). AP-PCR
uses primers of comparable length to standard PCR (18-24 bases). RAPD
analysis utilises shorter primers, typically 10 nucleotides in length and DAF
employs the shortest primers, usually 5-8 nucleotides. Each of these methods
uses low stringency PCR cycling parameters (i.e. a low PCR annealing
temperature). However, the products generated in DAF analysis were resolved in
polyacrylamide gels and were silver stained and amplicons from RAPD and APPCR were resolved by conventional agarose gel electrophoresis with ethidium
bromide staining.
Multiple arbitrary amplicon profiling (MAAPing) has been suggested as a
broad term to encompass all of these techniques. MAAPing describes the
common characteristics of each variation namely the arbitrary nature of the primertargeted sites and the amplification of a specific DNA fingerprint (Gaetano- Anolles

e\^., 1992a).
This system of nomenclature has not been universally adopted. It is evident
from recent publications that AP-PCR and RAPD are the terms most commonly
used and they are used interchangeably regardless of primer length.
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1.5.2: Principie of RAPP:
A sufficiently low PCR annealing temperature permits a primer(s) of arbitrary
sequence to anneal to many sites (which may contain a variety of mismatches)
throughout the bacterial genome. Some of these annealing sites will be within the
processive range for Tag DNA polymerase and therefore discrete PCR products
will be formed through thermocyclic amplification. Differences in the proximity,
number and location of primer-binding sites lead to the synthesis of numerous
amplicons all differing in size (Welsh etaj., 1990; Williams MiJ-, 1990; van
Belkum, 1995). The resulting mixture of amplified DNA fragments can be resolved
Into specific fingerprints by conventional agarose gel electrophoresis, (see Figure
1.9)

PCR
(RAPD)

Low stringency annealing of arbitrary primers to genomic DNA
Gel electrophoresis
of RAPD products

Figure 1.9: RAPD DNA fingerprinting strategy. Arrows in bold indicate the
primer annealing to pairs of sites that result in RAPD amplimers. The half
arrows (grey) indicate primer annealing to individual annealing sites that are
not near enough to result in product amplification. The PCR products are
resolved in an agarose gel to reveal differences between the two strains
(which reflects differences in their genomic sequences.)
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This random amplified polymorphic DNA analysis can be utilised to compare the
genomic sequences of two or more micro-organisms. The polymorphisms
observed most likely arise from nucleotide changes that alter primer binding sites,
deletions or insertions within amplified gene segments or other gene
rearrangements in the DNA from which the fingerprints are generated (Berg ^aj.,
1994).

1.5.3: Primer-template interactions:
A mechanism has been proposed to describe how a single primer can direct the
amplification of template DNA in an RAPD reaction. (Gaetano- Anolles et al.,
1992b and 1993; Bassam ^a]., 1994) This process can be divided into two
stages:
• Stage 1: In the first amplification cycle, following denaturation, the lower
annealing temperature permits primer ‘screening’ for possible annealing sites on
the template DNA. The primer anneals to many of these targets. A thermostable
polymerase anchors and initiates extension of the annealed primers. The
amplification products produced in the first round amplification should be
efficiently amplified in subsequent cycles as their terminal sequences are defined
by and therefore are complementary to the primer. However, the products derived
from a single primer amplification have palindromic ends and when present in low
concentrations these form hairpin-loop structures. The interference by hairpin-loop
formation on the amplification of each product will vary and only some will be
efficiently amplified in the cycles that follow. (Studies indicate that when a primer
is longer than 8 nucleotides it is better able to displace these loop structures.)
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• Stage 2: In the ‘late’ amplification cycles, product accumulation causes
exponential amplification to become linear. This occurs because the increased
mass of product reduces the efficiency of template denaturation and favours the
formation of product - product duplexes rather than primer - template interactions.
Amplicons present at low concentrations are now selected as templates for primer
annealing. These are preferentially amplified during the later cycles.

1.5.4: Implications of using RAPP as a typing procedure:
The development of RAPD has provided a microbial typing scheme with superior
typeability and discriminatory power when compared to traditional techniques
such as antibiograms, plasmid profiles, phage typing and PCR-RFLPs (Berg Maj.,
1994).
The major advantage of the assay is that no prior knowledge of template
DNA sequence is required (Tingey ^a]., 1993; Welsh et^., 1990). RAPD is a
rapid, relatively inexpensive and simple to perform assay. It is generally believed
that by choosing an appropriate primer, a fingerprint can be obtained for any
micro-organism. RAPD typing can allow identification of species/strain-specific
DNA fragments and thereby facilitate the development of DNA probes without
prior knowledge of the precise nucleotide sequence of the organism (e.g. Quere et
ai. in 1997 developed a 250 bp probe specific for Lactobacillus plantarum using
RAPD generated fragments unique to this organism).
The clinical applicability of RAPD typing has been questioned by reports of
lack of reproducibility (generally inter-laboratory). Experiments demonstrate that
despite the many advantages of RAPD typing, a number of parameters must be
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standardised before the assay can be utilised as a ‘universal’ typing strategy.
(BergetaJ., 1994; Power, 1996)

1.5.5: Factors affecting RAPP fingerprints:
A number of important parameters can affect the quality, quantity and
reproducibility of banding patterns produced using RAPD analysis. These include:
• Template DNA quality and concentration,
• Primer design characteristics,
• Type of thermocycler, and
• Thermostable DNA polymerase.

• Template DNA quality and concentration:
Recent reports highlight the contains conflicting views on the effects of template
concentration on RAPD profiles. Welsh and McClelland (1990) and van Belkum
(1994) suggested that RAPD fingerprints are conserved over a wide range of
template concentration. In contrast, Davin-Regli Mai- (1995), Ellisworth
(1993), and Gao

(1996) showed that variations in template concentrations

can cause amplification of variable profiles.
Various protocols have been employed to prepare DNA for RAPD analysis.
Some authors have advocated crude lysis procedures such as boiling to release
DNA from micro-organisms (van Belkum, 1994). Figure 1.10 shows a comparison
of RAPD fingerprints of Candida albicans performed on purified and crude cell
lysates. This clearly demonstrates that fingerprints generated using purified DNA
samples are consistent and reproducible for strains from the same patients and
profiles obtained using the crude lysates are inconsistent and are not
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reproducible. The inconsistencies associated with crude lysis procedures occur
because these methods do not permit exact quantification of the DNA. The DNA
may be sheared by these procedures or inhibitors may be present that alter the
efficiency of the thermostable DNA polymerase.
(a)

1

3

5

7

9

il

13

15

i7

Figure 1.10: Effect of template purity on RAPD fingerprints of Candida albicans.
(a) This gel shows the fingerprints generated using purified DNA for isolates from
4 patients: lane 2-6 isolates form patient 1, lane 7-11 isolates from patient 2, lanes
12-15 from patient 3 and lanes 16-20 isolates from patient 4. (b) This shows the
results obtained using crude boiied ceii extracts for fingerprinting (lanes as in gei
a). Lane 1 in each gei are the molecular weight markers.
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These studies demonstrate that a suitable DNA isolation procedure must be
identified and an optimal DNA concentration used if RAPD is to be utilised for
epidemiological strain comparisons.

• Primer design characteristics:
The primer sequence determines which sites on the template DNA are to be
amplified. Different primers should theoretically amplify distinct subsets of
fragments from a given template DNA. The fingerprints vary depending on the
number and frequency of annealing sites targeted by the individual primers.
Identification of an appropriate primer for RAPD should involve the screening of a
number of primers and/or primer combinations to obtain a high quality fingerprint.
Figure 1.11 shows the RAPD profiles obtained by Akopyanz ^aj. (1992) using 3
different 10-mers for typing 5 strains of Helicobacter pylori. It is evident that primer
1281 and 1254 provide informative fingerprints whereas primer 1292 is unsuitable
for H. pylori typing as very few amplification products were visible.

Primer

1281

1254

1292

Figure 1.11: Comparison of the use of three 10-mers (1281, 1254,
and 1292) for RAPD fingerprinting of Helicobacter pylori strains.
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The selection of appropriate primers should include control strains of known
epidemiology to allow assessment of the discriminatory capacity of the primers for
RAPD typing of a microbial species (Power, 1996). Similarly in analysing DNA
taken from a wide range of organisms, there appears to be an ‘optimal’ primer
required in each case. It is not unreasonable to suggest that this feature may
reflect the base content and subsequnently the codon-bias in these genomes
(unpublished observations of Cotter and Fanning).
Primer concentration can alter the banding patterns obtained in an RAPD
assay. It has been observed that increasing the ratio of primer: template leads to
the formation of smaller f^CR products. This may occur because at higher
concentrations the primer can anneal to less specific targets thus amplifying a
greater number of smaller products (Power, 1996). Figure 1.12 shows the effects
of varying primer concentration on the RAPD fingerprints of Helicobacter pylori
strain WV229. This figure also shows the shift to amplification of smaller
fragments when primer: template ratio is increased (Berg

1994).

picomoles primer/ 25 lU

Figure 1.12: Effects of primer concentration on the RAPD
profiles obtained for Helicobacter pylori strain WV229.
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• Type of thermocycler:
Variability in the reporduction of RAPD profiles has been attributed in some
studies to the make and model of thermocycler used (Meunier ^al., 1993; Penner
et aj., 1993).
Inter-laboratory reproducibility was assessed by Penner ^af. in a study
performed in 1993. Seven laboratories participated and each laboratory was
required to perform RAPD analyses on 2 genomic DNA samples with 5 different
primers using a standard (reference) procedure and the usual method employed
in their own laboratories. The results obtained when the standard method was
used by each participant were inconsistent and in a number of instances no
amplification products were observed. When each laboratory utilised the protocol
optimised in their own laboratory, RAPD polymorphisms could be successfully
reproduced. Several researchers have concluded that alterations in the
temperatures achieved by different thermocyclers, by as little as one degree
Celsius, can lead to variations in the RAPD profiles.
Figure 1.13 demonstrates the results of a temperature profile comparison of
two thermocyclers, performed by Penner

(1993). The two machines, a Coy

and a Techne thermocycler, were programmed identically. The exact
temperatures inside the reaction tubes were measured throughout the
amplification cycle using an external thermocouple inserted through the lid of the
tubes. The results demonstrate that using the different machines the temperatures
inside the reaction tubes were significantly different.
Adjusting the program of the Techne machine so the temperatures insides
the tubes mimicked exactly those of the Coy machine, significantly increased the
reproducibility of the fingerprints obtained.
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Figure 1.13: A comparison of the temperature profiles on two thermal
cyclers programmed identically. Denaturation 94*’C for 1 min, annealing
34°C for 1 min and extension 72°C for 2 min. Ramping rates were set
as fast as possible.

In contrast to Renner’s study above, it has been demonstrated that some primers
produce the same RAPD fingerprints with the same template DNA regardless of
the type of thermocycler employed (Power, 1996).
It can be concluded that when using different thermocyclers the ramping
rate and the temperatures within the reaction tubes must be similar if consistent
fingerprints are to obtained that will allow inter-laboratory comparison. Features
such as these have major implications for the adoption of a ‘universal’ typing
protocol.

• Thermostable DNA polymerase:
A number of studies have indicated that RAPD profiles are dependent on the
thermostable DNA polymerase utilised (Bassam et aj., 1992; Meunier^af., 1993;
SchienA/ater

1993). All commercially available polymerases synthesise
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DNA. However, they differ in certain characteristics (e.g. some have proof-reading
functions i.e. the 3’-5’ exonuclease activity, and some have reverse transcriptase
capacities). Scierwater Mai- (1993) compared the fingerprints obtained using 13
brands of thermostable DNA polymerases. Results demonstrated that 7 DNA
polymerases derived from Thermus aquaticus and one from Thermus flavis
produced similar (but not identical) banding patterns. Polymerases from other
sources amplified few if any amplification products. Fanning ^aj. (1997) have
compared the characterisitcs of all the tthermostable DNA polymerases available
and their results may be used to facilitate the selection of an appropriate enzyme
for particular applications.

Despite the many variables which can affect the RAPD profiles obtained, there is a
large volume of literature, which is continuously growing, describing the
successful use of RAPD for molecular typing of micro-organisms.
Intra-laboratory reproducibility is not generally a problem. Standard
techniques of DNA preparation and use of the same reagents and thermocyclers
within a laboratory has enabled many studies to utilise DNA comparatively to type
particular clusters or outbreaks of strains (Power, 1996). However, Bassam
(1994) have advocated a concept known as a “window of reproducibility”, this
involves determining the widest range of values for each reaction component over
which no variation occurs in the products amplified and then using the middle
value of this range. Further investigations are necessary to clarify the role of each
of the reaction variables. It is evident that the establishment of standard conditions
will be required in the future to allow direct comparisons of RAPD results between
laboratories (Penner^ai-, 1993).
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Reproducibility between laboratories may be improved by use of the
recently developed Ready-To-Go® RAPD analysis beads from Pharmacia Biotech
(Pharmacia, Uppsala, Sweden). These beads contain all the necessary
ingredients for successful RAPD analysis, pre-mixed and pre-dispensed as roomtemperature-stable dried beads. These beads are designed to reduce the number
of pipetting steps and ensure that each laboratory is utilising the same reagents,
thereby increasing the reproducibility of the RAPD technique, (see the
manufacturers instuctions for Ready-To-Go® RAPD analysis beads from
Pharmacia Biotech) These beads represent a significant advance in RAPD
technology. However standardisation of DMA extraction and quantification
procedures, thermocycler used and primer utilised are also required before RAPD
can be considered as definitive or ‘universal’ typing method.
In conclusion, at present RAPD is used successfully to comparatively type
micro-organisms within a laboratory setting. The advantages of RAPD including
speed, flexibility and decreased cost (when compared with other molecular
approaches) ensures that studies will continue towards developing a
standardised RAPD protocol that will permit inter-laboratory comparisons and
thereby provide the possibility of a ‘universal’ typing scheme.
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1.6: Repetitive sequence-based PCR (rep-PCR):
PCR fingerprinting using primers complementary to prokaryotic repeat elements
was first described by Versalovic et aj. in 1991. This repetitive sequence-based
PCR (rep-PCR) is similar to Alu-PCR used for fingerprinting human DNA (Nelson
^aj., 1989). Since its development rep-PCR has become an important
epidemiological tool. It has been used successfully for typing of microbial
pathogens, investigation of infectious disease outbreaks and identification of
sporadic and epidemic strains among outbreak isolates.
Table 1.6 shows some of the studies which utilise rep-PCR to type microbial
strains for epidemiological purposes.

Table 1.6: rep-PCR studies: Shows micro-organism typed and
repetitive sequence targeted
Organism
Repetitive element
Reference
Enterococcus faecalis

BoxA and REP

Malathum et al, 1998

Mvcobacterium tuberculosis

ERIC

Sechi ^al.,1998

Streotococccus oneumoniae

REP

McGee ^al., 1997

Hamoohilus somnus

REP, ERIC

Appuhamy etal.,1997

Xanthomonas fraaariae

REP< ERIC

Pooler etal.,1996

Salmonella Dublin

REP, ERIC

Kerouanton elM., 1996

Enterobacter aeroaenosa

REP, ERIC

Georghiou etal.,1995

Staohvlococcus aureus

REP

Lessing etal.,1995

Acinetobacter baumannii

REP, ERIC

Reboli elM.,1994

Leaionellasoecies

REP

Georghiou etal.,1994

Bradvrhizobium iaoonicum

REP, ERIC

Judd etal.,1993

Campvlobacter jejuni

ERIC

Endtz etal.,1993

Rhizobium meliloti

REP, ERIC

De Bruijn, 1992

Citrobacterdiversus

REP

Woods etal.,1992
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1.6.1: Repetitive DNA elements:
It is well established that eukaryotic genomes consist of numerous DNA repeat
sequences interspersed with single-copy sequences. Prokaryotic genomes,
6

9

although much smaller than eukaryotic genomes (10 bp as opposed to 10 bp),
also contain a wide variety of repeated DNA sequence elements (Lupski
1992).
Short interspersed repetitive DNA sequences (see Table 1.7) are one class
of prokaryotic repeat element (Lupski et ai., 1992: Versaolvic ^ aj., 1991),
characterised as follows:
- ranging from 15 to several hundred base pairs,
- non-coding, intercistronic sequences, and
- widely dispersed throughout the prokaryotic genome.

Table 1.7 The best characterised short interspersed repeti tive sequences.
Repeat
Organism in which originally
element

Size (bp)

REP (PU)

38

ERIC (IRU)

Ng-rep

126

26

identified

References(s)

Escherichia coli

Gilson etal.,1984

Salmonella tvDhimurium

Higgins ^^.,1982

Escherichia coli

Hulton ^ai.,1991

Salmonella typhimurium

Sharpies ^M-,1990

Neisseria aonorrhoeae

Correia etal-, 1990

Neisseria meningitidis
Dr-rep

150-192

Mx-rep

87

RepMPI

300

RepMP2

150

BOX elements
boxA

57

boxB

43

boxC

50

Deinococcus radiodurans

Lennon etal-,1991

Mvxococcus xanthus

Fujitani etal-. 1991

Mvcoolasma oneumoniae

Wenzel ^^.,1988

Streptococcus pneumoniae

Martin ^al.,1992
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Most investigators have concentrated on the characterisation of the REP
(repMitive extragenic palindromic) sequence (also known as palindromic unit or
PU), which was originally described in Escherichia coli and Salmonella
typhimurium. REP is a 38 nucleotide repeat sequence located in the untranslated
regions of operons and which has been found to be conserved in many bacterial
species. As this sequence is pallindromic , it can form a stable stem-loop structure
with a 5 bp variable loop in the central region of the sequence (Higgins et al.,
1982, Versalovic et aj., 1991).
REP sequences can occur singly or more often in multiple adjacent copies
(which are always separated by less than 25 bp and are in inverted orientation
with respect to each other). A conservative estimate of the total number of copies
of REP on the chromosome of E. cM and S. typhimurium would be between 5001000 which would represent 0.5-1% of their total genomes (Stern ^ aj., 1984).
Multiple functions have been proposed for REP sequences including:
- transcription termination,
- stabilisation of mRNA which can influence gene expression, and
- chromosomal domain organisation.
Although a number of specific REP sequences have been assigned particular
functions (Gilson Mil.,1990; Newbury

1993; Stern ^ aj., 1988), no single

function has been identified which explains their widespread distribution and
sequence conservation. Consequently, it has been suggested that REP
sequences may represent selfish DNA maintained in the prokaryotic genomes by
gene conversion (Higgins et aj., 1988).
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Another interspersed repetitive DNA element designated ERIC (enterobacterial
rep^itive intergenic consensus sequence), with no sequence similarity to the REP
sequence was originally identified in the enterobacteria. (Sharpies MaJ., 1990;
Hulton MaJ-, 1991) The ERIC sequence is approximately 126 bp in length (124127 bp) and includes a central core inverted repeat. As with REP elements, ERIC
sequences are located in non-coding transcribed regions of the chromosome.
They occur singly and can be in either orientation with respect to transcription. It
has been suggested that these ERIC sequences represent a class of selfish DNA
sequence, maintained in diverse bacterial genomes by mechanisms similar to
those described for REP sequences (Hulton ^aj., 1991).

A 26 bp consensus repeat sequence (with 5 variant positions) was identified in the
genome of Neisseria gonorrhoeae (N g-rep) by Correia ^al. (1986). This
element was found to be repeated at least 20 times in the entire genome.
Originally hybridisation experiments concluded that the Ng-rep element was
present only in Neisseria gonorrhoeae and Neisseria meningitidis. However,
more recent studies detected the Ng- rep sequence in many micro-organisms
(Lupski Mai., 1992).

A study performed by Lennon

(1991) identified a highly conserved repetitive

DNA element (desinated Di-Rep) within the genome of Deinococcus
radiodurans. This element was of variable length ranging between 150-192 bp
depending upon the presence or absence of one or two 21 bp internal sequences.
These authors suggest that the dyad symmetry within the element may indicate
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involvemant of this sequence in transcriptional and/or transalational control within
this organism’s genome.

Studies performed by Fujitani Mai- (1991) identified a number of repeat elements
within the genome of Myxococcus xanthus (these sequences were designated
RMX by these authors and have been referred to as Mx-rep elsewhere (Lupski M
1992). These repeat elements consist of an 87 bp core consensus sequence
but some of these sequences share homology with DNA outside this core region.

It is estimated that approximately 6% of the genome of Mycoplasma pneumoniae
consists of repeated DNA elements. Two such repeat elements found in Mpneumoniae are RepMPI (300 bp) and RepMP2 (150 bp). Studies indicate that
RepMPI appears at least 10 times and RepMP2 at least 8 times in the genome.
The function of these repeat elements are unknown but it has been observed that
RepMP2 is a translated part of the gene for the major cytadhesin protein PI, which
is responsible for adsorption of JM- pneumoniae to its host cell (Wenzel et
1988). Colman

(1990) documented the presence of another novel repeat in

M- pneumoniae designated SDC 1. This repeat is more than 400 bp long and it
has been concluded that this repeat element is species specific to M- pneumoniae
as it has not been found in other Mycoplasma spp (Colman Maf., 1990).

The BOX elements were the first repetitive sequences found in a Gram-positive
organism, namely Streptococcus pneumoniae (Martin et al.. 1992). There are
three different BOX elements. BoxA (57 bp) was found to be present in many
diverse bacteria including E. cdi and S. tvphimurium. However, the boxB (43 bp)
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and box C (50 bp) repeats were only found in Streptococcus pneumoniae (Koeuth
e{^., 1995).

Repetitive sequences are ubiquitous in prokaryotic genomes, despite intensive
investigations, the precise role of these elements remains a subject of debate.
However, the widespread distribution and conservation of these prokaryotic short
repeats implies they are important in the structure and evolution of these genomes
(Lupski et^-, 1992).

1.6.2: Principle of rep-PCR:
Repetitive DMA sequences are dispersed throughout prokaryotic genomes.
These repeat elements are separated by varying distances in different bacterial
strains. rep-PCR is based on the PCR amplification of the DMA between
prokaryotic repeats.
Outwardly facing primers complementary to interspersed repetitive
sequences (with the base inosine at redundant/non-conserved positions) are
employed to direct the amplification of the intervening DMA between two repeats.
The primers bind to the repetitive sequences in the prokaryotic genome and if the
primer annealing sites are in the proper orientation and within a distance that can
be amplified by Tag DMA polymerase, an amplification product is obtained.
Multiple amplicons are produced and can be size fractionated by agarose
gel electrophoresis to reveal a specific DMA fingerprint for a bacterial strain
(Versalovic ^ ai., 1991). (see Figure 1.14)
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Figure 1.14: rep-PCR fingerprinting strategy. Outwardly facing primers,
complementary to repeat motif elements present in microbial genomes,
are used to direct amplification of the intervening sequences. The random
distribution of these elements generates variably size DNA fragments upon
amplification, which can be resolved by agarose gel electrophoresis. These
fragment arrays (or fingerprints) are characteristic of individual microbial strains.

1.6.3: Implications of rep-PCR in clinical applications:
For rep-PCR fingerprinting, it is important that the repetitive sequences used in
genomic fingerprinting are stable for a particular strain over long periods of time.
This has been clearly demonstrated in studies on the ATCC 11633 strain of
Xanthomonas campestris pv. vesicatoria group A. This strain was first described
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in the 1940s and isolates obtained from Taiwan, Mexico and various locations in
the U.S. over the last few years have nearly identical fingerprint profiles when
compared with the original isolate (Gao ^aj., 1996; Louwz et aj., 1994).
An essential characteristic of rep-PCR is an ability to discriminate between
distinct bacterial isolates with sufficient resolution and reproducibility. Sechi ^aj.
(1998) utilises rep-PCR based on the ERIC repetitive element to distinguish
between strains of Mycobacterium tuberculosis. IS 6110 fingerprinting has been
used worldwide to classify M- tuberculosis strains and therefore this strategy was
used as a reference method. ERIC-PCR was able to differentiate 3 strains of Mtuberculosis that infected the same patient whereas IS 6110 fingerprinting was
unable to discriminate between these strains. These strains were confirmed to be
different by PCR-GTG and PCR-ribotyping systems (Sechi etai-, 1998).
It is clear from the many studies which use rep-PCR that it meets the criteria
of a ‘universal’ typing strategy. With rep-PCR, all strains are typeable,
discriminatory capacity is excellent and high reproducibility is attainable with the
use of standardised amplification conditions.

1.6.4: Differences between rep-PCR and RAPP:
The major difference between rep-PCR and RAPD is the length of the primers
used for PCR amplification and the corresponding PCR amplification conditions.
Arbitrary primers typically 10 bases in length (but primer length can vary from 5 to
34 nt) are employed for RAPD analysis. rep-PCR involves the use of primers of
18-24 bp which target repetitive sequences (with high homology) in prokaryotic
genomes. The use of repetitive sequence primers in rep-PCR allows high
stringency PCR cycling conditions to be used to generate fingerprint profiles
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(RAPD is a low stringency PCR amplification protocol with annealing temperatures
that can be as low as 25°C). High stringency rep-PCR reduces experimental
variation and PCR artefacts which may occur in approaches such as RAPD where
the annealing temperature is low (Louwz ^ai., 1994).
rep-PCR is applicable for the typing a wide variety of bacterial species e.g.
ERIC-PCR is a versatile typing scheme as is evident from its ability to type
numerous Gram-positive and Gram-negative bacteria including Enterobacter
aerogenes (Georghou Mai-, 1994), Acinetobacter baumannii (Reboli M^-, 1994),
Escherichia coli (Dalla-Costa MM-, 1998), Staphylococcus aureus (Lipman MiJ.,
1996) and Listeria spp. (Jersek M aj-, 1996). RAPD fingerprinting (of different
bacterial species) requires testing a number of arbitrary primers to obtain optimal
results. The selected arbitrary primer may yield suitable fingerprint profiles in a
particular microbial species and may fail to amplify DMA of another species. repPCR eliminates the necessity for screening large numbers of primers as in RAPD
analysis. It enables a rational approach to primer design such that a limited set of
repetitive sequence primers can be tested to elucidate an effective PCR
fingerprinting method for any bacterial species.
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1.7: Fluorescent [F]- DNA fingerprinting:
The application of RAPD and rep-PCR fingerprinting in large-scale
epidemiological investigations is confounded by the limiting technical features of
conventional agarose gel electrophoresis. Difficulties are encountered when
attempting to align banding patterns from different gels over long periods of time.
Variations in electrophoertic separation reduces the accuracy of fragment size
estimation, making data reliability problematic (Butler ^ai., 1996; Grundmann et
aj., 1995a).
In recent years, a step towards automating of RAPD and rep-PCR has been
described (Del Vecchio

1995; Grundmann ^ aj., 1995 a and b; Versalovic et

ai., 1995). These techniques involve PCR amplification combined with the
detection of fluorescent products using either single or multi-dye analysis in
automated DNA sequencers (e.g. the Pharmacia ALF analyser or Perkin Elmer
Applied Biosystems ABI 310, 373 and 377 genetic analysers).
Two types of fluorescent PCR-based fingerprinting have been reported, namely:
1. RAPD-ALFA (RAPD-automated laser fluorescent analysis) which
involves the generation of fluorescent random-primed amplicons that are
subsequently analysed using the Pharmacia ALF DNA sequencer (Grundmann ^
a]., 1995 a and b; Niemann ^aj., 1997).
2. FERP (fluorophore-enhanced-repetitive-PCR) which combines rep-PCR
with fluorescent detection of the DNA fragments amplified using an ABI genetic
analyser with GeneScan analysis software (Del Vecchio et al.. 1995; Versalovic^
al., 1995).
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Both are based on the same principle: Briefly a fluorescent dye is covalently linked
to the 5’- end of the oligoonucleotide used for PCR fingerprinting (either the 5’ end
of the single arbitrary primer used for RAPD-ALFA or to the 5’- end of one of the
two repetitive sequence primers used for FERP). The [F]-labelled amplimers are
detected after PCR using a commercially available laser scanning device as
outlined above. During electrophoresis the fluorescent amplicons are excited by
the argon laser resulting in a signal being emitted that is recorded by the
photomultiplier tube in the scanning unit. The emitted light signals are collected at
regular intervals throughout the electrophoretic process (e.g. every 2.5 sec), these
signals are digitised and sent to a dedicated computer for processing and storage.
The result format is that of a multicoloured electropherogram with its
corresponding tabular data (Grundmann et a]., 1995 a and b; Versalovic et a].,
1994).
Differentially labelled internal standards are included in all lanes of the gel.
the analysis software can use these size standards to create a calibration curve of
peak detection time that can then be used to automatically size the PCR products.
The use of these internal standards in addition serves to compensate for potential
variability in lane to lane band migration which may result from inconsistencies in
the gel matrix (Butler

1996). Furthermore this feature ensures consistent

quality in terms of both data collection and retrospective analysis.
This technology has been applied successfully to a variety of pathogenic
micro-organisms including Citrobacter diversus. Escherichia coli Streptococcus
pneumoniae. Pseudomonas aeruginosa and Staphylococcus aureus (Cotter ^
al., 1998; Del Vecchio et ai., 1995; Grundmann etaj., 1995b; Versalovic et
1994). Results have indicated that PCR fingerprinting profiles were identical
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irrespective of whether they were generated with fluorescently labelled or
unlabeled primers (Niemann Maj., 1997; Cotter and Fanning unpublished data).
In a study performed by Del Vecchio et a]., (1995), rep-PCR and FERP were used
to type strains of methicillin-resistant Staphylococcus aureus. All amplified bands
visible by rep-PCR were observed by FERP. Notably however, a high intensity
band at 325 bp in an agarose gel was resolved into two distinct bands after FERP
analysis. This increased resolution suggests that fluorescent analysis is a more
sensitive approach when compared with unlabelled RAPD or rep-PCR using
agarose gels for fragment separation. The added resolution provided by FERP
could be important in strain differentiation helping to document strain evolution.
Versalovic Maj. (1994) have demonstrated that identical DNA fingerprint
patterns (with only minor variations in peak intensity) were obtained using FERP
with either purified DNA or intact whole microbial cells. This finding has been
confirmed for a variety of Gram-positive and Gram-negative organisms. FERP
DNA fingerprints generated directly from bacterial cells can considerably
increases the speed of fingerprinting and may permit concurrent analysis of an
epidemic.
Grundmann ^ aj. (1995a) assessed the efficiency of RAPD-ALFA for
epidemiological analysis of a cluster of Pseudomonas aeruginosa strains causing
a ventilator-associated pneumonia in a medical ICU. Restriction endonuclease
analysis of genomic DNA resolved by PFGE was the reference method used.
RAPD-ALFA typed each of the isolates and the results were in concordance with
PFGE results. The high resolution obtained by RAPD-ALFA matched that of
PFGE. It was estimated that approximately 90 hours were required for PFGE
whereas RAPD-ALFA results were available after six hours isolated from colonies
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on an agar plate. The speed and sensitivity of these fluorescent fingerprinting
strategies may provide a suitable typing scheme for routine epidemiological
investigations (Grundmann ^aj., 1995 b).
A comparative study was performed by Niemann et aj. (1997) to evaluate
the resolving power of RAPD-ALFA and FERP (using ERIC derived primers) for
discrimination of Rhizobium meliloti strains. Comparison of the strain
classifications obtained using RAPD-ALFA and rep-PCR showed that the Rh.
meliloti strains were grouped almost identically by both methods. Among a
population of 21 strains, RAPD-ALFA resolved 12 groups (designated A-L) and
ERIC-FERP revealed 11 groups (1-11). The results of the study showed that
RAPD-ALFA was more discriminating among the Rh. meliloti strains analysed than
ERIC-FERP although both approaches were suitable for typing as they could
reveal genetic relatedness among strains at a fine scale. RAPD-ALFA requires
the testing of a number of arbitrary primers to select for an appropriate primer that
provides optimal results. Therefore, it has been suggested that FERP (because it
is based on conserved repetitive sequences) may provide a more versatile assay
that could be used for a wide variety of microbial species. (Niemann Mai-, 1997)
Another significant advance in this automated technology has been primer
multiplexing which has been demonstrated in studies performed by Versalovic M
al- (1994). and Del Vecchio Maj. (1995). Detection of specific bacterial genes
(e.g. toxins, adhesion protein genes, antibiotic resistance genes) can be
combined with fluorescent fingerprinting. Versalovic adapted FERP to allow
simultaneous strain differentiation and detection of Shiga-like toxin 11 (SLT-II) of
enterohaemorrhagic Escherichia coli strains. The analysis was performed using a
fluorescent ROX-tagged primer complementary to the BOX repetitive sequence in
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combination with a primer set for the amplification of a segment of the SLT-II gene
(one of which was labelled with a TAMRA fluorescent dye). The results indicated
that a simultaneous DNA fingerprint and SLT-II detection is possible using
fluorescent GeneScan technology. Only strains of enterohaemorrhagic E. coN
which produce the SLT-II toxin are implicated in the pathogenesis of haemolytic
uraemic syndrome. The development of multiplex assays are important because
they permit fast and sensitive evaluation of potential public health problems by
providing simultaneous gene detection and strain typing data (Versalovic et M-,
1994).
Although FERP does represent a significant step towards an automated
strain typing system, it is hoped that improvements in the software will permit the
establishment of fingerprint databases. Such databases will enable archiving of
DNA fingerprint data and comparison of new isolates with those previously
entered in the database. These comparisons will allow the identification of
aggressive pathogenic strains and implementation of appropriate control
measures. In 1994, the Centre for Disease Control and Prevention in the USA
began the development of Emerging Infections Programs (EIPs) in state
departments. EIPs are sites that conduct special surveillance programs which
perform collaborative epidemiological studies between health departments and
academic institutions. These networks provide data on the prevalence of different
infections, the emergence of new strains and evaluate prevention efforts
(Foodborne Disease Active Surveillance Network, 1996). Niemann

(1997)

have reported the establishment of a limited database for Rhizobium meliloti. it is
hoped that global databases will be developed in the near future for all microbial
pathogens.
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Cost is a limiting factor in the widespread application of these fluorescent
technologies. DNA sequencers, such as the ALF and ABI systems, are expensive
(however laboratories may already have acquired these instruments for other
purposes and fluorescent fingerprinting may represent an additional application of
these analysers). Fluorescently labelled oligonucleotides (although becoming
more competitively priced) are significantly more expensive than their unlabelled
counterparts.
For comparative studies on small numbers of isolates, visual inspection of
agarose gels is sufficient. The inherent problems of inter-gel comparisons, when
studying large numbers of isolates, warrants the use of automated technologies.
The cost of RAPD-ALFA and FERP can be justified in large scale investigations or
in studies where high resolution of microbial strains is required. Also it is only
through computerised systems, such as RAPD-ALFA and FERP that microbial
databases can be established.
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Section 2
Materials

and

Experimental

Methods

Objectives
The number of cases of methicillin-resistant Staphylococcus aureus reported by
Irish hospitals each year continues to increase. Prevention of infection is possible
and essential as the options for treatment are very limited. Extensive surveillance
programs are necessary to allow epidemiological evaluation of the MRSA status
within a health care facility. Such programs require sensitive and specific MRSA
detection assays and strain typing systems.

With a view to developing a combined MRSA detection and molecular typing
strategy, the main objectives of:
(i)

Development of a multiplex-PCR (mPCR) assay to facilitate
sensitive and specific detection of clinical MRSA isolates.

(ii)

Assessment of the genetic relationship(s) among 2 hospital
outbreaks of MRSA using an optimised PCR-based DNA
fingerprinting strategy.
Subsequent automation of (i) and (ii) above.

(iii)

Sequence characterisation of selected DNA fragments from RW3A
fingerprinting arrays, to determine their genomic origins.
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This section is divided into two parts:
Section 2.1 Materials describes the chemicals, reagents, buffers and equipment
necessary for the experimental work performed.
Section 2.2 Experimental Methods describes in detail the methodologies used to
achieve the objectives set out in this project.

2.1: Materials:
All reagents marked with an asterisk (*) were autclaved at 121°C for 15 min.

2.1.1: Bacterial Isolates:
All clinical isolates of MRSA were obtained from two outbreaks in the Cork
University Hospital. Outbreak 1 occurred from January to June of 1995 and
outbreak 2 occurred during the same period of 1996. Isolates of methicillinsensitive S. aureus (MSSA), coagulase negative staphylococci (CNS) and other
microbial species were also acquired as control strains.
All strains were preserved and stored on cryobeads at -20°C (Technical
Service Consultants Ltd, Lancashire, UK).

2.1.2: Comparison of DNA Extraction Procedures for MRSA:
2.1.2.1: Lysis buffer technique:
Cellular lysis buffer*: 10 mM Tris-HCI [pH 8.3], 50 mM KCI. 0.1% Tween 20.
This buffer was aliquolted and stored at 4°C.

2.1.2.2: CTAB lysis procedure:
10X TE buffer*:

100 mM Tris-HCI [pH 8.0], 10 mM EDTA.
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1X TE buffer*:

1 volume of 10X TE buffer was added to 9 volumes of sterile
dH20.

0.1XTE buffer*:

One volume of 10X TE buffer was added to 99 volumes of
sterile dH20.

Lysozyme:

Ten milligrams of lysozyme (Sigma, Poole, UK) in 1 ml of 1X
TE buffer giving a final concentration of 10 mg/ml. Aliquoted
and stored at -20°C.

Proteinase K:

Prepared to a final concentration of 10 mg/ml in IX TE buffer.
Aliquoted and stored at -20 °C.
Obtained in lyophilised form from Sigma (Sigma, Poole, UK).

10% SDS:

1 gram of sodium dodecyl sulphate (SDS) was added to
10 ml of sterile dH20 and heated to 65°C to dissolve the SDS.

24:1 chloroform-isoamylalcohol : 48 ml of chloroform and 2 ml of isoamylalcohol
were mixed and stored at room temp.
5 M NaCI*:

ASM solution was prepared by dissolving 29.2 g of NaCI in
100 ml of distilled water.

70% Ethanol:

Stored at 4 C.

Isopropanol:

Stored in a dark bottle at room temperature.

CTAB/NaCI:

To 80 ml of sterile water was added 4.1 g of NaCI. While
stirring this NaCI solution, 10 g of N-cetyl-N, N, N, trimethyl
ammonium bromide (CTAB) (obtained from Sigma [Sigma,
Poole, UK]) was added. This mixture was heated to 65°C to
dissolve the detergent and then the volume was adjusted to
100 ml. This solution was then stored at room temperature.
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2.1.2.3: Lysostaphin lysis procedure:
1M NaCI*:

Prepared by dissolving 5.84 g of NaCI in 100 ml of distilled
water.

TE solution*: 50 mM Tris-HCI [pH 8.0], 50 mM EDTA
Lysostaphin:

Obtained from Sigma (Sigma, Poole, U.K).
Prepared to give a final enzyme activity of 15-20 U/uL in
sterile dH20. Aliquoted and stored at -20 °C.

20% SDS:

Twenty milligrams of sodium dodecyl sulplhate (SDS) was
added to 20 ml of sterile dH20 and heated to 65°C dissolve
the SDS.

Proteinase K:

Obtained from Sigma (Sigma, Poole, Dorset, U.K).
Prepared to a final concentration of 10 mg/ml in sterile dH20.
Aliquoted and stored at -20 °C.

Phenol:Chloroform:lsoamylalcohol mix:
To 100 ml of liquid phenol, 100 ml of 1M Tris-HCI [pH 8.0]
was added and stirred overnight at room temperature or until
the pH of the phenol phase was 7.4. One hundred millilitres
of a chloroform:isoamylalcohol (1:1) mix was then added to
the phenol phase and mixed for 3-4 hr. A few crystals of
8-hydroxyquinilone was added to give a yellow colour.
3M ammonium acetate: This solution was prepared by dissolving 11.6 g of
ammonim acetate in 50 ml of sterile water. This solution was
filter sterilsed and then stored at room temperature.
Ethanol (100% and 70%): Stored at 4°C.
IX TE solution*:

10 mM Tris-HCI [pH 8.0], 1 mM EDTA
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2.1.3: Agarose gel electrophoresis:
Agaroses:
Agarose obtained from Promega (Promega, Madison, Wl).
NuSieve""" Agarose was purchased from FMC Bioproducts (FMC
Bioproducts, Rockland, ME).

Ethidium bromide:
Obtained from Sigma (Sigma, Poole, UK) and prepared to give a 10 mg/ml
final concentration in sterile distilled H2O.

Electrophoresis buffers:
10X Tris-Acetate-EDTA (TAE)*: 40 mM Tris, 40 mM glacial acetic acid, 2 mM
EDTA [pH 7.8].
10X Tris-Borate-EDTA (TBE)*: 90 mM Tris, 90 mM boric acid, 2.5 mM
EDTA [pH 8.3].
10X Loading buffer: 6.6 ml glycerol, 3.3 ml 10X TBE, 100 |il 10% (w/v)
bromophenol blue.

Molecular weight markers:
To allow size estimations of DMA fragments, three molecular weight markers were
used. The grade III and grade V molecular weight markers were obtained from
Boehringer Mannheim (Boehringer Mannheim, Germany) and the (|)X174
DNA/Haelll marker was obtained from Promega (Promega, Madison, Wl.)
i. Grade III DNA molecular weight markers: lambda DMA cleaved with
EcoRI and Hind III. This consists of 13 DNA fragments ranging in size from
125 bp to 21.2 kb.
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ii. Grade V molecular weight markers: The size range of these markers is
8 -587 bp (22 fragments) and these were generated by digesting pBR322
with Haelll.
iii. The (j)X174/Haelll marker was made by complete digestion of (j)X174
DNA with the Haelll restriction endonuclease. The eleven DMA fragments
in this marker range in length from 72 bp to 1.3 kb.
(see Appendix 1 for details of molecular sizes of these markers)

2.1.4: Polymerase Chain Reaction (PCR):
2.1.4.1: Reagents for PCR:
Tag DNA polymerase:
Tag DNA polymaerase was obtained from Promega (Promega, Madison, Wl). The
enzyme was supplied with a 10X reaction buffer (500 mM KCI, 100 mM Tris-HCI
[pH 9], 1% Triton-X-100) and 25 mM MgCl2 (PCR-grade). These reagents were
stored as recommended at -20^0.

dNTP mix:
Deoxyribonucleoside triphosphates were obtained from Promega (Promega,
Madison, Wl) at a concentration of 100 mM. A working dNTP mix was prepared by
mixing 2.5 |il of each dNTP (dATP, dGTP, dCTP and dTTP) in 190 pi of sterile
dH20. The final concentration of each dNTP in the mixture was 1.25 mM. The
stock dNTPs and the working mixture were stored frozen at -20^0 prior to use.

Gitschier PCR buffer:
A 10X Gitschier PCR buffer contained 166 mM ammonium sulphate, 670 mM TrisHCI. 67 mM MgCl2, 100 mM p-mercaptoethanol and 67 pM EDTA (Kogan ^a]..
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1987). This buffer was used when DNA fingerprinting with REPIR-Dt and REP2Dt primers.

DMSO:
Dimethyl sulphoxide was obtained from Sigma (Sigma, Poole, UK).

Sterile water and mineral oil:
Distilled / HPLC grade dH20 and mineral oil (Sigma, Poole, Dorset, UK) were
sterilised by autoclaving at 121°C for 15 mins.

2.1.4.2: PCR primers:
/.

DNA fingerprinting primers:

To obtain a suitable primer for fingerprinting MRSA isolates, a variety of primers
were screened to determine their typeablility and discriminatory capacity (LC-1;
LC-2; LC-3; LC-4: LC-5; REPIR-Dt, REP2-Dt [Versalovic^ai, 1991]; RW3A [Del
Vecchio ^ai, 1995]). The sequence of these primers are shown below in table
2.1. These oligonucleotides synthesised and purified by PAGE (R&D Systems,
Abingdon, UK).
The concentration of these primers was calculated as follows:

Concentration of primer =

Absorbance260nm
Molecular weight of primer

The molecular weight of the primer was calculated by multiplying the molecular
weight of the individual bases by the number of that particular base in the primer
sequence:
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Mol. wt. of adenine (A) = 15.4 iimol/ml
Mol. wt .of thymine (T) = 8.8 jimol/ml
Mol. wt. of cytosine (C) = 7.3 |imol/ml
Mol. wt. of guanine (G) = 11.7 |imol/ml

All primers were aliqouted after synthesis and stored in small volumes at -20^C to
obviate repeated freeze thawing.

Table 2.1: DNA fingerprinting primers:
Primer
Sequence (5’->3’)

Reference

LC-1

TGTTGC GCAG

-

LC-2

TCT GTA TTG TCT TTT TCA CC

-

LC-3

TTA ATA GCA CCC GGT ACA AGT

-

LC-4

1TA CGG CGT TAG TAT CCT CTC TA

-

LC-5

GGT CTC GGT CAG ATA TGT GAT TC

-

REP1R-Dt
REP2-Dt
RW3A

III NCG NCG NCA TCN GGC

Versalovic etal., 1994

NCG NCT TAT CIG GCC TAG
TCG CTC AAA ACA ACG ACA CC

Del Vecchio et^M 1995

R-Dt and REP2-Dt were used together in a rep-PCR strategy.)
Other characteristics of these primers are reviewed in table 3.7.

The annealing temperature (T annealing) ^or each of these primers was
calculated using the following formula:

T melting point = 2 (A+T) + 4 (G+C)

T annealing = T melting point - 5
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a. Triplex-PCR primers:
Direct MRSA detection was performed in a multiplex-PCR assay designed to
permit simultaneous amplification of DNA targets specific to MRSA. The DNA
sequences of the primers used in this PCR were taken from previously published
work (Brakstad et al, 1992; Corbett

1994; Cotter et al., 1997; Kizaki M ai.,

1994) and were as shown in table 2.2.
The primers were obtained in a purified form from R&D Systems (R&D Systems,
Abingdon, UK), and the concentrations and annealing temperatures of each of the
primers were calculated using the formulas shown above.

2.1.5: GeneScan Analysis:
2.1.5.1: Fluorescent PCR primers:
Fingerprinting primer:
• 6-carboxyfluorescein (FAM) labelled RW3A (Del Vecchio ^al., 1995) was the
main primer used in fluorescent MRSA fingerprinting.

Triplex-PCR:
• 4,7,2’,7’-tetrachloro-6-carboxyfluorescein (TET)-labelled mecA antisense primer
TET-labelled fern A antisense primer
TET-labelled nuc antisense primer
The sequences of these primers were as in section 2.1.4.2

All fluorescently labelled oligonucleotides were obtained from Perkin-Elmer
Applied Biosystems (ABI, Cheshire, UK).
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2.1.5.2: Purification of PCR products:
All PCR products for GeneScan analysis were purified according to the
manufacturers instructions to remove excess primers, nucleotides, polymerases,
and salts using the QIAquick PCR purification spin columns. This purification kit
was purchased from QIAGEN Ltd. (QIAGEN Ltd., West Sussex, UK) and contained
spin columns, collection tubes and buffers PB and PE (96-100% ethanol must be
added to PE prior to use).

2.1.5.3: Genetic analyzer reagents:
Obtained from PE Applied Biosystems (ABI, Cheshire, UK).
- GeneScan™ Polymer
- 10X 310 Genetic Analyzer Buffer (GAB)
Additional requirements;
- 0.5 M EDTA and HPLC grade water (obtained from Merck, Darmstadt,
Germany).

Preparation:
• 10 ml 2.5% GeneScan™ polymer was prepared by combining the following:
- 3.5 g GeneScan™ polymer
- 1 ml genetic analyzer buffer (10X)
- 20 ^il EDTA (0.5 M)
- 5.5 ml HPLC water
• 20 ml IX genetic analyzer buffer was prepared by adding:
- 2 ml genetic analyzer buffer
- 40 ^1 EDTA (0.5 M)
- 18 ml HPLC water

87

2.1.5.4: GeneScan molecular weight standards:
GeneScarT 2500-ROX or -TAMRA:
This standard is prepared by restriction endonuclease digestion of lambda phage
CNA with Pst1 followed by ligation of the fragments with a ROX (6-carboxy-Xrhodamine) or TAMRA (N,N,N’,N’-tetramethyl-6-carboxy-rhodamine) dye. This
s:andard consists of 28 fragments ranging in size from 55 to 14,097 bp.

GeneScan™ 500-TAMRA:
This standard consists of fragments of between 35 and 500 bp in size. It is
prepared by PM1 digestion of proprietary plasmid DNA followed by ligation of a
TAMRA labelled 22-mer oligonucleotide to the cut ends. A subsequent enzymatic
digestion with BstUI yields DNA fragments with a single TAMRA dye.
(see Appendix 2 for details of these GeneScan standards)

2.1.6: Characterisation of amplicons of interest from RW3A
fingerprints:
2.1.6.1: Extraction of band of interest from agarose gel:
This was performed using the QIAquick Gel Extraction Kit from QIAGEN Ltd., West
Sussex, U.K. This kit contains spin cloumns, collection tubes, buffer QG and PE
(96 -100% ethanol must be added to PE buffer prior to use).
Isopropanol (100%) is also required for this extraction procedure.

2.1.6.2: Cloning DNA fragments of interest:
• The Original TA Cloning® Kit (Invitrogen BV, Netherlands) was used for cloning
of DNA fragments of interest following reamplification.
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This kit was supplied in two boxes:
Box 1: TA Cloning® Reagents were stored at - 20°C
This contains:
- Linearised pCR®2.1 (25 ng/|il) vector in 10 mM Tris-HCI [pH 7.5], 1 mM
EDTA. (see Appendix 3 for plasmid map),
~ 10X ligation buffer: 60 mM Tris-HCI [pH 7.5], 60 mM MgCl2, 50 mM NaCI,
1 mg/ml bovine serum albumin, 70 mM p-mercaptoethanol,
1 mM ATP, 20 mM dithiothreitol, 10 mM spermidine),
- T4 DMA Ligase (4.0 Weiss units/|il),
- Sterile water (deionised, autoclaved water), and
- The necessary reagents for the PCR amplification of a control DMA
segment (i.e. 100 mM dNTPs, 10X PCR buffer, forward and reverse primers
and control DMA template) which is then ligated to the vector.

Box 2: One Shot'"' Competent Cells which were stored at -80°C.
This contains:
- Aliqouted INVaF’ super competent E. cM cells,
- (3-mercaptoethanol (0.5 M),
- SOC medium containing 2% tryptone, 0.5% yeast extract, 10 mM NaCI,
2.5 mM KCI, 10 mM MgCl2, 10 mM MgS04, 20 mM dextrose, and
- Transformation control plasmid- pUC18.
Genotype of INVaF’ cells: F’ endAI recAl hsdR17 (rk’,mk'^) supE44 thi-1 gyrA96
relAI (l)80lacZAM15 A(iacZYA-argF) U169 X-
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Additional requirements for cloning:
• X-Gal stock solution: 40 mg/ml 5-bromo-4-chlroro-3-indolyl-p-D-galactoside (XGal) in DMF.
• LB agar plates containing 1% tryptone, 0.5% yeast extract, 1% NaCI , 15 g/l
agar (pH 7). Ampillicillin (50^g/ml) andX-Gal stock (40 mg/ml) were added
to the cooled autoclaved agar before the plates were poured.

2.1.6.3: Quick screen for plasmids with insert:
• Buffer 1: 0.2 N NaOH, 1% SDS, (freshly prepared and stored at room
temperature).

• Buffer 2: 3 M potassium acetate, 1.8 M formic acid

• Lysis buffer was prepared as follows:
- 9 volumes of 2.5% bromophenol blue, 0.25% xylene cyanol, 25% Ficoll type
400,
- 11 volumes of sterile distilled water, and
- 40 volumes of buffer 1.

The lysis buffer and buffer 2 were made in advance and stored at room
temperature.

2.1.6.4: Isolation of plasmids from cells:
• Wizard® Plus SV Minipreps DMA Purification System (Promega, Madison Wl)
was used according the manufacturers instructions. Each kit contains the
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reagents for plasmid isolations from 1-10 ml of bacterial culture. The kit contains
the following:
- Cell resuspension solution (50 mM Tris-HCI [pH 7.5], 10 mM EDTA, 100 iig/l
RNase A.),
- Cell lysis solution (0.2 M NaOH, 1% SDS),
- Neutralisation solution (4.09 M guanidine hydrochloride, 0.759 M potassium
acetate, 2.12 M glacial acetic acid [pH 4.2]),
- Column wash solution (95% ethanol must be added as instructed.
Final concentration = 60 mM potassium acetate, 10 mM Tris-HCI [pH 7.5], and
60% ethanol),
- Miniprep spin columns,
- Collection tubes,
- Alkaline protease solution, and
- Nuclease-free water.

Also required:
• Tryptone soya broth: Supplied by Oxoid, Hampshire, UK.
Formula: Pancreatic digest of casein (17 g/l), papaic digest of soybean (3 g/l),
NaCI (5 g/l), dipotassium phosphate (2.5 g/l), and glucose (2.5 g/l).
Preparation: 100 ml of broth was prepared and aliquoted into 5 ml volumes and
these were then autoclaved at 121°C for 15 min.

• EcoRI (12 U /|il) obtained from Promega, Madison, Wl, the enzyme is supplied
with buffer H for maximal activity.
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2.1.6.5: DNA sequencing reagents:
Sequencing reactions were performed using ABI 377 sequencers located at the
Medical Genetics Centre, Uppsala, Sweden. For sequencing using the ABI 377
DNA sequencers dye primer sequencing chemistries were utilised.

This protocol required:
• ABI Prism™ Dye Primer Cycle Sequencing Core Kit: This kit contains:
- 5X sequencing buffer (400 mM Tris-HCI [pH 9.0], 10 mM MgCy
- 100 M-l each of d/dd C mix, d/dd A mix,
- 200 111 each of d/dd T mix, and d/dd C mix,
- 100 111 of AmpliTaq DNA polymerase FS,
- 40 pmol of FAM Dye T7 primer; use with d/dd C mix,
- 40 pmol of JOE Dye T7 primer, use with d/dd A mix,
- 80 pmol TAMRA Dye T7 primer, use with d/dd G mix, and
- 80 pmol ROX Dye T7 primer, use with d/dd T mix.
The AmpliTaq enzyme was diluted prior to use by adding 1 |ii of the AmpliTaq
DNA polymerase FS, 1 |il of 5X sequencing buffer and 5 |il of sterile water.

• A 4% polyacrylamide gel was prepared for the ABI Prism™ 377 DNA sequencer
using analar grade urea, 40% acrylamide stock (38 grams of acrylamide and
2 grams of bis-acrylamide), 10X TBE, 10% ammonium persulphate and TEMED
(N,N,N’,N-tetramethyl-ethylenediamine).

Also required for this protocol were 95% ethanol, deionised formamide, a loading
buffer consisting of 25 mM EDTA [pH 8.0] with blue dextran (50 mg/ml), and sterile
water.
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• The T7 promoter sequencing primer and the M13 reverse sequencing primer
were obtained from Boehringer Mannheim (Boehringer Mannheim, Germany).
The sequences of these primers were:
T7:

5’- d(CGC GCG TAA TAG GAG TGA GTA TAG) -3’

M13: 5’- d(GAG GAA AGA GGT ATG AG)

In additon to the above 95% ethanol, 70% ethanol, and 3 M sodium acetate were
also required.

2.1.7: DIG-detection strategies of MRSA:
2.1.7.1: DIG-labelling of PGR products:
PGR DIG labelling mix was obtained from Boehringer Mannheim (Boehringer
Mannheim, Germany. This mix consists of a 10X solution of 2 mM each of dATP,
dGTP, dGTP, 1.9 mM dTTP and 0.1 mM DIG-11-dUTP prepared in distilled water
(pH 7.0).
Precipitation of DIG-labelled PGR product was achieved using 4 M LiGI and cold
absolute ethanol.

2.1.7.2: Detection of DIG-labelled PGR product:
DIG Nucleic Acid Detection Kit purchased from Boehringer Mannheim (Boehringer
Mannheim, Germany). This kit contains DIG-labelled control DNA, DNA dilution
buffer, Anti-DIG-Alkaline Phosphatase (AP) conjugate (750 units/ml), NBT/BGIP
(NBT = 4-nitrobluetetrazolium, BGIP = 5-bromo-4-chloro-indolyl phosphate), stock
solution in 67% DMSO, and blocking reagent.
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2.1.7.3: Materials for colourimetric “dot blot” analysis:
•Buffer 1: 10 mM Tris-HCI [pH 7.5], 150 mM NaCI.

•Buffer 2: This buffer was freshly prepared by dissolving 1.5 g of blocking reagent
in 150 ml of buffer 1 at 50-70°C for 2 hr.

•Buffers: 100 mM Tris- HCI [pH 9.5], 100 mM NaCI, 50 mM MgCl2.

•Buffer 4: 10 mM Tris-HCI (pH 8.0), I mM EDTA.

• DIG-antibody-AP-conjugate (from the nucleic acid detection kit) was diluted to
150 mU/ml in buffer 1.

• The nylon membranes used for the ‘dot blot’ were lmmobilon™-N Transfer
membranes from Millipore (Millipore, Hertfordshire, UK).

2.1.7.3: Materials for Colour Amplified PCR detection system (CAPS):
•Coating buffer: 0.05 M Na2C03, 0.05 M NaHC03 [pH 9.6].

• Washing solution: 10 mM Tris-HCI [pH 8.0], 150 mM NaCI, 0.05% Triton X-100.

•Sample buffer (PBST): 1 in 10 dilution of PBS (phosphate buffered saline) stock
(Sigma, Poole, UK) [pH 7.2], 0.05% Tween-20.

•Conjugate buffer: 10 mM Tris-HCI [pH 7.5], 150 mM NaCI, 1% blocking reagent.
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• Anti-DIG Fab fragments from sheep obtained from Boehringer Mannheim (0.20.4 |ig/ml).

• The DIG-antibody-AP conjugate was diluted to 150 mU/ml in conjugate buffer.

• Colour detection for this assay was using the Ampak™ Amplification Kit K6200
(Dako Diagnositcs, Cambridgeshire, UK)

2.1.8: Investigation of the ‘Accordion Effect’:
• TURBOBLOTTER™ Rapid Downward Transfer Systems with nytran membranes
(7x8 cm) obtained from Schleicher & Schuell, New Hampshire, USA. This
system contained all the necessary components for transfer of DNA from an
agarose gel to a nytran membrane including the buffer and stack trays, the various
blotting papers and buffer wicks required and a wick cover.

• Buffer required for TURBOBLOTTER™transfer:
- Denaturation buffer: 0.5 M NaOH, 1.5 M NaCI
- 20 X SSC (transfer buffer): 3 M NaCI, 0.3 M Na citrate [pH 7.0]
- Neutralisation buffer: 5 M Tris-HCI [pH 7.0], 1.5 M NaCI

• Hybridisation buffer: 5 X SSC, 0.02% w/v SDS, 1 gram of blocking reagent from
the DIG-nucleic acid detection kit (see Section 2.1.7.2).

• Hybridisation wash buffers:
- Wash buffer 1: 2 X SSC, 0.1% SDS
- Wash Buffer 2: 0.1 X SSC, 0.1% SDS
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• Dot blot buffers (1-4) as in section 2.1.7.3.

2.1.9: Investigation of the clinical utility of the 190 bp DIG probe for
MRSA detection:
• The nylon membranes used for this probing assay were lmmobilon™-N Trasnfer
membranes from Milipore.

• Denaturation/lysis (DL) buffer: 0.5 N NaOH, 1% SDS
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2.2 Experimental Methods:

2.2.1: Bacterial Cultures:
2.2.1.1: Antibiotic sensitivity testing:
DNAse positive staphylococci were examined for methicillin sensitivity on 5%
NaCI agar, using a E test strip as described by Bignardi MaJ. (1993). Other
antibiotic sensitivities were determined by the Stokes method (British Society of
Antimicrobial Chemotherapy, 1991). Iso-sensitest agar was used with
Staphylococcus aureus ACTC 6574 as the control organism. Antibiotic discs
included ciprofloxacin (5 ^ig), erythromycin (5 ^ig), fucidin (10 ^ig), gentamicin
(lO^ig), methicillin (25 jig), mupirocin (5 |ig), netilimicin (10 ^ig), ofloxacin (5 |ig),
penicillin (1 [ig), rifampicin (2 ing), teicoplanin (30 ^g), tetracycline (10 ^ig), and
vancomycin (30 ^ig).

2.2.2: Comparison of DNA Extraction Procedures for MRSA:
2.2.2.1: Lysis buffer technique:
Five colonies of an overnight culture of MRSA were resuspended in 20 ^il of lysis
buffer. The mixture was then heated to 99°C for 5 min in a heating block. The
bacterial cell debris was removed by centrifugation at high speed for 2 min.
Following the latter step, the supernatant contained the DNA.

2.2.2.2: CTAB Lvsis:
- The cells from 1.5 ml of an overnight MRSA culture were treated by heating to
80°C for 20 min.
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- The cells were then centrifuged for 5 min at high speed and the pellet was
resuspended in 500 )il of 1X TE buffer by vortexing.
- Fifty microlitres of lysozyme (10 mg/ml) was added, mixed and incubated for 1 hr
at 37°C.
- To this mixture 70 ^il of 10% SDS and 6 ^il of 10 mg/ml proteinase K was added
and then incubated at 65°C for 10 min.
- Following incubation, 100 |liI of 5 M NaCI and 80

\i\

of CTAB/NaCI were added

and the solution was vortexed until it became milky white in texture and then was
incubated at 65°C for 10 min.
- An equal volume (0.7 ml) of chloroform-isoamylalcohol was added, vortexed and
centrifuged at high speed for 5 min.
- The supernatant was transferred to a clean tube and 0.6 volumes of isopropanol
was added and the mixture placed at -20°C to precipitate the nucleic acids.
-The precipitated nucleic acid was then retrieved by centrifugation at high speed
for 15 min and the DNA pellet was washed with 1 ml of cold 70% ethanol to
remove residual CTAB and NaCI.
- The sample was again centrifuged and the pellet was allowed to air dry before
dissolving it in 20 ^il of 0.1 X TE buffer.

2.2.2.3: Lysostaphin lysis:
This extraction method was a modification of the procedure described by
Versalovic

(1994).

- Cells from 2 ml of a MRSA overnight culture were pelleted by centrifugation at
high speed for 2 min. The cells were washed with 1 M NaCI and TE buffer (50 mM
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Tris-HCI [pH 8.0], 50 mM EDTA) before resuspension in 0.7 ml of the same TE
buffer.
- Initially to lyse the cells, 50 U of lysostaphin were added and this mixture
incubated at 37°C for 30 min.
- Twenty microlitres of 20% SDS was added and incubation continued at 65 °C for
10 min.
- To complete cell lysis, 60 ^il of proteinase K was added and this mixture was
maintained at 37 °C for 1 hr and then at 65°C for 30 min.
- The DMA was separated from the protein fraction by performing 2 phenolchloroform extractions. To the lysed cells 1 ml of the phenol-chloroform mixture
was added and mixed vigorously (by inverting) for 5 min. This mixture was
centrifuged at high speed for 10 min and the aqueous phase transferred to a clean
microcentrifuge tube. Then a second extraction was performed on the
supernatant.
- The nucleic acid was precipitated by adding 0.33 volumes of 3 M ammonium
acetate. Precipitation was allowed to proceed at -20 °C overnight.
- Following precipitation, the purified DMA was pelleted by centrifugation at high
speed for 30 min. Then the DMA pellet was washed with 70% ethanol and
resuspended in 200 |il of IX TE solution.

To asses the integrity of the DMA sample using these extraction procedures 10 |il
of the DMA mixture was run on a 1% agarose gel. The DMA concentration of the
samples were quantitated spectrophotometrically at 260 nm.
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2.2.3: Agarose gel electrophoresis:
Electrophoresis was performed in a Horizon® horizontal gel apparatus from Life
Technologies (Supplier: BioSciences, Dublin) for 1-2 hr at 70V using a Pharmacia
power supply (Pharmacia, Uppsala, Sweden). Different gels were employed for
the experimental procedures depending upon the resolution required:
(i) A 1% agarose gel (Promega, Madison Wl) in IX Tris-Acetate-EDTA
(TAE) buffer, containing 0.3 mg/ml ethidium bromide (EtBr) , was used for
determining the integrity of the DMA isolated using different lysis
procedures.
(ii) Triplex-PCR products were resolved in a 2% NuSieve™ agarose gel
(1.7% NuSieve"’ agarose and 0.3% agarose) in IX TAE buffer containing
0.3 mg/ml EtBr.
(iii) DMA fingerprinting products were separated in either a 1 or 2% agarose
gel in IX TAE buffer containing EtBr.
All ethidium bromide stained fragments were visualised on a UV transilluminator
and photographed using a Polaroid Land Camera (Model MP4) on Polaroid 667
black and white film (Sigma, Poole, UK).
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2.2.4: Polymerase Chain Reaction:
2.2.4.1: DNA fingerprinting:
A variety of different primers were tested to identify a suitable DNA fingerprinting
strategy for MRSA isolates. Five isolates of MRSA were analysed using this
primer collection and the results were compared.
For each of the 7 different primer(s) used, the PCR reaction volume was
50 |il. For all primers, except for Rep 1 Dt and Rep 2R Dt, 200 ng of genomic DNA
template was added to a PCR cocktail containing 5 ^1 of 10X PCR reaction buffer,
2.5 mM MgCl2, 8 ^il of the dNTP working solution (resulting in a final concentration
of 200

|liM

each of dATP, dCTP, dGTP and dTTP) and 2.5 U of Tag DNA

polymerase. The concentration of each primer added for fingerprinting was 50
pmol. However 75 pmol of RW3A was added as recommended by Del Vecchio et
ai. (1995).
The PCR fingerprinting using the REPIR-Dt and REP2-Dt primers was
performed using a 50 ^il reaction volume which contained 50 pmol of each primer,
100 ng of template DNA, 1.25 mM of each dNTP, 2.5 U of Tag polymerase, 5 ^il of
Gitschier buffer (Kogan et al-, 1987) and 10% DMSO (this was used as a
cosolvent to enhance PCR amplification by altering genomic template melting
temperature [Innis etai., 1995]).
The total reaction was overlaid with 50 |il of sterile mineral oil and amplified
in a Pharmacia LKB-Gene-ATAQ Controller thermocycler (Pharmacia, Uppsala,
Sweden). The cycling parameters varied depending upon the primer used to
generate the fingerprints.
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• LC-1., LC-2, LC-3, LC-4 and LC-5 were random primers used for RAPD
fingerprinting analysis of the MRSA strains. The amplification profile used for
these primers was as follows:

1 cycle

94°C for 5 min
94°C for 1 min

30 cycles

36°C for 1 min
72°C for 1 min

1 cycle

72°C for 5 min

Hold

4°C

• REP1R- Dt and REP2-Dt were used together to amplify the regions between
repeat elements in the DNA template (i.e. in a rep-PCR approach, see Section
3.5.1). The amplification profile was the same as that described by Versalovic et
aj. (1994) and is shown below:

1 cycle

95 C for 5 min
90 C for 1 min

30 cycles

40°C for 1 min
65°C for 8 min

1 cycle

65°C for 16 min

Hold

4^C

• For RW3A fingerprinting the amplification profile recommended in the paper by
Del Vecchio ^aj. (1995) was used. The cycling parameters were as follows:
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1 cycle

95 C for 5 min
94 C for 1 min

30 cycles

54°C for 1 min
72°C for 2 min

1 cycle

72 C for 5 min
4^

Hold

The PCR products generated during PCR amplification with each of the primers
(except RW3A) were resolved in a 1% agarose gel. The fingerprint profiles
obtained using RW3A were separated in a 2% agarose gel as used by Del
Vecchio et af. (1995).
Comparison of the PCR profiles attained using the different oligonucleotides
showed RW3A to be an appropriate primer for MRSA fingerprinting.
To determine if the fingerprints achieved using the RW3A primer could be
improved, the PCR reaction was carried out using the Gitschier buffer system and
with varying DMA concentration of genomic DMA template (50 ng to 200 ng). It
was established from these trials that the following reaction conditions are most
suitable for RW3A fingerprinting of MRSA in this study:
- 200 ng of DMA,
- 2.5 mM MgCl2,
- IX PCR buffer (Promega),
- 200 ^iM of each dNTP,
- 2.5 U Tag DMA polymerase (Promega), and
- 75 pmoles of RW3A primer.
The amplification profile was as in the paper by Del Vecchio et al (see above).
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This RW3A fingerprinting strategy was used to epidemiologically type two
outbreaks of MRSA in the Cork University Hospital (outbreak 1 = 48 strains and
outbreak 2 = 39 strains). Other microbial species were analysed using this
fingerprinting scheme for comparative purposes.

2.2.4.2: Triplex-PCR:
The multiplex (triplex) PCR was carried out in a 50 |il reaction volume containing
200 ng of template DMA, 5 ^il of 10X Promega PCR reaction buffer (Promega,
Madison Wl), 4 mM MgCl2, 200

of each dNTP, 2.5 U of Tag polymerase. Into

this cocktail 12.5 pmoles of each of the six primers were added and used to
amplify the pre-selected MRSA genomic targets (the primer used were directed
against the following genes: mecA. femA. and ouc). The mixture was overlaid with
50 ^il of sterile mineral oil as before and amplified using the following parameters
in a Pharmacia LKB-Gene-ATAQ Controller thermocycler (Pharmacia, Uppsala,
Sweden):
1 cycle

95°C for 3 min
94°C for 1 min

25 cycles

55°C for 30 sec
72°C for 1 min

1 cycle

72°C for 5 min

Hold

4^C

Amplified products were analysed on a high resolution 2% agarose gel (1.7%
NuSieve™ agarose and 0.3% agarose) in IX TAE buffer containing 0.3 mg/I
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ethidium bromide. A grade V molecular weight marker (Boehringer Mannheim,
Germany) was included in each gel to authenticate the amplified DNA fragments.

2.2.4.3: COGEDET analysis:
For combined gene detection and epidemiological typing (COGEDET) analysis of
MRSA strains, a 50 |il RW3A fingerprinting reaction was prepared as described in
section 2.2.4.1. These tubes were placed in the Pharmacia thermocycler and
amplified as follows:
95°C for 5 min

1 cycle

94 °C for 1 min
10 cycles

54°C for 1 min
72°C for 2 min
4^C

Hold

After these 10 amplification cycles, 12.5 pmoles of the MRSA specific gene target
primers (mecA and femA) were added to the reactions and the amplification
proceeded using the following cycling parameters:
94°C for 1 min
20 cycles

55°C for 30 sec
72°C for 1 min
72°C for 5 min

1 cycle

4‘'C

Hold

The products amplified using this system were analysed by electrophoresis in a
2% agarose gel.

105

2.2.5: GeneScan Analysis:
2.2.5.1: Fluorescent [F]-PCR:
Fluorescent fingerprinting of MRSA with 6-FAM RW3A was carried out using the
same PCR reaction conditions described for the unlabelled RW3A fingerprinting
protocol.
Fluorescent triplex-PCR was performed as described previously for
unlabelled triplex-PCR however the mecA. femA and nuc antisense primers were
replaced with the TET-labelled antisense oligonucleotides. After PCR each of the
three DNA amplicons contained a TET-fluorophore.
A fluorescent COGEDET scheme for combined MRSA detection and typing
was performed as described in section 2.2.4.3 for the unlabelled assay. The
RW3A primer was labelled with a 6-FAM fluorophore and the mecA and femA
reverse primers were labelled with TET.
Inclusion of fluorophores covalently linked to the primers used for RW3A
fingerprinting, triplex-PCR and COGEDET analysis ensured that each PCR
product contained a [F]-tag which permitted their direct detection in an automated
fluorescent detection format such as the ABI Prism™ 310 genetic analyser (Applied
Biosystems, Foster City, CA).

2.2.5.2: Purification of PCR products:
PCR products from fluorescent fingerprinting, triplex-PCR, and COGEDET assays
were purified prior to GeneScan analysis. The QIAquick PCR purification kit
(QIAGEN Ltd., West Sussex, UK) which is designed to purify DNA products
ranging in size from 100 bp to 10 kb was used for this purpose. The purification kit
was used according to the manufacturers instructions:
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-Five volumes of PB kit buffer were added and mixed with 1 volume of the PCR
reaction to be purified. A QIAquick spin column was placed in a 2 ml collection
tube and the sample was applied.
-A brief centrifugation of 30-60 sec was performed to bind the DNA to the silica gel
membrane of the spin column.
-DNA remains adsorbed to the silica-membrane at high salt concentrations, while
contaminants (primers, nucleotides, polymerases, and salts) are removed via a
washing step with 0.75 ml of PE kit buffer.
-The purified sample DNA was eluted from the column with 50 pi of sterile water
(which lowers the pH and therefore releases the DNA from the silica-membrane).
For elution of the PCR products amplified in the DNA fingerprinting strategy, the
water used for elution was preheated to 60°C to maximise the recovery yield of the
larger products.
All PCR products purified and eluted in water were stored at -20°C so as to avoid
DNA degradation in the absence of a suitable buffering agent.

2.2.5.3: GeneScan analysis:
The ABI Prism™ 310 Genetic Analyser (Applied Biosystems, Foster City, CA) can
detect [F]-labelled PCR products generated in the latter assays. This analyser
combines capillary electrophoresis of DNA samples with argon laser detection of
the [F]-PCR products. The multiple fluorescent dyes are excited by an argon laser
emitting light of a specific wavelength, which is characteristic for each dye used.
The transmitted light is collected by a charge-coupled device (CCD) camera. The
data collection software records the emitted light signals and stores them as
electrical signals for processing. A dedicated Apple Power PC (Apple Computer
107

Inc., Cuppertino, CA) linked to the analyser facilitates automatic analysis of the
collected data and provides DNA size and quantitation information for each
sample tested.

Setting up the instrument for GeneScan analysis: (see figure 2.1)
Initially the pump block is washed thoroughly with water (first with warm water and
then with cool HPLC water) to ensure the narrow channels within the block were
not obstructed. A GeneScan capillary (total length = 47 cm, and length to laser
detector = 36 cm) was installed as shown in figure 2.1. During capillary
installation, the capillary window (which was cleaned with a methanol wipe) was
aligned carefully with the laser to allow detection of the fluorescent products
during electrophoresis. The buffer reservoir (see figure 2.1) was filled with IX
genetic analyser buffer (GAB) and placed as shown attached to the pump block.
The 2.5 ml high-pressure syringe was filled with 2.5% GeneScan polymer. Once
filled the syringe was threaded through the aluminium syringe guide plate and
screwed tightly into the block. The channels to the waste and buffer vials were
filled manually with polymer from the syringe to ensure continuity of the electric
current. The syringe drive toggle was moved to the right and then moved down
until the toggle was 1-2 mm from the glass syringe plunger. IX GAB was placed
at position 1 of the autosampler tray and HPLC grade water placed was at
positions 2 and 3 in this tray.
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. Capillary

Syringe drive

Heat plate

Syringe
Gel Pump button

Heater door

Tray button

Buffer reservoir

^
/ Pump block
LED Status indicators
Drip tray

^ Cathode electrode
Laser detector door
(covers detector
window)

Autosampler

Figure 2.1: Illustration of the various components of the
ABI Prism™ 310 Genetic analyser.

Sample preparation:

Each PCR sample to be analysed was combined with a differentially labelled
internal lane standard. The inclusion of these standards allowed a precise size
estimation for each of the analysed PCR products. Initially a standard was
prepared and electrophresed without sample to ensure the analyser was
operating appropriately. Sample and standards were prepared In 0.5 ml genetic
analyser tubes as follows:
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Reagent
HPLC water
Purified PCR samples
Standard*

Sample

Standard

48 pi

12 pi

1 pi
0.5 pi

0.5 pi

[ The standards utilised were dependent upon the size range of the expected
PCR products. In general for the fingerprinting experiments the GS 2500
standards were used and for triplex-PCR the GS 500 standards were used. The
label on the standards was selected so as to emit light of a wavelength different to
that of the sample.]
Septa were Inserted Into the sample tubes which were then placed in the
autosampler tray of the analyser

Figure 2.1).

Following these preparations, a sample sheet was created using the ABI Prism™
310 collection software. A sample sheet associates sample information (such as
name and fluorescent tag used for both the sample and the standard) with the
sample position in the autosampler tray (see Figure 2.2 for an example of a typical
sample sheet).

Figure 2.2: A GeneScan sample sheet.

no

The next step involved the preparation of a GeneScan injection list. The data
stored in the sample sheet is first imported into the injection list (see Figure 2.3 for
a typical GeneScan injection list).

Injection List
W.V#

Figure 2.3: A GeneScan injection list.

In the injection list the module (which contains all the parameters essential for
analysis) was specified. The modules used for GeneScan analysis were Push Fill
modules, whereby the syringe drive toggle pushes the syringe filled with polymer
until the

filled with polymer. Using Push Fill modules, each sample is

electroinjected into the capillary for 10 sec and electrophoresed for 20 min at 11
kV at 30 °C through the 2.5% GeneScan polymer.
All results were stored and analysed on the dedicated Apple Macintosh
Power PC computer linked to the system. The analysis software compares the
internal standard in each sample with a previous size standard which had been
assigned sizes for each of the peaks. If the standards match then accurate size
estimations of the PCR products in the electrophoresed sample can be obtained.
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2.2.6: Characterisation of amplicons of interest from RW3A
fingerprints:
2.2.6.1: Extraction of DNA band of interest from agarose gel:
The MRSA fingerprint containing the band of interest was repeated in a 100 |il
volume. Eighty microlitres of this sample was electrophoresed in a single lane of
a 2% agarose gel.
The QIAquick Gel Extraction Kit (QIAGEN Ltd., West Sussex, UK) is
designed to permit the extraction of DNA fragments ranging in size from 70 bp to
10 kb from standard or low-melt agarose gels in TAE or TBE. The protocol
outlined by the manufacturers was as follows:
- The DNA fragment of interest was excised from the agarose gel using a clean,
sharp scalpel.
- The slice was weighed in an eppendorf tube and 3 volumes of QG kit buffer were
added to 1 volume of gel. This mixture was then incubated at 50°C to dissolve the
agarose. (Following gel dissolution, the yellow colour of the QG buffer must be
maintained, thereby ensuring the pH is less than 7.5 and therefore will allow DNA
to bind to the QIAquick membrane.)
- Next, 1 gel volume of isopropanol was added to the sample and once mixed this
solution was applied to a QIAqucik spin column placed in a collection tube.
Centrifugation for 1 min adsorbed DNA to the column membrane.
- Any remaining traces of agarose were removed by washing the column with
0.5 ml of QG buffer.
- The membrane bound DNA was purified by washing with 0.75 ml of PE kit buffer.
- Elution with 50 |il of sterile water retrieved the DNA from the membrane and the
DNA was then stored at -20°C.
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After extraction, the excised fragment was amplified using the RW3A primer. This
PCR was performed as described previously (see Section 2.2.4.1) with minor
modifications: the primer concentration was 32.5 pmoles, amplification was for 20
cycles and a final extension step was extended to 7 minutes.
The aim of this PCR was two-fold:
1. This PCR amplification confirmed that the band was excised from the
agarose gel free of other DNA
2. Also Tag DNA polymerase has a non-template dependent activity which
adds a single deoxyadenosine (A) to 3’ ends of the PCR products. Therefore,
reamplification of the excised fragment in this PCR provides a product with Taqgenerated 3’ A-overhangs which are essential for ligation of the product into the
pCR® 2.1 vector (which has complementary 3’ T-overhangs) (see Section 2.2.62
below).

2.2.6.2: Cloning of the fragments of interest:
Ligation:
The reamplified fragments were ligated into the pCR® 2.1 vector using the
following reaction:
Sterile water

5^il

10X ligation buffer

1 |il

pCR ® vector

2 Hi

PCR product

1 |ll

T4 DNA Ligase

1 Hi

Total

10 III
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Ligation proceeded at 14°C overnight. The reaction was then centrifuged and
placed on ice (or stored at - 20°C until required).

2.2.6.3: Transformation into INVaF' cells:
- The appropriate number of vials of One Shot""" cells (super-competent INVaF’
cells) were thawed on ice.
- 2 |il of 0.5 M p-mercaptoethanol were added to each vial and the mix was stirred
gently with the pipette tip.
- 1-2 pi of the ligation reaction was added to the cells and stirred.
- The vials were then incubated on ice for 30 min after which the cells were heat
shocked at 42°C for 30 sec and immediately placed on ice again for 2 min.
- To each vial 250 pi of SOC medium was added followed by incubation at 37°C
for 1 hr (shaking at 225 rpm). After incubation the vials were then placed on ice.
- From each transformation mix 100 pi was removed and inoculated onto a
previously prepared LB agar plates containing ampicillin and X-Gal. These plates
were incubated overnight at 37°C and then placed at 4°C for 3 hr to permit colour
development.
Blue colonies =

no insert in plasmid vector

White colonies =

transformants that may contain plasmids with inserts.

2.2.6.4: Quick screen for plasmids with inserts:
This procedure was performed on transformants grown on LB-Amp-X-Gal plates to
determine if the plasmids contained the insert of interest. A blue colony was also
screened for comparative purposes (i.e. as a plasmid without insert). This
technique was performed as follows:
- A P20 pipette was used to pick the white colonies to be screened from the agar
plates.
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- The pipette tip was then touched on a gridded fresh agar plate (to preserve the
clone) and the remainder of the colony was transferred to an eppendorf containing
8 111 of lysis buffer. The colony was then gently resuspended in the buffer by
pipetting up and down 4-5 times.
- To this mixture was added 1.5 ^l of buffer 2 (3 M potassium acetate, 1.8 M formic
acid) and the tubes were then centrifuged for 4 minutes.
- The supernatant obtained for samples was then electrophoresed in a 0.8%
agarose gel.
A shift upwards in the size of the electrophoresis products of the white colonies,
when compared with those of the blue colony, was indicative of the presence of an
insert within the plasmid vector.

2.2.6.5: Isolation of the plasmid from INVaF’ cells:
Isolation of plasmids from INVaF’ cells was performed using the Wizard® Plus SV
miniprep DNA purification kit (Promega, Madison, Wl).
- The screened colony believed to contain the correct plasmid construct was
cultured overnight in 5 ml of tryptic soy broth.
- Three millilitres of the bacterial culture were centrifuged at high speed for 5 min
and the supernatant was removed.
- The pelleted cells were then resuspended in 250 ^il of cell resuspension kit
solution by vortexing and then the mixed cells were transferred to a 1.5 ml
eppendorf tube.
- Cell lysis kit solution (250 ^il) was added to initiate cell lysis and all tubes were
inverted 4 times. This mixture was incubated for 1-5 min until the supernatant
cleared.
- Ten microlitres of alkaline protease solution was then added and the tubes were
mixed again by inversion, this incubation was maintained for less than 5 min.
- Neutralisation solution was then added (350 ^il) and thoroughly mixed. The
lysate was centrifuged at high speed for 10 min.
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- Cleared supernatant was transferred to a Wizard® miniprep spin column and
centrifuged for 1 min. The flow through was discarded and the spin column
placed in a collection tube. This column was washed with 750

\i\

and then 250

[i\

of column wash solution provided with the kit.
- The column was transferred to a sterile eppendorf and the plasmid eluted in
100 ^il of nuclease free water.
- Isolated plasmid was concentrated for DNA sequencing using an ammonium
acetate/ethanol precipitation. Briefly the 100 ^1 eluted DNA was mixed with 50 |il
of 7.5 M ammonium acetate and 375 ^il of 95% ethanol. The sample was
centrifuged for 15 min at high speed and the supernatant was carefully removed.
Pelleted plasmid DNA was washed with 70% ethanol and the plasmid was
resuspended in 25 |il of nuclease-free water.
- Plasmids eluted in water were stored at - 20°C until required.

2.2.6.6: Restriction digest of isolated plasmid:
The site of the insert in the vector is flanked on either side by an EcoRI restriction
site (see Appendix 3). To confirm the presence of the insert in the isolated
plasmid a restriction enzyme digest with EcoRI was performed as follows:

Digest:
Plasmid

15^1

Enzyme (EcoRI)

1 |il

Buffer H (10X)

2 Hi

Water

2 Hi

The tubes were placed at 37 C for 1.5 hr and the products were electrophoresed
in a 1.5% agarose gel.
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2.2.6.7: DNA sequencing of the plasmid inserts:
Dye primer sequencing:
Four tubes were prepared as follows for dye-primer sequencing of each sample
(Note the dye labelled primer used for sequencing was either the T7 promoter
primer or the M13 reverse primer):

Reagent

A(hI)

C(nl)

G(nl)

T(nl)

d/ddNTP

1

1

2

2

Dye labelled Primer

1

1

2

2

5X sequencing buffer

1

1

2

2

Diluted AmpliTaq FS enzyme

1

1

2

2

Plasmid DNA template (180 ng/^l)

1

1

2

2

Total tube volume

5

5

10

10

These tubes were placed in an MJ Research thermocycler (MJ Research INC.,
MA, USA) and the cycling parameters were as follows (for double-stranded DNA
templates using T7 dye primers);
95°C for 20 sec
45 °C for 20 sec

20 cycles

68 °C for 60 sec
95 °C for 25 sec

15 cycles

68 °C for 60 sec
Hold

The cycling parameters when using the M13 reverse primer for sequencing were
as follows:
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95°C for 20 sec
15 cycles

55 °C for 20 sec
68 °C for 60 sec

15 cycles

95 °C for 25 sec
68 °C for 60 sec

Hold

4°C

Following amplification, the A, G, C, and T reaction labelled products, of the T7
promoter sequencing, for each sample were pooled (i.e. transferred to 80^1 of
95% ethanol). The nucleic acids were precipitated for 15 min at room temperature
and then centrifuged for 30 min and then the DNA pellet was dried in a speed vac
for 2-4 minutes. The sample was then resuspended in 6 |il of loading buffer (25
mM EDTA containing 50 mg/ml dextran blue) and 2.5 ^il of this mix was loaded into
the wells of a 36 well, 4% polyacrylamide gel. This procedure was also performed
for the Ml3 reverse sequences of each sample.
The results were stored in a dedicated Apple Macintosh computer.
Analysis of the sequence data obtained for each fragment was performed using
Sequencher™ 3.0 software (Gene Codes Corporation, Ann Arbor, Ml). In this
package, the sequence data was edited to remove vector sequence and contig
assembly of the forward and reverse reads for each fragment was performed. The
RW3A primer sequence was located on each end of the fragments and using the
analysis software a restriction map of each fragment was constructed. The edited
files were then searched against the National Centre for Biotechnology
Information (NCBI) genetic databases. Accession numbers were obtained from
NCBI for these sequences using the Bankit option in the NCBI internet site.
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2.2.7: DIG-detection strategies for MRSA:
2.2.7.1: DIG-labelling of PCR products:
For each genomic sample tested, three individual PCR reactions were performed;
a mecA-. a femA- and a nuc- (as described in Section 2.2.4.1 for triplex PCR
however only one set of primers was included). The PCR products amplified were
DIG-labelled by inclusion in the PCR of a PCR-DIG labelling mix (instead of the
more common balanced dNTP working solution). The incorporation of the
digoxigenin label was confirmed by agarose gel electrophoresis analysis which
demonstrated an upward band shift when compared to an unlabelled fragment.
Ten microlitres of the labelled PCR products was purified by precipitation
with 0.14 volumes of 4 M LiCI and 4 volumes of cold absolute ethanol at -20°C for
12 hours. The labelled DNA was recovered by centrifuging at high speed for 30
min and the pellet obtained was resuspended in 100 ^il of sterile water for “dot
blot” analysis and 100 ^il of PBST for CAPS detection.

2.2.7.2: Detection of DIG-labelled PCR product:
“Dot-Blot” detection:
The “dot blot” detection strategy is as shown in figure 2.4. Resuspended DIGlabelled sample was applied to the nylon membrane under vacuum using a “dot
blot” apparatus (Milliblot Systems, Millipore, France). Initially the membrane was
washed with 10 ml of buffer 1 (for dot blot buffer 1-4 see Section 2.1.7.3) and then
incubated for 30 min in buffer 2. The filter was then washed briefly with buffer 1
and incubated with 20 ml of DIG-antibody-AP conjugate (150 mU/ml) for 30
minutes. The unbound antibody was removed by washing twice with buffer 1.
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Finally the membrane was equilibrated with buffer 3. Freshly prepared colour
solution was then added to the membrane and colour development was allowed
to proceed for 5-30 min in the dark. The colour reaction was stopped by
incubating the membrane in 50 ml of buffer 4.

substrate

product

Anti-DIG-AP-conjugate

DIG-labclled PCR product

membrane

Figure 2.4: Dot Blot detection strategy: DIG>labelled PCR product is
immobilised on a nylon membrane. Incubation of the membrane with
Anti-DIG-alkaline phosphatase (AP) conjugate binds the tagged antibody
to the PCR product. A chromogenic substrate is then added which is
converted to a coloured product by the action of the alkaline phosphatase
(AP). A coloured dot is visible on the nylon membrane at the site of the
immobilised DIG-labelled PCR product interaction.

“Colour amplified PCR detection system” (CAPS):
The CAPS detection strategy was originally described by Fanning Mai- (1995)
and O’ Meara Mai- (1995) and is schematically outlined in figure 2.5 (a and b).
Wells of the microtitre plate were coated overnight at 4°C with 100 pi of antiDIG-polyclonal Fab (diluted 1 in 10

-4

in coating buffer). Each well was washed in

triplicate with 300 pi of washing buffer (for CAPS buffers see Section 2.1.7.4) after
antibody coating and then blotted dry. One hundred microlitres of the standards
and samples were added to the appropriate well and the plate was then sealed
and incubated at 37°C for I hr (the DIG-DNA standards were prepared in PBST
and ranged in concentration from 0.015-1 ng of DIG-labelled DNA). Another
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washing step was performed and then 100

\i\

DlG-labelled-AP-conjugate was

added to each well and the plate was held at 37°C for I hour.

substrate

Anti-DlG-AP-conjugate

DIG-labelled PCR product

Anti-DIG-Fab fragemtns

microtitre plate

Figure 2.5 a: CAPS assay detection of PCR amplified DIG-labelled DNA
immobilised on a microtitre plate coated with Anti-DIG-Fab fragments.

El
E2
E3

Alkaline Phosphatase
Diaphorase
Alcohol Dehydrogenase

Figure 2.5 b: Enzymatic amplification cascade of the Ampak^’^ amplification
kit. The primary enzyme (El) cleaves NADPH producing NADH. This
NADH enters a redox cycle driven by diapharase (E2) and alcohol
dehydrogenase (E3). This cycle leads to the generation of formazan which
can be measured spectrophotometrically at 490 nm.

The Ampak amplification kit (Dako Diagnostics, Cambridgeshire, UK) was used
for CAPS detection of the AP- antibody conjugate. This procedure was carried out
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by first washing the plate with 300 \i\ of Ampak™ buffer and then adding to each
well 50 |il of substrate solution. The plate was then incubated at 37°C for 20 min
after which 50 ^1 of the kit amplifier solution was added to each well followed by a
10 minute incubation. The reaction was stopped using the stop solution provided
in the kit. Each well was then read against a reagent blank (PBST) in a microtitre
plate reader at 490 nm (Dynatech MR7000).

2.2.8:

Investigation of the “Accordion Effect”:

Characterisation of large DNA fragments (>1000 bp) from RW3A fingerprints (as
described in Section 2.2.6) was complicated by the collapsing nature of the
fragment after purification and amplification into smaller bands visible upon
agarose gel electrophoresis (ranging in size from 190-580 bp), thereby preventing
cloning and sequencing.
Hypothesis: Upon reamplification of the larger fragments, internal priming
sites are targeted resulting in the amplification of a number of smaller products,
giving rise to the ‘Accordion Effect’. This has significant implications for
fingerprinting as the profiles obtained may not represent the entire genome but a
portion of the template that is continuously resampled internally.
The experimental procedures utilised to determine if the smallest of these
‘collapsed products’ (190 bp) was present in each of the reamplified products
were as follows:

2.2.8.1: DIG labelling of the 190 bp product:
This product was reamplified by RW3A fingerprinting as described in section
2.2.6.1, however the PCR-DIG labelling mix was included in the reaction to label
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the 190 bp product with digoxigenin. The inclusion of the DIG label was confirmed
by agarose gel electrophoresis and then the product was purified using a
LiCI/ethanol purification as previously described in section 2.2.7.1. The probe was
then quantitated spectrophotometrically at 260 nm.

2.2.8.2: Transfer of the ‘collapsed products’ from the agarose gel to a nytran
membrane:
Transfer of the ‘collapsed’ products to a nytran membrane was achieved using the
turboblotter"

Rapid Downward transfer system (Schleicher & Schuell, New

Hampshire, USA). This procedure was divided into two parts:
(i) Denaturation of the DNA within gel:
Initially the gel was placed in denaturation buffer (see Section 2.1.8) and shaken
gently at room temperature for 30 minutes. The gel was rinsed in distilled water
and placed in neutralisation buffer (see section 2.1.8) which was shaken gently at
room temperature for 30 min. The gel was then soaked in transfer buffer for 30
minutes again shaking gently.

(ii) Transfer of products from gel to membrane:
The nytran membrane was immersed in distilled water and then soaked in 20 X
SSC transfer buffer. The transfer apparatus, TURBOBLOTTER™, was assembled
on a level surface and as shown in figure 2.6.

The buffer tray was filled with transfer buffer and the transfer was initiated by
connecting the buffer tray to the gel stack using the buffer wick. The wick cover
was placed on top of the transfer system and transfer was allowed to proceed
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overnight. Following transfer the membrane was neutralised using 2X SSC and
then the membrane is baked at 80°C for 2 hours.

wick Cover
(printed side up)
Buffer Wick*

Buffer Tray

0.2 imi Nytran®/
BAo Membrane
GB002* (1)

GB002 (4)

GB004 (20)

Stack Tray

Figure 2.6: TURBOBLOTTER

apparatus set up for transfer of DNA from an

agarose gel to a nytran membrane.
(Note: GB002 = thin blotting paper and GB004 = thick blotting paper, the
number in brackets in this figure indicate the number of sheets of blotting
paper for assembly of the transfer device.)

124

2.2.8.3: Probing of the nytran membrane with 190 bp DIG probe:
The strategy of this probing experiment is shown in figure 2.7 below:

substrate

coloured product
Anti-DIG-AP conjugate

DIG-Labelled 190 bp probe
PCR product bound to membrane

Figure 2.7: This figure demonstrates the probing strategy using the
190 bp DIG-labelled probe for detection of complementary sequences in
the PCR products. (This is also the approach used in Section 2.2.9 for
assessment of the clinical utility of this probe for MRSA detection,
however in this case the target is lysed bacterial cells immobilised on the
nytran membrane)

- The filter is initially soaked (or prehybridised) with 11.2 ml of hybridisation buffer
(see Section 2.1.8) for 30 minutes at 55°C (20 ml/100 cm^ therefore 11.2 ml was
used for a nytran membrane area of 7 x 8 cm^).
- The 190 bp DNA probe was denatured by boiling for 5 minutes and then placed
on ice. The probe was mixed with prewarmed hybridisation buffer.
- The membrane was then incubated with 1.4 ml of this probe/hybridisation buffer
shaking overnight at 55°C (2.5 ml/100 cm^ therefore 1.4 ml was used for a nytran
membrane 7x8 cm^).
- Post hybridisation washes included washing twice with wash buffer 1 (see
Section 2.1.8) for 5 min at room temperature, followed by washing twice with wash
buffer 2 (see Section 2.1.8) for 15 min at 68°C while shaking.
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- The remainder of this experiment involved the detection of the DIG-labelled
probe and was performed as described for dot blot detection in section 2.2.7.2 and
included incubation with Anti-DIG-AP-conjugate and colour development.

2.2.9: Assessment of the clinical utility of the 190 bp DIG probe for
MRSA detection:
- The bacterial cultures to be tested were grown overnight in 2 ml of tryptic soy
broth at 37°C. These strains included MRSA, MSSA, CNS, Listeria spp..
Acinetobacter baumannii. Escherichia coli. Proteus mirabilis and Serratia
marcescens.
- A Millipore nylon membrane was pre-soaked as recommended by the
manufacturer, firstly in 100% methanol for 1-3 sec and then for 3 min in distilled
water. The membrane was then immersed in the denaturation/lysis buffer (see
Section 2.1.9) and incubated for 15 min in this solution.
- Using the “dot blot” vacuum apparatus, 400 pi of the bacterial cultures to be
tested were pulled under vacuum onto the pre-soaked membrane.
- The membrane was then placed on a filter and incubated at 98°C for 10 min to
effect cell lysis and denaturation of the released DNA.
- The membrane was then washed twice with neutralisation buffer (see Section
2.1.8) and then with 5 X SSC.
- The remainder of this experiment involved the probing of the membrane with the
190 bp probe and was as previously described in section 2.2.8.3.
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Section 3
Results and Discussion

3.1: Antibiotic susceptibility testing:
The MRSA isolates from two CUH outbreaks were tested to determine their
susceptibility to a variety of antimicrobial agents including ciprofloxacin (cip),
erythromycin (ery), fucidin (fd), gentamicin (gen), methicillin (meth), mupirocin
(mup), netilimicin (net), ofloxacin (ofl), penicillin (pen), rifampicin (rif), teicoplanin
(teic), tetracycline (tet) and vancomycin (vane).

Outbreak 1:
This outbreak comprised 48 MRSA clinical isolates cultured from a variety of
patient samples including groin and wound swabs, urine or catheter sites.
Antibiogram analysis resolved these outbreak strains into three groups
designated A to C as shown in table 3.1 below:

Table 3.1: Antibiogram patterns of MRSA outbreak 1
Antibiogram
Resistant to

Sensitive to

A

cip,ery,gen, meth, ofl, pen

fd, mup, net, rif, teic, tet,vanc

B

cip,ery, meth, ofl, pen

fd, gen, mup, net, rif, teic, tet,vane

C

cip,ery,gen, meth, mup, ofl, pen

fd, net, rif, teic, tet,vane

Antibiogram profile A (gentamicin resistant, mupirocin sensitive) was
commonest, constituting 35% (17/48) of the outbreak isolates. Antibiogram B
(gentamicin sensitive, mupirocin sensitive) represented 19% (9/48) of the
collection whilst antibiogram C accounted for 11% (5/48). A comparison of the
assigned groupings of antibiogram analysis and DNA fingerprinting using
RW3A (for this collection of strains) is shown in table 3.8 in section 3.5.
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Outbreak 2:
Thirty-three of the thirty-nine clinical isolates, collected from various patient sites
during outbreak 2 in CUH, were tested for suscpetibility to the above
antimicrobial agents. The resultant antibiogram profiles again divided the
collection into three main groups designated A, B, and C (Note, these groupings
were the same as those of outbreak 1):

Profile A (sensitive to mupirocin and resistant to gentamicin) was the
predominant antibiogram consisting of approximately 60% of the strains from
outbreak 2 (29/39). Antibiogram B (sensitive to gentamicin and mupirocin) and
C (resistant to gentamicin and mupirocin) each accounted for 13% of the strains
tested. Table 3.9 (Section 3.5) compares the groupings assigned by
antibiogram profiling and RW3A rep-PCR fingerprinting for this collection of
strain

The results of these analyses suggest that the two MRSA outbreaks in each
case consist of three strain groups. Evidence for the existence of such groups
was based solely on the susceptibility of the individual strains to mupirocin and
gentamicin. These MRSA strains demonstrated similar susceptibility to other
antimicrobial agents tested and it is this lack of discrimination which frequently
limits the use of antibiograms for MRSA typing.
Determination of antibiogram profiles are easily performed in routine
clinical laboratories and therefore provide a readily available ‘first-line’ typing
system. Antibiogram profiles may indicate the presence of problematic strains
or transmission by a particular vector, however it is evident that for reliable and
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effective epidemiological assessment of MRSA, supplementary tests are
required (Mulligan et ai-, 1993). Therefore to further investigate the (genomic)
relationship(s) among the MRSA strains in these two outbreaks a DNA
fingerprinting strategy was employed.
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3.2: DNA isolation procedures:
The major aim of the work undertaken in this study was the development of
DNA-based detection and typing strategies for MRSA. The first critical step was
the establishment of a DNA extraction protocol that would consistently yield high
quality DNA from MRSA strains which would be suitable for these applications.
Three DNA isolation procedures were compared by assessing the DNA
extracted from a limited number of MRSA strains.
The first of these methods involved boiling the bacterial sample in a lysis
buffer to release the genomic DNA from MRSA strains (see Section 2.2.1). This
technique had previously been successful in extracting DNA from Gram
negative bacteria such as Escherichia coli and Acinetobacter baumannii
(O’Meara ^aj., 1995; Sheehan ^aj., 1996). Despite many attempts (which
involved varying the culture:lysis buffer ratio and increasing the boiling time)
DNA was not extracted from the MRSA strains. This technique successfully
released DNA from an E. coli culture (see Figure 3.1 a). In this case, failure
most likely reflects the differing prokaryotic cell wall compositions of Gram
positive and Gram-negative bacteria. Gram-negative micro-organisms have a
very thin peptidoglycan layer in their cell wall (1-3 nm) whereas Gram-positive
bacteria have a much thicker peptidoglycan layer (7-8 nm). Therefore, it was
concluded that a more rigorous extraction protocol was neccessary for isolation
of DNA from MRSA strains.
The efficacy of two multi-step DNA isolation protocols designated CTAB
lysis and lysostaphin lysis (Versalovic ^aj., 1994) was assessed for
applicability to MRSA strains. These methodologies utilised degradative
enzymes and detergents to break the cell wall structural framework and phenol-
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Figure 3.1 (a-c): A 1% agarose gel in 1X TAE buffer and stained with 0.3
mg/ml EtBr showing the efficiency of various extraction procedures for isolation
of genomic DNA from MRSA strains.

a. Lysis buffer extraction procedure.
Lane M, grade III molecular weight markers; lane 1, MRSA 34219; lane 2, MRSA
34385; lane 3, MRSA 25085; lane 4, MRSA 33788; lane 5, Escherichia coli 6.
b. CTAB lysis protocol.
Lane M, grade III molecular weight markers; lane 1, MRSA 34219; lane 2, MRSA
34385; lane 3, MRSA 25085; lane 4, MRSA 33788; lane 5, MRSA 35961.
c. Lysostaphin DNA isolation method.
Lane M, grade III molecular weight markers; lane 1, MRSA 34219; lane 2, MRSA
34385; lane 3, MRSA 25085; lane 4, MRSA 33788; lane 5, MRSA 35961.
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chloroform extractions to remove protein complexes (see Section 2.2.2 and
2.2.3).
Ten microlitres of the genomic DNA released from each strain using
these multi-step assays was evaluated using agarose gel electrophoresis.
Extraction of chromosomal DNA from each of the 5 MRSA strains was visible
upon electrophoresis (see Figure 3.1 b and c), however in addition, plasmid
DNA was seen when the products of the lysostaphin lysis procedure were
resolved (see Figure 3.1 c)
Comparing the results of these two procedures, it is evident from the
agarose gels that a significantly higher yield of DNA was obtained for strains
34219, 34385, and 33788 using the lysostaphin lysis procedure (see Figure 3.1
b and c, lanes 1,2, and 4). It was concluded by analysis of the agarose gels that
the DNA extracted using lysostaphin lysis was of superior quality and quantity
when compared with the DNA isolated using the CTAB lysis protocol.
Therefore, DNA was extracted from all organisms used in this study using this
technique. The DNA obtained was quantitated spectrophotometrically at 260
nm and then its concentration was adjusted to 200 ng/^l.
In the development of rapid DNA-based detection strategies, extraction
procedures such as CTAB lysis and lysostaphin lysis cannot be justified as they
considerably lengthen assay time. However, for epidemiological typing using
PCR-based DNA fingerprinting approaches, such as RAPD, many authors
advocate the use of purified DNA to eliminate the variability associated with
template quality and thereby improve the reproducibility of the results obtained
(Gao et aj., 1996; Power, 1996). Even with these time-consuming DNA
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extraction methods, PCR-based DNA fingerprinting procedures are more rapid
and less labour intentsive than typing methods such as ribotyping and PFGE.
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3.3: Triplex PCR:
Detection of MRSA strains in a typical hospital laboratory is performed using
routine culture and sensitivity methods. MRSA detection using these
approaches takes approximately 48 hours. The organism must first be identified
as a Staphylococcus aureus strain (by colonial morphology, coagulase and
DNase tests) and then susceptibility of the micro-organism to methicillin is
assessed by traditional sensitivity testing.

It is well recognised that these

methods can be affected by assay variables such as incubation time and
temperature, pH, and NaCI concentration (Salisbury ^aj., 1997; Schimitz^^.,
1997), and by the heteroresistant nature of methicillin resistance expression of
most MRSA strains (Dominguez et^-, 1997; Morita, 1994). DNA based
detection systems permit direct sampling of the organisms DNA eliminating the
variability associated with conventional phenotypic-based approaches.
In considering the limiting features of current methods, a multiplex PCR
(mPCR) was developed to identify MRSA by simultaneous amplification of three
gene targets specific to the organism. Combined (or multi-target) PCR detection
strategies are effective particularly in the context of high-throughput sampling as
they decrease the time and cost associated with individual PCR reactions
Initially the gene targets selected were a 604 bp segment of the mecA
gene (methicillin-resistance gene), a 467 bp portion of the fern A gene (encoding
an enzyme involved in the synthesis of peptidoglycan precursors in S. aureus)
(Kizaki ^ a]., 1994), and a 137 bp segment of the spa gene (which codes for the
S. aureus specific protein A) (Corbett ^al., 1994). Many attempts to optimise
the combined detection of these targets were performed (see Section 3.3.1
below) (varying the primer concentration, MgCl2 concentration, number of
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amplification cycles, and the annealing temperature), however an optimised
triplex-PCR assay was finally achieved by replacing the spa gene target with a
267 bp segment of the nuc gene (encoding the thermonuclease gene of S.
aureus) (Brakstad et ai-, 1992).

3.3.1: Optimisation of a Triplex-PCR assay for MRSA detection:
spa gene target amplification:
Initially amplification of the spa gene target was performed for 4 MRSA strains
(238, 9845, 10712, and 36197) as described by Corbett
50 pmoles each of the spa oligonucleotides, 4 mM MgCl2, 200

(1994), using
jiM

dNTPs, and

2.5 U of Tag polymerase, followed by 25 amplification cycles of 92°C for 1 min,
55 °C for 30 sec, 72 °C for 1 min. The result of this PCR assay is shown in figure
3.2 (a). The 137 bp spa amplicon is clearly amplified for each strain tested but
there are additional non-specific bands amplified in 2 strains (10712 and 36197,
see Figure 3.2 a, lanes 2 and 3).
To overcome the problem of non-specific amplification a MgCl2 titration
was performed. The spa gene was amplified from strain 36197 with varying
concentrations of MgCl2 ranging from 1-4 mM (all other parameters were
maintained as above). The results of this titration are shown in figure 3.2 b. The
spa gene product was not amplified with 1 mM MgCl2 but was visible at 2-4 mM
MgCl2. Non-specific amplicons were present, however the intensity of this non
specific amplification was decreased at 4 mM MgCl2. Therefore this
concentration of MgCl2 was utilised in all future amplifications of the spa target.
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To eliminate the extraneous bands amplified using spa-PCR. the
annealing temperature of the PCR was varied. It was determined that
amplification of the 137 bp product was achieved with annealing temperatures
of 55-57 °C. Above 57 °C amplification of the spa gene target was not consistent
(results not shown). Therefore using an annealing temperature of 57 °C and 4
mM MgCl2, PCR of the spa target of MRSA 36197 was performed with
decreased concentrations of the spa primers (i.e. 10 and 20 pmoles).
Amplification of the 137 bp segment of the spa gene occurred at each primer
concentration (see Figure 3.2 c), however at 10 pmoles it was evident that the
amplification of the non-specific bands was reduced.

mecA- femA amplification:
Simultaneous amplification of the mecA and femA targets was attempted as
their individual PCR amplification conditions seemed compatible (Kizaki ^af.,
1994).
Initially the combined mecA-femA-PCR of MRSA 36197 was performed
using 2.5 mM MgCl2, 200 ^iM of each dNTP, 0.5 U of Tag polymerase. The
amplification profile consisted of 30 reiterated cycles of 95 °C for 1 min, 55 °C for
1 min, and 72 °C for 2 min. The concentration of the mecA and femA primers
added to the PCR was varied (100 pmoles, 50 pmoles and 20 pmoles) to
determine an optimal concentration for simultaneous amplification. The results
of this investigation are shown in figure 3.2 (d). Amplification of both targets
(mecA- 604 bp and femA-467 bp) occurs at each primer concentration. Twenty
picomoles of the primers was selected as the most appropriate concentration as
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Figure 3.2 (a-h): Agarose gels (2% NuSieve'" consisting of 1.7% NuSieve'"'
and 0.3% agarose) showing results of optimisation experiments involved in the
development of a triplex-PCR assay for MRSA detection.

a. PCR products generated using reaction conditions described by Corbett ^ af.
(1994) for amplification of the spa gene target from MRSA strains. Lane M,
grade V molecular weight marker; lane 1, MRSA 238; lane 2, 36196; lane 3,
MRSA 10712; lane 4, MRSA 9845.

b. Results of a MgCl titration to improve spa amplification from MRSA strain
2

36197.
Lane M, grade V molecular weight markers; Lane N, Negative; lane 1, 1 mM
MgCl ; lane 2, 2 mM MgCl ; lane 3, 4 mm MgCl .
2

2

2

c. Titration of the primers used for amplification of the spa gene segments
(MRSA strain 36197).
Lane 1,10 pmoles; lane 2, 20 pmoles; lane 3, 50 pmoles.

d. Electrophoresis of products of a primer titration for combined detection of the
mecA and fern A gene targets of MRSA strain 10712.
Lane M, grade V molecular weight markers; lane 1, 100 pmoles; lane 2, 50
pmoles; lane 3, 20 pmoles.
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Figure 3.2 contd:
e. Products of a combined mecA-femA PCR amplified using reaction conditions
optimised for spa target from MRSA strains.
Lane M, grade V molecular weight markers; lane 1, MRSA 238; lane 2, MRSA
36197; lane 3, MRSA 10712; lane 4, MRSA 9845.

f. Electrophoresis of amplified products from a triplex-PCR assay (mecA. femA
and spa) applied to MRSA strains.
Lane M, grade V molecular weight marker, lane 1, MRSA 238; lane 2, MRSA
36197, lane 3, MRSA 10712.

g. Agarose gel showing of amplification of the nuc gene target from MRSA strain
10712.
Lane M, grade III and V molecular weight marker; lane 1, MRSA 10712.

h. Results of optimised quadruplex- and and triplex-PCR assay for detection of
MRSA strain 01712.
Lane M, grade V molecular weight marker; lane 1, quadruplex assay; lane 2,
triplex assay.
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Triplex

resolution of the gene products was greatest at this concentration and
amplification using less of the primers decreased the cost of the assay.
Amplification of the mecA and femA gene segments of four MRSA strains
was attempted using the reaction conditions optimised for spa amplification i.e.
4 mM MgCl2, 10 pmoles of each of the primers, 25 amplification cycles with an
annealing temperature of 57 °C. The results of this analysis are shown in figure
3.2 (e). It is evident that the mecA and femA gene products are efficiently
amplified using these reaction conditions.

Triplex-PCR:
Having successfully optimised a system for simultaneous amplification of mecA
and femA gene targets, the next step in the development of a triplex-PCR
detection strategy was to combine this assay with amplification of the spa gene
target. Triplex-PCR analysis to amplifiy the mecA. femA. and spa gene targets of
three MRSA strains was performed using the reaction conditions established
above (i.e. 4 mM MgCl2, 10 pmoles of each primer, 25 amplification cycles with
an annealing temperature of 57°C. Figure 3.2 (f) demonstrates that the mecA
and femA targets were efficiently amplified for each of the 3 MRSA strains,
however amplification of the spa target was inconsistent (i.e. a 137 bp fragment
was amplified for strains 238 and 36197 [see Figure 3.2 f, lane 1 and 2] but not
for strain 10712 [see Figure 3.2 f, lane 3]). Corbett

(1994) suggest that the

spa gene may only be present in 95% of Staphylococcus aureus and this,
together with the problems associated with its amplification, led to the
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replacement of this spa gene target with a 267 bp segment of the nuc gene
(encoding the thermonuclease of S. aureus).
Amplification of the nuc gene segment was performed using the
conditions described by Brakstad et^. (1992), however the concentration of
MgCl2 was again increased to 4 mM and the primer concentration was 10
pmoles. These conditions permitted specific amplification of the 267 bp nuc
gene product, (see Figure 3.2 g).
A triplex-PCR was performed using the three gene targets mecA. femA.
and nuc for strain 10712. This PCR permitted clear amplification of the 3 DNA
segments and non-specific amplification was not encountered (see Figure 3.2 h,
lane 1). Quadruplex-PCR was also possible by combining this triplex-PCR with
amplification of the spa target (see Figure 3.2 h, lane 2). As the information
content of the detection system was not enhanced by inclusion of the spa gene
target (given the previous inconsistent amplifications) and also because
amplification of a fourth target increases the cost of the assay, the spa gene
target was not included in further analyses.

The expected results when analysing members of the genus staphylococcus,
using this optimised triplex-PCR system are shown in the table 3.3 below:

Table 3.3: Triplex-PCR assay results
Strain

mec A

fern A

nuc

(604 bp)

(467 bp)

(267 bp)

MRSA

+

+

+

MSSA

-

+

+

+/-

-

-

CNS

143

Amplification of the three gene segments (mecA-604 bp; femA-467 bp; and nuc267 bp) occurs for methicillin-resistant strains of Staphylococcus aureus.
Methicillin-sensitive S. aureus (MSSA) strains show amplification of only the S.
aureus specific genes (i.e. fern A and nuc targets) whereas coagulase negative
staphylococci do not exhibit amplification of the S. aureus specific genes but
may amplify the mecA gene segment depending upon the methicillin resistance
status of each individual CNS strain (Cotter eta]., 1997).

3.3.2: Triplex-PCR analysis of outbreak 1:
As a means of testing the efficiency of this method, the mPCR assay was applied
to purified DNA isolated from each of 48 MRSA strains taken from outbreak 1 at
Cork University hospital (CUH). The results of these investigations are shown in
figure 3.3 (a to c). These figures show that each of the outbreak isolates (with
the exception of strain 665) amplified the three expected DNA targets outlined in
table 3.3 above confirming each of these isolates to be an MRSA strain. Only
the mecA gene segment was amplified in strain 665 (see Figure 3.3 c, lane 2),
prompting a retest of this strain using conventional methods. From this data it
was concluded that strain 665 was in fact a CNS strain that should not have
been included with the outbreak isolates. This finding correlates with the RW3A
fingerprinting data which assigned this strain to the miscellaneous group of
fingerprint profiles (see figure 3.13 c, lane ).

The specificity of this mPCR assay was further confirmed by testing 20 MSSA
strains, 20 CNS, and a wide variety of Gram-positive and -negative microbial
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species (see lanes 19 and 20 in Figures 3.3 a, b, and c and Figure 3.4). These
results clearly demonstrate that the femA and nuc gene targets are only
amplified in S. aureus isolates and that the mecA gene can be amplified in
microbial strains other than S. aureus (such as CNS) that exhibit resistance to
methicillin. It is for this reason that a mPCR assay is necessary for MRSA
detection. The mecA gene is not specific for MRSA (Kobayashi et

1994) and

therefore the amplification of this gene must be combined with that of an S.
aureus specific gene to provide definitive confirmation of the presence of an
MRSA strain. The S. aureus specific gene target selected must be genome
specific (present in all of the S. aureus isolates). Targets such as toxin genes
(e.g. the enterotoxins A-E, exfoliative toxins A and B, and TSST-1), and other
virulence determinants should be avoided as these are only present in certain
toxin producing or pathogenic strains. The nuc gene represents an ideal target
for inclusion in mPCR assay design as it has been shown to be present in all S.
aureus strains tested. Similarly, the femA gene is specific to S. aureus isolates.
Another important consideration when amplifying multiple products in a
PCR reaction, is that the products are significantly different in size allowing easy
interpretation of agarose gel results. For the triplex-PCR described here, 2%
agarose gels could easily resolve the three differentially sized PCR products
although improved resolution of the amplified products was attained using 2%
NuSieve" agarose gels (usually consisting of a mixture of 1.7% NuSieve™
agarose and 0.3% agarose).
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Figure 3.3 (a-c): Triplex-PCR assay performed on clinical isolates of MRSA
from the Cork University Hospital (CUH) outbreak 1 resolved on a 2%
NuSieve^^ agarose gel.

a. Lane M, grade V molecular weight markers; lane 1, MRSA 36197; lane 2,
MRSA 10712; lane 3, MRSA 18780; lane 4, MRSA 10231; lane 5, MRSA 11678;
lane 6, MRSA 14688; lane 7, MRSA 647; lane 8, MRSA 11130; lane 9, MRSA
13314; lane 10, MRSA 18409; lane 11, MRSA 646; lane 12, MRSA 12129; lane
13, MRSA 12096; lane 14, MRSA 14659; lane 15, MRSA 36464; lane 16,
15025; lane 17, MSSA 23668, lane 18, CNS 23714, lane N, Negative.

b. Lane M, grade V molecular weight markers; lane 1, MRSA 12175; lane 2,
MRSA 12515; lane 3, MRSA 15004; lane 4, MRSA 10422; lane 5, MRSA 13995;
lane 6, MRSA 14206; lane 7, MRSA 8516; lane 8, MRSA 10322; lane 9, MRSA
13606; lane 10, MRSA 14281; lane 11, MRSA 238; lane 12, MRSA 14627; lane
13, MRSA 12153; lane 14, MRSA 20552; lane 15, MRSA 5236; lane 16, 15025;
lane 17, MSSA 23488, lane 18, CNS 23727, lane N, Negative.

c. Lane M, grade V molecular weight markers; lane 1, MRSA 9845; lane 2, CNS
665: lane 3, MRSA 14001; lane 4, MRSA 36365; lane 5, MRSA 10673; lane 6,
MRSA 14364; lane 7, MRSA 8533; lane 8, MRSA 11418; lane 9, MRSA 7687;
lane 10, MRSA 11602; lane 11, MRSA 13579; lane 12, MRSA 13590; lane 13,
MRSA 8212; lane 14, MRSA 11134; lane 15, MRSA 12095; lane 16, 13225;
lane 17, MSSA 23740, lane 18, CNS 9427, lane N, Negative.

Figure 3.4: Electrophoresis results of triplex-PCR analysis of various microbial
species.
Lane M, grade V molecular weight markers; lane 1, MRSA 28805; lane 2, MSSA
4245; lane 3, CNS 23714; lane 4, Listeria monocytogenes 7: lane 5,
Acinetobacter baumannii 22158; lane 6, Escherichia coli 6; lane 7, Serratia
marcescens 8988; lane 8, Pseudomonas aeruginosa 6028; lane 9, Salmonella
enteritidis 5488, lane N, Negative.
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3.3.3: Analysis of BORSA strains using triplex-PCR:
DNA based detection systems for MRSA allow the identification of the so-called
borderline resistant Staphylococcus aureus (BORSA) strains. These strains
exhibit low level resistance to methicillin but do not possess the mecA gene.
The mec-independent resistance of these clinical isolates may occur due to:
(i) the production of elevated levels of p-lactamase (Brakstad ^aj., 1997),
(ii) the presence of a methicllinase enzyme (Barg et al-, 1991; Chambers,
1997), or
(iii) alterations in the structure of the PBPs (Dominguez ^aj., 1997).
Ten suspected clinical isolates of borderline-resistant S. aureus were obtained
from Dr. Niamh O’ Sullivan, St. James’ Hospital, Dublin. The methicillinresistance status of these strains was difficult to interpret using routine sensitivity
testing. For most of these isolates (using disc diffusion tests) it was evident that
the main population of cells were sensitive to methicillin, with only a minor
subpopulation resistant to this agent. The MIC to methicillin and oxacillin for
each strain was determined using the British Society for Antimicrobial
Chemotherapy guidelines (British Society of Antimicrobial Chemotherapy,
1991) and these results are shown in table 3.4.
Table 3.4: VIICs of methicillin and oxacillin for a
number o BORSA strains
Strain
Methicillin
Oxacillin
MIC (uq/ml)
MIC (uq/ml)
B1
1
2
B2
1
8
B3
1
8
B4
1
8
B5
1
32
B6
1
16
B7
1
4
1
B8
8
B9
2
0.25
1
B10
8
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These guidelines suggest that strains with MICs of >2-4 ^rg/ml are resistant to
methicillin. Using the oxacillin MIC test results, a number of strains (B2, B3, B4,
B5, B6, B8, B10) would be considered methicillin resistant. However, it has
been reported that because of the heterogeneous nature of resistance to
methicillin, MIC determination is not sufficient to identify strains of S. aureus
(Hiramatsu ^ aj., 1992). In an attempt to clarify the nature of these problematic
S. aureus isolates, all strains were tested using the triplex-PCR assay described
above.
Each of the strains analysed (with the exception of B9) amplified all three
gene targets. These isolates clearly represent MRSA isolates with at least a
subpopulation of cells resistant to methicillin due to the presence of the mecA
gene. Triplex-PCR of strain B9 did not amplify a mecA gene fragment (see
Figure 3.5, lane 9). This DMA based assay confirms that the low level resistance
to methicillin exhibited by the subpopulation of strain B9 cannot be attributed to
the presence of the mecA gene and therefore this strain may represent a
genuine BORSA isolate. BORSA strains may be treated with flucloxacillin and
do not necessitate aggressive vancomycin therapy. Clearly, the
heteroresistance exhibited by strains of MRSA and the existence of BORSA
strains complicates identification of MRSA strains. However, the development of
PCR approaches for MRSA detection facilitates identification of truly methicillin
resistant strains and thereby permits the restricted use of vancomycin for these
strains.
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Figure 3.5: Results of triplex-PCR performed on suspected BORSA isolates.
Lane M, grade V molecular weight marker; lane 1, B1; lane 2, B2; lane 3, B3;
lane 4, B4; lane 5, B5; lane 6, B6; lane 7, B7; lane 8, B8; lane 9, B9; lane 10,
BIO.

Figure 3.6: A 2% NuSieve’"' agarose gel showing results of triplex-PCR used
for direct detection of MRSA from patients swabs.
Lane M, grade V molecular weight markers; lane 2, swab 33073; lane 2, swab
33126; lane 3, swab 33051; lane 4, swab 33171; lane 5, swab 33165; lane 6,
swab 33049; lane 7, swab 33276; lane 8, swab 33089.

150

Figure 3.5:
M1

23456789 10

mecA
femA
nuc

Figure 3.6:
M12345

67

8M

mec A
fem A
nuc

151

3.3.4: Direct detection of MRSA in patients swabs using triplex-PCR:
The mPCR assay as described takes approximately 5 hours depending upon
the make of thermocycler employed. The DNA isolation protocol is the time
consuming step that lengthens the assay time from sample acquisition to
confirmation of a final result. Applications of PCR assays directly to patient
samples such as blood cultures have been previously documented (Brakstad ^
aj., 1993; Schimitz

1997). By using rapid DNA purification methods, these

PCR assays may gain acceptance in routine clinical settings in time.
To assess the ability of this triplex-PCR to provide results directly from
patients swabs, a blind assay was performed in collaboration with the Medical
Microbiology Laboratory at CUH. Duplicate swabs were obtained from each of
eight hospitalised patients. One swab was sent for routine microbiological
investigation and the other was subjected to mPCR and the results obtained
independently by both methods were compared.
Preparation of the swabs for mPCR was minimal and involved the careful
mixing of patients swabs with 20

|liI

of 10X PCR buffer. These samples were

incubated at room temperature for 5 minutes to allow cell lysis to occur. The
samples were then centrifuged at 14,000g for 2 minutes to remove cell debris
and the supernatant was retained and used for triplex-PCR.
Following PCR amplification, the products from each of the 8 patient
samples were resolved in a 2% NuSieve™ agarose gel (see Figure 3.6). The
three MRSA specific DNA fragments (see Table 3.3) were amplified from three
of the patients swabs - 33073, 33126, and 33276 (see Figure 3.3, lanes 1,2,
and 7), confirming these swabs contained MRSA isolates. Three of the samples
(33051, 33049, and 33089) contained methicillin-sensitive Staphylococcus
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aureus since only the S. aureus specific bands, femA and nuc (see Figure 3.3,
lane 3, 6, and 8), were amplified. No amplicons were detected in the final two
specimens (33171 and 33165) and it was concluded therefore that these
samples were negative for both MRSA and MSSA. Microbiological analysis of
the duplicate swabs CUH confirmed these results.
This trial demonstrates the ease with which triplex-PCR can be applied
directly to patients samples for the detection of MRSA. The assay format
decreased significantly the time taken for MRSA detection. Assay time was
reduced from 48 hours (by conventional tests) to 5 hours using triplex-PCR and
thereby provides a “same-day” result. In addition to the obvious advantage
provided by eliminating the time-consuming and laborious culture of the
organism and extraction of genomic DNA, omitting these steps also decrease
the expense of performing the test by excluding the cost of media and cell wall
degradative enzymes such as lysostaphin and proteinase K.
Direct detection using mPCR could not replace routine culture of patients
swabs as this assay is only capable of MRSA and MSSA detection. However
direct detection triplex-PCR could provide a valuable tool for infection control
programmes by providing a rapid ‘first-line’ screening method for assessment of
the MRSA status of patients and staff in a health care facility. The assay would
enable rapid identification of potential reservoirs which in turn would enable the
implementation of focused control measures aimed at preventing further
pathogen transmission
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3.4: Diqoxiqenin (DIG)-detection strategies for MRSA:
The application of PCR in routine clinical laboratories, where large sample
throughput is essential, is hindered by the conventional techniques used to
detect amplified products. PCR products are usually detected by agarose gel
electrophoresis and nucleic acid hybridisation assays (using radiolabelled
probes), however these approaches cannot be readily incorporated into
laboratory practice. The hazards associated with the use of radiolabelled
probes also limits applicability of these systems in routine clinical settings.
An ideal detection strategy would combine the sensitivity and specificity
of PCR with a detection format that would be rapid, reliable, convenient, and
have potential for automation. Such a detection strategy should be designed to
facilitate high sample throughput and use the equipment available in clinical
diagnostic laboratories.
In recent years, the advent of a number of non-isotopic detection formats
such as dot blots (Conrads Mai-, 1996; Fanning Mai-, 1998; lida

1993;

Panigrahi et a]., 1987) and immunoassays (Fanning et aj., 1995; Lundeberg ^
aj., 1994; Rothschild Maj., 1995) has provided systems for sensitive detection of
pathogenic bacteria which have the potential for use in clinical laboratories.
The aim of this work was to develop a rapid diagnostic tool for MRSA
detection by combining triplex-PCR with a solid phase detection format. Two
approaches were assessed namely a "dot blot" assay and a colour amplified
PCR detection system (CAPS) assay. The principles of these strategies are
shown in figures 2.4 and 2.5 a.
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3.4.1: DIG-labelling of PCR products:
For each bacterial strain analysed three individual PCR reactions were
performed (mecA-PCR. femA-PCR and nuc-PCR). The products of these
reactions were labelled by including a dNTP mix containing DIG-11-dUTP in the
PCR reaction. Incorporation of this nucleotide into the PCR products was
confirmed by agarose gel electrophoresis. The bulky nature of the digoxigenin
molecule restricts the mobility of the amplicon through an agarose gel. Initially,
to evaluate the efficacy of DIG-labelling, the three PCR reactions were
performed for a single MRSA strain both with and without DIG-11-dUTP. The
results of this comparison are shown in figure 3.7. It is clear from this data that
the decreased mobility of the amplicons when DIG-dUTP is present in the PCR,
signifies incorporation of the labelled nucleotide during the amplification of the
mecA. femA and nuc gene targets. The incorporation of DIG-11-dUTP in the
PCR amplicons is critical as this labelling forms the basis of the two solid phase
detection strategies decribed below.

3.4.2: "Dot blot" analysis:
Incorporation of DIG-dUTP into the three PCR reactions (outlined above)
enabled the development of a colorometric "dot blot" detection system. Clinical
isolates of MRSA, MSSA, CNS, and other microbial species were analysed
using this format. Initially PCR amplification of the three targets was performed
and analysed by agarose gel electrophoresis. The results are shown in figures
3.8 a-c respectively. An unlabelled mecA, femA. and nuc amplicon is included
in each gel for comparison. Examination of these gels confirms that for each
microbial sample DIG-labelling occurred, as evidenced by decreased mobility of
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Figure 3.7: Agarose gel (2% NuSieve " agarose) showing DIG-dUTP labelling
of triplex-PCR targets from MRSA strain 36197. Unlabelled amplicons were
included in this gel for comparative purposes.
Lane M, grade V molecular weight markers; lane N, negative; lane 1, mecA
amplicon; lane 2, DIG-mecA amplicon ; lane 3, femA amplicon; lane 4,
DIG-femA amplicon; lane 5, nuc amplicon; lane 6, DIG-nuc amplicon.
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Figure 3.8 (a-c): These gels show DIG-labelling of mecA. femA. and nuc
amplicons respectively from various microbial species.
Lane M, grade V molecular weight markers; lane 1 in each gel contains the
appropriate unlabelled amplicon; lane 2, MRSA 12175; lane 3, MRSA 5236;
lane 3, MRSA 36464; lane 4, CNS 1315; lane 5, CNS 1346; lane 6, MSSA
23662; lane 7, MSSA 23668; lane 8, Escherichia coli 6085; lane 9,
Acinetobacter baumannii 45057: lane 10, Listeria monocytogenes 7: lane N,
negative.

Figure 3.8 d: “Dot Blot” analysis of DIG-labelled PCR products (analysed
above using agarose gel electrophoresis) from various microbial species.
Strain 1, MRSA 12175; strain 2, MRSA 5236; lane 3, MRSA 36464; strain 4,
CNS 1315, strain 5, CNS 1346; strain 6, MSSA 23662; strain 7, MSSA 23668;
strain 8, Escherichia coli 6085: strain 9, Acinetobacter baumannii 45057; strain
10, Listeria monocytogenes 7.
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the labelled amplicons after gel resolution. The results of the “dot blot” assay
are shown in figure 3.8 d. Three coloured dots, corresponding to the mecA.
femA. and nuc gene targets confirms detection of an MRSA isolate. An MSSA
strain is confirmed by two coloured dots representing the femA and nuc targets.
The specificity of this “dot blot” system was demonstrated by including a variety
of Gram-positive and Gram-negative micro-organisms in the analysis. No dots
were evident for the three targets for non-MRSA strains (see Figure 3.8 d).

3.4.3: CAPS assay:
A previously described immunoassay system termed colour amplified PCR
detection system (CAPS) (Fanning

1995) was adapted for MRSA

detection (see Figure 2.2.5).
Initially control DIG-labelled DNA was serially diluted over a range of
concentrations (15 pg-1 ng) and analysed by CAPS. The diluted standards were
analysed in duplicate and the average absorbance reading (of these duplicates)
is shown in table 3.5. Optical density at 490 nm increased with increasing
concentrations of DIG-labelled DNA (see Table 3.5 and Figure 3.9).
The applicability of this approach for MRSA detection was assessed.
Three PCR reactions (again using the targets outlined above) which
incorporated DIG-label were performed for each bacterial strain tested. Clinical
isolates of MRSA, MSSA, CNS, and other bacterial species were analysed by
CAPS. Three wells of the microtitre plate were used for each microbial sample
(representing the mecA. femA. and nuc targets). Table 3.6 a shows the
absorbance values at 490 nm obtained for each sample in this assay. This
detection system is qualitative i.e. a positive or negative result was obtained for
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Table 3.5: Absorbance at 490 nm (average of triplicates) obtained using
CAPS analysis of varying concentrations of DIG-dUTP labelled DNA
Cone. DNA (pg)

Abs. @ 490 nm

15

0.053

31

0.1

62.5

0.213

125

0.398

250

0.645

500

0.842

1000

1.02

Figure 3.9: Standard curve of DIG-dUTP labelled DNA
(Standards were analysed in triplicate and the average absorbance was plotted)
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each well. All absorbance readings below 0.01 were considered negative. All
positive results obtained were significantly higher than this cut-off value, ranging
from 0.147-1.845. The qualitative data is shown in table 3.6 b.

Table 3.6: CAPS assay results for a variety of microbial species
(a.) Absorbance readings at 490 nm
Abs @ 490 nm
Strains

mecA

femA

nuc

MRSA 12175

1.845

0.502

0.198

MRSA 5236

1.088

0.316

0.359

MRSA 36464

1.188

0.393

0.181

CNS 1315

0.001

0.004

0.003

CNS 1346

0.001

0.001

0.001

MSSA 23662

0.003

0.147

0.180

MSSA 4241

0.001

0.218

0.322

E. coli 6085

0.000

0.002

0.007

Acietobacter 45057

0.006

0.001

0.002

Listeria 7

0.003

0.000

0.000

Negative

0.001

0.000

0.005

b.) Qualitiative interpretation of absorbance ds
Abs @ 490 nm
Strains

mecA

femA

nuc

MRSA 12175

+

+

+

MRSA 5236

+

+

+

MRSA 36464

+

+

+

CNS 1315

-

-

-

CNS 1346

-

-

-

MSSA 23662

-

+

+

MSSA 4241

-

+

+

E. coli 6085

-

-

-

Acietobacter 45057

-

-

-

Listeria 7

-

-

-

Negative

-

-

-
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Three coloured wells were evident for an MRSA strain. A MSSA exhibited
positivity only in the fern A and nuc wells.
These results indicate that a CAPS detection format, using a three well
microtitre plate approach, can be applied for the specific detection of MRSA.

Both the "dot blot" and CAPS assays described above for MRSA detection are
non-isotopic systems utilising digoxigenin (DIG):anti-DIG reactions (Kessler,
1991). Specificity of this reaction is assured as digoxigenin is unique to Digitalis
plants and therefore the two bioanalytical systems developed are highly specific
for MRSA detection. Microtitre plate assays such as CAPS are advantageous
as they permit the simultaneous analysis of many samples utilising the existing
instrumentation in many laboratories.
However a significant limitation of these DIG-based detection assays is
that they are designed as two-phase systems (i.e. they involve a PCR
amplification and a detection phase). Ramussen ^aj. (1994) have described a
one phase detection format for bovine leukaemia virus and Salmonella strains.
This system termed DIAPOPS (detection of immobilised amplified product in a
one phase system) involves the use of primer coated microtitre plate wells. In
this system, simultaneous amplification and capture during PCR enables
immediate detection of amplified products (Ramussen ^aj., 1994). In the future,
development of such one-phase systems would facilitate use of DIG:anti-DIG
detection strategies in routine laboratories.
In addition, the widespread clinical application of these "dot blot" and
CAPS strategies for MRSA detection is prohibited by the time and cost retraints
assocaited with using three gene targets. In the future, identification of a MRSA
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specific marker would improve these technologies by enabling a single PCR
reaction and subsequently a single dot/well detection format.
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3.5: DNA fingerprinting of MRSA:
The objective of this work was to design a suitable PCR-based DNA
fingerprinting strategy and then to apply this procedure to investigate the genetic
relationship(s) among the two CUH MRSA outbreaks (previously investigated by
antibiogram analysis, see Section 3.1).

3.5.1: Selection of an appropriate primer for DNA fingerprinting of MRSA:
It is well recognised that the sequence of the primer used for DNA-fingerprinting
is critical as it determines the number and frequency of annealing targets on the
genome template and therefore dictates the information content of the resultant
fingerprints (Akopyanz et al., 1992; Power, 1996). Initially to identify an
appropriate oligonucleotide capable of revealing polymorphisms in different
MRSA genomes, a number of primers were screened.
RAPD fingerprinting was performed using five primers (designated LC-1,
LC-2, LC-3, LC-4, and LC-5, see Table 3.7). In RAPD, a single primer of
arbitrary sequence anneals to the DNA template at low annealing temperature
(typically 36°C) and directs the PCR-mediated amplification of variable length
DNA fragments (i.e. fingerprints) for each primertemplate combination (Welsh ^
^., 1990; Williams Mai., 1990; Gaetano- Anolles M a}., 1991).
Using another fingerprinting approach, termed repetitive sequencebased PGR or rep-PGR, conserved structural repeat motifs were used as
amplification platforms for fingerprinting of MRSA strains. Various repeat
elements have been found in the genomes of micro-organisms and many of
these elements have been exploited for strain differentiation in rep-PGR
fingerprinting assays (Lupski Mai., 1992). Oligonucleotide primers for rep-PGR
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are designed to face outwards (i.e. away from the corresponding repeat motifs)
and direct the amplification of intervening regions which produce strain specific
DNA profiles (Versalovic Mai-, 1991). In this study, rep-PCR was performed
using two methods (i.e. REP-Dt primers and RW3A). The REP-Dt primers are
degenerate oligonucleotides complementary to repetitive extragenic
pallindromic (REP) element (see Table 3.7 below for degenerate positions) and
the RW3A primer is derived from the Rep-MP-3 repeat element of Mycoplasma
pneumoniae (Del Vecchio Mai-, 1995).
Each of these primers was used to fingerprint 5 MRSA isolates (strains
238, 5236, 9845, 10712, and 36197) (as described in Section 2.2.4.1) and the
results obtained for each primer-template combination are shown in figures 3.10
(a-g).
A review of the characteristics of the primers used and the fingerprinting results
obtained is shown in table 3.7 below.

Table 3.7: Characteristics of the primers assessed for MRSA typing
Name

Sequence (5’-^3’)

Number of
bases
(-mer)

%G + C

Number of
bands

LC-1

TgT TgC gCA g

10

60

2-6

LC-2

TCT gTA TTg TCT TTT TCA CC

20

35

4-6

LC-3

TTA ATA gCA CCC ggT ACA AgC

21

48

4-7

LC-4

TTA Cgg CgT TAG TAT CCT CTC TA

23

43

6-8

LC-5

ggT CTC ggT CAg ATA TgT gAT TC

23

48

2-7

Rep1R-Dt
Rep2-Dt

IIINCg NCg NCA TCN ggC
NCg NCT TAT CNg gCC TAG

18

NA
NA

5-7

RW3A

TCg CTC AAA ACA ACg ACA CC

20

50

5-11

Note:

l=lnosine, N=A,G C or T (both designations reflect degenerate positions).
NA indicates that %G+C is not applicable when primers contain I or N nucleotides.
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Figure 3.10 (a-g): Agarose gels showing DNA profiles obtained using
different primers for fingerprinting MRSA strains.
In each gel: Lane M, grade III molecular weight markers; lane 1, MRSA 238;
lane 2, MRSA 36197; lane 3, MRSA 10712; lane 4, MRSA 9845; lane 5, MRSA
5236.
Primers used in each gel were as follows:
a.

LC-1

b.

LC-2

c.

LC-3

d.

LC-4

©■

LC-5

f.

Repi R-Dt and Rep2-Dt

fl-

RW3A
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A number of criteria were used to evaluate these fingerprinting strategies, prior
to selection of a suitable method for MRSA typing:
• Typeability: Amplicons were obtained for each primentemplate combination.
The number of products varied considerably e.g. LC-1 amplified from two
(MRSA 5236) to 6 (MRSA 10712 and 36197) DNA fragments (see Figure 3.10
a), whereas RW3A produced from five (MRSA 10712 and 36197) to 11 (MRSA
5236 and 9845) amplicons (see Figure 3.10 g). The base composition of the
Staphylococcus aureus is approximately 35% G+C and therefore the limited
number of amplification products with LC-1 may reflect the increased G+C
content (60%) of this oligonucleotide when compared with the others used (see
Table 3.7). Although each of these approaches demonstrates 100% typeability,
it is evident that the complexity and information content of the fingerprints
generated is characteristic for each individual primentemplate interaction.

• Resolution: An ideal fingerprinting method should amplify variably sized PCR
products where upon agarose gel electrophoresis would reveal strain-specific
DNA profiles that are easily interpreted by simple visual inspection.
A number of the primers assessed (i.e. LC-1, LC-2, LC-4, and REP-Dt)
only amplified fragments within a limited size range (approximately from 500 to
3000 bp), (Figure 3.10 a, b, d and f). These restricted profiles can complicate
the comparative studies which are necessary for epidemiological investigations
e.g. the REP-Dt fingerprints (see Figure 3.10 f) consist of 5-7 ethidium bromide
stained bands but the profiles are compacted to within a small molecular weight
range and therefore differences between the strains are not immediately
obvious.
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Amplifcation patterns generated using primers LC-3, LC-5 and RW3A
demonstrated a broad spectrum of amplicon size, typically ranging from 300 to
5000 bp (see Figure 3.10 c, e, and g). These profiles can be easily interpreted
for strain comparisons by visual inspection.

• Discrimination: A good typing scheme must reveal polymorphisms between
the different MRSA genomic templates and thereby permit discrimination of
different strains of the pathogen.
Differentiation between the MRSA strains tested is clearly visible with 5 of
7 primers tested (LC-2, LC-3, LC-4, LC-5, and RW3A, see Figure 3.7 b, c, d, e,
and g). It is evident from these approaches that MRSA strains 10712 and 36197
are similar (if not identical) to each other but significantly different from the other
strains analysed. The correlation between the results obtained using these five
fingerprinting strategies for the MRSA strains tested confirms that the groups
assigned were genuine and furthermore it confirms that each of these typing
strategies exhibits good discriminatory ability.

It was concluded from these assessments that RW3A fingerprinting provided the
most effective means of strain differentiation for MRSA isolates as;
- all MRSA strains were typeable using this procedure,
- a broad spectrum of variably sized, well resolved DNA fragments were
amplified, and
- strain differentiation was clearly evident even within a small group of
strains.
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In addition, the high stringency amplification conditions of the RW3A rep-PCR
assay design were favoured over the less stringent RAPD systems (the
reproducibility of which may be affected by many variables e.g. DNA quality and
concentration [Power, 1996], primer characteristics [Akopyanz M al-, 1992],
thermostable DNA polymerase [Schierwater ^aj., 1993], and make of
thermocycler utilised [Penner ^al., 1993], see Section 1.5.5.), as these rep-PCR
strategies are not as susceptible to assay variables and therefore yield
consistently reproducible DNA fingerprints (Gao et al., 1996; Louwz MM-, 1994).

Having identified the fingerprinting potential of RW3A, attempts were then made
to improve the quality of the RW3A fingerprints of MRSA strains by undertaking
assay optimisation experiments.
Initially the quantity of DNA added to the PCR was varied. RW3A fingerprinting
of MRSA strain 36197 was performed using 50-200 ng of genomic template in a
50

PCR reaction volume. All other reaction parameters were maintained as

described in section 2.2.4.1. The results of this analysis are shown in figure
3.11. Over this limited range of template concentrations, the DNA fingerprints
had identical banding patterns (Figure 3.11). However, the intensities of the
amplified products differed when the concentration of template was altered.
Decreasing the template to 50 ng resulted in a shift towards an increased
intensity of the lower molecular weight DNA fragments. At the upper end of
template concentration (200 ng of DNA), the banding pattern exhibited a more
uniform distribution (i.e. no fragment was excessively amplified), for example
compare lanes 1 and 4 in figure 3.11. These studies confirm that changing the
concentration of DNA over this limited range did not significantly alter the
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Figure 3.11: Effect of varying DNA template concentration on the RW3A
fingerprint of MRSA strain 36197.
Lane M, grade III molecular weight size standard; lane 1, 50 ng of DNA; lane 2,
100 ng of DNA; lane 3, 150 ng of DNA; lane 4, 200 ng of DNA.

Fiaure 3.12: Comparison of 2 buffer systems (Promega and Gitschier) for
RW3A fingerprinting of MRSA strains.
Lane M, grade III molecular weight markers; lane 1, MRSA 238; lane 2, MRSA
36197; lane 3, MRSA 10712; lane 4 MRSA 9845; lane N, negative; lane S,
grade V molecular weight size standard.
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amplicon profiles obtained, but as a more uniform profile was achieved with 200
ng of DNA, RW3A fingerprinting of both MRSA outbreaks was performed using
this concentration of DNA.

Versalovic ^aj. (1994) utilsied a Gitschier buffer system (Kogan et aj., 1987) for
rep-PCR of a wide variety of pathogenic micro-organisms. The RW3A
fingerprints shown in figure 3.10 (g) were generated using a Promega 10X PCR
buffer (which was supplied with the Tag DNA polymerase enzyme. The
composition of these buffers is described in section 2.1.4.1. A comparative
study was performed whereby 4 MRSA strains (238, 9845, 10712, and 36197)
were subjected to RW3A fingerprinting using both of these buffer systems to
determine if improved DNA fingerprints could be achieved using the Gitschier
buffer system.
Figure 3.12 shows the result of this comparative analysis. It can be seen
clearly from this figure that the Promega buffer system amplifies fingerprints from
each of the 4 MRSA strains tested, whereas the Gitschier buffer system inhibits
amplification of any DNA product. As the Promega Tag DNA polymerase was
used for both assays, it can be assumed that this enzyme has limited (if any)
activity in the Gitschier buffer and therefore the most suitable PCR buffer for
RW3A fingerprinting was the Promega buffer.

3.5.2: Analysis of MRSA outbreaks using RW3A fingerprinting:
Total genomic DNA was extracted from all outbreak strains using the
lysostaphin lysis procedure (see Section 2.2.2.3). To assess the genetic
relatedness among the strains in each outbreak, this template DNA was
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subjected to RW3A fingerprinting, as described in section 2.2.4.1. All strains
tested produced numerous (2-13) ethidium bromide stained DNA fragments
ranging in size from 100 bp-5.1 kb (Cotter etaj., 1997; Cotter

1998).

Outbreak 1:
This outbreak occurred in CUH from January to June of 1995. Visual inspection
of the amplification profiles of the 48 MRSA strains in collection 1 assigned 67%
(32 of the 48 isolates) to two RW3A-REP groups. These groups were
designated REP group I consisting of 23 strains (see Figure 3.13 a, lanes 1-11
and Figure 3.13 b, lanes 1-12) and REP group II encompassing 9 isolates (see
Figure 3.13 b, lanes 13-21). The remaining 38% of the outbreak strains
exhibited significantly different fingerprint patterns from each other and from
REP group I and II and therefore it was concluded that these strains represented
a diverse (unrelated) miscellaneous group of isolates. There was no suggestion
of temporal or geographic clustering of the outbreak organisms.
Hierarchical clustering analysis (or quantitative analysis) of the RW3A
fingerprint patterns was performed for the three gels containing outbreak 1
strains. A binary matrix (wherein presence of a band=1; absence of a band=0),
was constructed. This allowed similarity coefficients to be calculated from
Tanimoto distances djj after pairwise comparisons (Rogers et aj., 1960).
Sij = 1-dij.

(i,j= 1,2,3,...... m)

djj in turn was determined from the logical operation:
dj^ = AND(Xi,Xj) / OR(Xi,Xj)

The latter is a normalised Hamming distance and is metric (Spath ^aj., 1982).
An agglomerative hierarchical clustering was performed on djj using the
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Centroid Method as the criterion for cluster relatedness. Finally a “SYSTAT”
software package was used to calculate all numerical results.
Similarity coefficients were calculated by quantitative comparisons of the
RW3A banding patterns of collection 1 which enabled the construction of a
dendrogram (see Figure 3.14) showing the genetic relationship(s) among the
analysed strains. This hierarchical clustering analysis confirmed the results of
the visual comparison. The collection was divided into two main groups
(consisting of 23 and 9 strains each) and a cluster of diverse strains.
The results obtained using antibiogram analysis and RW3A fingerprinting
for the MRSA strains of collection 1 were compared (see Table 3.8). REP group
I was most likely to be of antibiogram A (gentamicin resistant, mupirocin
sensitive). Antibiogram analysis was performed on 15 of the 23 MRSA strains in
REP group I, and 12/15 of these strains (80%) were antibiogram A. The
remaining 3 of the 15 strains were antibiogram C (gentamicin and mupirocin
resistant). Antibiogram B (gentamicin and mupirocin sensitive) was associated
with REP group II. The antibiogram profile was determined for only 4 of the 9
strains in REP group II and of these 3 strains (33%-3/9) were antibiogram B (the
fourth isolate tested had antibiogram profile type A). The REP miscellaneous
group comprised strains with all three antibiogram profiles (see Table 3.8).
The clinical details were available for 38 patients, four infections were
recorded, 3 wound infections and one septicaemia. All infections corresponded
to different RW3A-REP groupings and antibiogram profiles (see Table 3.8).
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Figure 3.13 (a-c>: RW3A primer derived DNA fingerprints from MRSA clinical
isolates. Analysis of amplified products by gel electrophoresis in 2% agarose
gel.

a. Lane M, grade III and V molecular weight size standard; lane 1, MRSA
36197; lane 2, MRSA 10712; lane 3, MRSA 18780; lane 4, MRSA 10231; lane
5, MRSA 14688; lane 6, MRSA 11678; lane 7, MRSA 647; lane 8, MRSA 34646;
lane 9, MRSA 11130; lane 10, MRSA 13314; lane 11, MRSA 18409.

b. Lane M, grade III and V molecular weight markers; lane 1, MRSA 646; lane 2,
MRSA 12129; lane 3, MRSA 12096; lane 4, MRSA 14659; lane 5, MRSA 15025;
lane 6, MRSA 12175; lane 7, MRSA 12515; lane 8, MRSA 15004; lane 9, MRSA
14022; lane 10, MRSA 13995; lane 11, MRSA 14206; lane 12, MRSA 36351;
lane 13, MRSA 8516; lane 14, MRSA 10322; lane 15, MRSA 13606; lane 16.
MRSA 14281; lane 17, MRSA 238; lane 18, MRSA 14627; lane 19, MRSA
12153; lane 20, MRSA 20552, lane 21, MRSA 5126.

c. Lane M, grade III and V molecular weight standard; lane N, negative; lane 1,
MRSA 9845; lane 2, MRSA 665; lane 3, MRSA 14001; lane 4, MRSA 36565;
lane 5, MRSA 10673; lane 6, MRSA 14364; lane 7, MRSA 8533; lane 8, MRSA
11418; lane 9, MRSA 7687; lane 10, MRSA 11602; lane 11, MRSA 13579; lane
12, MRSA 13590; lane 13, MRSA 8212; lane 14, MRSA 11134; lane 15, MRSA
12095; lane 16, MRSA 13225.
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Figure 3.14: Dendrogram illustrating the similarity between the MRSA
isolates in this outbreak 1 using the Centroid Linkage method.
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Table 3.8: Strain no., specimen site, antibiogram type, clinical significance and R3WAREP patterns of an MRSA outbreak 1.
Strain No.
36197
10712
18780
10231
14688
11678
647
11130
13314
18409
646
12129
12096
14659
36464
15025
12175
12515
15004
10422
13995
14206
36351

Site
Unknown
Groin swab
Unknown
Sputum
Unknown
Tap
Unknown
Unknown
Wound/S
Urine
Unknown
Leg ulcer
Unknown
Unknown
Unknown
Thigh
Unknown
Wound/S
Toe
Unknown
Unknown
Unknown
PM spec

8516
10322
13606
14281
238
14627
12153
20552
5236

Sputum
Unknown
Unknown
Wound/S
Unknown
Unknown
Unknown
Urine
Unknown

/
/
B
B
B
/
/
A
/

colonisation

9845
665
14001
36565
10673
14364
8533
11418
7687
11602
13579
13590
8212
11134
12095
13225

Blood/C
Unknown
Unknown
Unknown
Wound/S
Ulcer
Cath. Site
Unknown
Unknown
Wound/S
Unknown
Unknown
Unknown
Sputum
Unknown
Unknown

C
C
B
B
B
B
A
/
A
A
/
A
B
B
/
/

bacteraemia
colonisation
colonisation
colonisation
infection
colonisation
colonisation

Antiibiogram Type Clinical Sig.
colonisation
/
colonisation
C
/
A
colonisation
colonisation
A
colonisation
C
/
/
A
colonisation
A
colonisation
A
infection
A
colonisation
/
/
A
colonisation
A
colonisation
A
colonisation
A
colonisation
A
colonisation
/
A
colonisation
/
C
colonisation

A = Resistant to cip, ery, gen, meth, ofl, pen.
B = Resistant to cip, ery, meth, ofl, pen.
C = Resistant to cip, ery, gen, meth, mup, ofl, pen.
/ = No Antibiogram result.

-

colonisation
colonisation
colonisation
-

colonisation
-

-

colonisation
colonisation
-

colonisation
colonisation
colonisation
-

-

R3W-REP
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
II
II
II
II
II
II
II
II
II
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.
Misc.

Sensitive to fd, mup, net, rif, teic, tet, vane.
Sensitive to fd, gen, mup,net, rif, teic, tet, vane.
Sensitive to fd, net, rif, teic, tet, vane.
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Outbreak 2:
This outbreak occurred in the early months of 1996 at CUH. Each of the 39
clinical MRSA isolates in this collection was successfully amplified using the
RW3A primer. Strain-specific profiles for each isolate were resolved in 2%
agarose gels. The fingerprints contained distinct ethidium bromide stained
fragments with similar size ranges as before (Figure 3.15 a-c). Visual inspection
and hierarchical clustering analysis (as described for outbreak 1) suggested the
existence of four strain clusters within outbreak 2. Group I and II are very closely
related (determined by similarity indexes as before) and together consisted of
24 strains representing 62% (24/39) of the outbreak (see Figure 3.15 [a and b,
lanes 1 -24], and Figure 3.16). Visual examination of fingerprint profiles is
subjective and therefore an alternative interpretation of this data is that the
assigned REP groups I and II are in fact subgroups of one main class. Group III
comprised 10 of the 39 isolates (26%). The remainder of the collection
consisted of strains with diverse unrelated fingerprint patterns (i.e 5/39-12%)
(see Figures 3.15 and 3.16). Comparing the profiles obtained using RW3A
fingerprinting, it is evident that the “miscellaneous” group of isolates is distinct
from strains in group I, 11 and III. This data suggests that these strains are
sporadic isolates which do not play a significant role in the outbreak under
investigation.
Table 3.9 shows a comparison of the results of antibiogram analysis and
RW3A fingerprinting for collection 2 from CUH. Twenty-one of the strains in
RW3A-REP groups I and II had antibiogram analysis performed. Among these
strains the predominant antibiogram profile was A (gentamicin resistant,
mupirocin sensitive) (17/21 strains-81%). The remaining strains in these two
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Figure 3.15 (a-c): Electrophoretic DNA fingerprint patterns of ail MRSA
strains of CUH outbreak 2 typed using the RW3A primer.

a. Lane M, grade iii molecuiar weight size standard; lane 1, MRSA 27828; lane
2, MRSA 25126; lane 3, MRSA 26193; lane 4, MRSA 28805; lane 5, MRSA
29040; lane 6, MRSA 40366; lane 7, MRSA 34323; lane 8, MRSA 34646; lane
9, MRSA 34957; lane 10, MRSA 41782; lane 11, MRSA 50366; lane 12, MRSA
36055; lane 13, MRSA 25517.

b. Lane M, grade III molecular weight markers; lane 1, MRSA 32602; lane 2,
MRSA 36640; lane 3, MRSA 36207; lane 4, MRSA 36336; lane 5, MRSA 27842;
lane 6, MRSA 26996; lane 7, MRSA 32479; lane 8, MRSA 36723; lane 9, MRSA
37684; lane 10, MRSA 37067; lane 11, MRSA 37808; lane 12, MRSA 34219;
lane 13, MRSA 28566.

c. Lane M, grade III molecular weight standard; lane 1, MRSA 33788; lane 2,
MRSA 37200; lane 3, MRSA 47588; lane 4, MRSA 34385; lane 5, MRSA 34610;
lane 6, MRSA 26714; lane 7, MRSA 27652; lane 8, MRSA 26261; lane 9, MRSA
37935; lane 10, MRSA 37866; lane 11, MRSA 36297; lane 12, MRSA 25825;
lane 13, MRSA 27848.
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Figure 3.16: Dendrogram constructed using the Centroid Linkage method
showing the cluster analysis of MRSA isolates in CUH outbreak 2..
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Figure 3.16:
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Table 3.9: MRSA isolates of outbreak 2 fingerprinted by rep-PCR with the
RW3A primer together with sample acquisition site and antibiogram profile.
Antibiogram Type
C
A
A
C
A
A
A
A
/
A

RW3A-REP
1
1
1
1
1
1
1
1
1
1

Strain No.
29040
50366
36055
25517
32602
27842
26996
32479
36723
37684

Site
Swab-wound
Unknown
Unknown
Swab-knee
Swab-ulcer
Swab-pubic
Swab-nasal
Swab-ulcer
Swab-wound
Unknown

27828
25126
26193
28805
40336
34323
34646
34957
41782
36640
36207
36336
37067
37808

Swab-ear
Swab-wound
Swab-wound
Unknown
MSU
Unknown
Swab-leg
Swab-I.V. site
MSU
Swab-elbow
Unknown
Swab-wound
Swab-graft
Unknown

C
A
/
A
A
A
A
A
C
/
A
A
A
A

II
II
II
II
II
II
II
II
II
II
II
II
II
II

33788
34610
26714
27652
26261
37935
37866
36297
25825
27848

Unknown
Swab-ulcer
Unknown
Swab-heel
Sputum
Sputum
Unknown
Swab
Swab
Swab-ulcer

A
B
C
A
B
/
A
/
B
/

III
III
III
III
III
III
III
III
III.
Ill

34219
28566
37200
47588
34385

Swab-stump
Unknown
Swab-wound
MSU
Unknown

B
A
A
A
B

Misc.
Misc.
Misc.
Misc.
Misc.

A = Resistant to cip, ery, gen, meth, ofl, pen.
B = Resistant to cip, ery, meth, ofl, pen.
C= Resistant to cip, ery, gen, meth, mup, ofl, pen.
/ = No Antibiogram result.

Sensitive to fd, mup, net, rif, teic, tet, vane.
Sensitive to fd, gen, mup,net, rif, teic, tet, vane.
Sensitive to fd, net, rif, teic, tet, vane.
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groups were antibiogram C-resistant to gentamicin and mupirocin (4/21-19%).
RW3A-REP group Mi represents a cluster of MRSA strains with diverse
antibiogram profiles (i.e. A, B, and C). The antibiogram profiles of the RW3AREP miscellaneous strains were either A (3/5 strains) or B-sensitive to
gentamicin and mupirocin (2/5 strains).

Comparing figures 3.13 and 3.15 it is evident that the DNA fingerprints obtained
from both outbreaks are similar (if not identical). By visual inspection it can be
inferred that the REP group I strains of outbreak 1 have a near identical fragment
array as the group I and II strains of outbreak 2. Also, the assigned REP group II
strains of outbreak 1 have a banding pattern shared with the group III strains of
outbreak 2. This data seems to suggest that the same MRSA strains were
responsible for both outbreaks. Re-emergence of the same strains
demonstrates the difficulties encountered in attempting to control spread of this
pathogen.

RW3A fingerprinting of non-MRSA isolates:
DNA was extracted from a variety of Gram-positive and Gram-negative bacteria
using appropriate techniques. This DNA was amplified in an RW3A-PCR as
described for MRSA fingerprinting in section 2.2.4.1. The amplification products
were resolved in 2% agarose and the results are shown in figure 3.17.
RW3A fingerprints of non-MRSA isolates were distinct from those of
MRSA strains. Even when strains within the staphylococcus genus were
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Figure 3.17: Gels showing results of RW3A fingerprinting of various microbial
species.
Lane M, grade III and V molecular weight markers; lane 1, MRSA 28805; lane 2,
MSSA 4245; lane 3, CNS 23714; lane 4, Listeria monocytogenes 7: lane 5,
Escherichia coli 6; lane 6, Acinetobacter baumannii 22158; lane 7, Serratia
marcescens 8988; lane 8, Salmonella enteritidis 5488; lane 9, Pseudomonas
aeruginosa 6028; lane N, negative
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Figure 3.17:
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analysed the patterns produced were significantly different from those of MRSA
strains (see Figure 3.17, lanes 1 to 3).

Lack of reproducibility and the ever increasing number of non-typeable strains
using phenotypic typing strategies has prompted the development of DNAbased typing schemes for MRSA. In recent years epidemiological studies have
increasingly relied on genotypic approaches, such as DNA hybridisation
assays, DNA fingerprinting and DNA sequencing, to differentiate MRSA strains.
The clinical applicability of a rep-PCR fingerprinting strategy-RW3A
fingerprinting was assessed in this study. All MRSA strains analysed were
typeable using this method. The procedure was highly discriminatory, resolving
the 48 MRSA strains in outbreak 1 into 18 different banding patterns and the 39
strains in collection 2 into 8 banding patterns. Assay reproducibility was
confirmed after several passages of the strains. From these results it can be
concluded that RW3A fingerprinting provides a much needed, reliable tool for
epidemiological typing of MRSA strains. Moreover, PCR-based fingerprinting
strategies such as the strategy described here offer a more convenient, less
time-consuming and labour intensive typing method than other genotypic
approaches such as ribotyping and PFGE.
The RW3A primer used for fingerprinting of the MRSA strains was derived
from the REP-MP3 sequence of Mycoplasma pneumoniae. The high stringency
amplification conditions used in the in vitro amplification reaction (i.e. annealing
temperature = 54°C) indicates sequence homology between this primer and
MRSA genomic DNA. DNA fingerprinting of other bacterial species, including
Pseudomonas aeruginosa. Salmonella enteritidis. and Escherichia coli. was
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performed using this primer for comparative purposes (see Figure 3.17 , lanes 6,
7, and 9). This data suggests that the REP-MP3 repetitive element represents a
widely dispersed and conserved DNA repeat element present in many
prokaryotic genomes. Studies performed by Gillings et a]. (1997) have shown
that ERIC primers utilised in a rep-PCR strategy can generate fingerprints from
the DNA of various bacteria, fungi, bacteriophages, plants and vertebrae when
the annealing temperature is 52°C. At higher annealing temperatures (66°C)
most of these bands failed to amplify, with the exception of a subset of bands
from enterobacterial DNA targets. These authors suggest that ERIC-PCR does
not necessarily direct amplification from genuine ERIC sequences and therefore
this strategy may represent a highly reproducible and sensitive variation of
RAPD fingerprinting (Gillings e\^., 1997). These observations may explain the
ability of RW3A to fingerprint many diverse bacterial species however further
investigations are required to confirm this theory. This data does not however
diminish the clinical utility of this typing strategy, RW3A fingerprinting remains an
effective and highly discriminatory means of differentiating MRSA strains.
Although RW3A fingerprints of non-MRSA isolates were clearly distinct
from those of MRSA strains, a single-step PCR assay providing a combined
detection and typing strategy for MRSA would improve the results obtained
using this method. Such an approach termed COGEDET (for combined gene
detection and epidemiological typing) has been described by Saulnier ^ aj.,
1997. These authors describe a variant of low stringency RAPD which includes
the use of a pair of gene-specific primers that permit the simultaneous
production of banding patterns for strain typing and a specific amplicon for gene
detection, which are analysed by agarose gel electrophoresis. COGEDET was
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evaluated for the detection and typing of three bacterial species,
Staphylococcus aureus with specific detection of the toxic shock syndrome toxin
gene (t^) encoding the TSST-1 toxin, Clostridium difficile and the toxA gene
encoding toxin A and Escherichia coli utilsiing the cjifl gene encoding the
cytotoxic necrotizing factor (CNF). It was concluded that the typing
performances with COGEDET compared favourably with conventional RAPD
and the efficiency of gene detection was comparable with conventional PCR.
Interpretation of COGEDET results can be difficult when complex banding
patterns are produced and false-positive gene detection may occur when the
fingerprint patterns include a non-specific band with a size close to that
expected for the specific amplicon. Also COGEDET represents a low-stringency
modified RAPD assay and therefore the reproducibility may be affected by the
same reaction variables that affect traditional RAPD (template concentration and
purity, type of thermocycler, brand of thermostable DNA polymerase etc.).
Inclusion of differentially labelled fluorescent tags in multiplex PCR
assays followed by analysis using GeneScan technology has been describced
by Versalovic ^al. (1994). Utilisation of such an assay system may permit
simultaneous detection and typing of MRSA strains by combining fluorescent
triplex-PCR and fluorescent RW3A fingerprinting.
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3.6: GeneScan analysis:
The development of GeneScan technology has provided an automated system
which can accurately size and quantitate DNA fragments. The system is flexible
and permits the labelling of DNA fragments with up to three differentially
coloured fluorescent dyes with a fourth dye-colour used for labelling of the
internal size standards. This versatility provides an ideal system for a combined
PCR detection and molecular typing strategy.
In this section, the products of fluorescent [F]- triplex-PCR and RW3A
fingerprinting assays were analysed using GeneScan technology in an ABI
Prism’"’ 310 genetic analyser. These two fluorescent PCR strategies were then
multiplexed to permit the development of a simultaneous detection and typing
scheme for MRSA strains.

3.6.1: Fluorescent [F]- triplex-PCR:
The first step in the development of a fluorescent triplex-PCR assay for MRSA
detection was the amplification and detection using the ABI Prism™ 310 genetic
analyser of a single gene target (e.g. the 604 bp mecA gene segment). mecA
amplification was achieved as previously described (see Section 2.2.4.2),
however a fluorescent mecA amplicon was generated by inclusion in the PCR of
5’-TET (4,7,2’,7’-tetrachloro-6-carboxyfluorescein) labelled antisense primer.
Products of this amplification were analysed after genescanning in the ABI
Prism™ 310 genetic analyser (see section 2.2.5.3) and the result is shown in
figure 3.18 (a). This electropherogram shows the internal lane standard (GS
2500 TAMRA, see Appendix 2) as red peaks with the green peaks
corresponding to the mecA PCR product. A distinct 610 bp (mecAl green peak
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Figure 3.18 (a and b): GeneScan analysis of a TET-labelled mecA-PCR
amplification product from strain 36197.
Trace 3.18 (a) shows the unpurified product and trace (b) demonstrates analysis
of the product following QIAquick PCR purification.
The red peaks correspond to the GS 500 TAMRA internal standard (Appendix 2)
and the green peaks represent the PCR products.
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Figure 3.18:

(a) Unpurified mecA PCR product

(b) QIAquick purifed mecA PCR product
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was detected, but in addition a number of non-specific fluorescent low molecular
weight amplicons were also visible. To eliminate these spurious peaks, the
amplification products were purified using a QIAquick PCR purification kit and
the purified product was then reanalysed. The resultant electropherogram
shows (Figure 3.18 b), a well defined peak at 610 bp corresponding to the mecA
gene target. All non-specific peaks were eliminated.
It was concluded from this analysis that
1. All PCR products must be purified prior to GeneScan analysis in the
ABI Prism™ 310 genetic analyser. The QIAquick PCR purification kit offers a
simple and effective means of purifying PCR samples to facilitate fluorescent
analysis.
2. Inclusion of fluorescent labels on PCR products during amplification
decreases the electrophoretic mobility of the resultant amplicons. Therefore a
small increase was observed in the size estimations of labelled DNA fragments
using GeneScan analysis (i.e. the mecA gene target is 604 bp however the
fluorescent mecA amplicon GeneScan analysis consistently sized this amplicon
at 610 bp by comparison with an internal size standard).

Amplification of the three gene targets previously outlined for MRSA detection
was performed as described in section 2.2.4.2. The antisense primer for each
target was labelled with a 5’-TET label. GeneScan analysis was performed for
MRSA, MSSA, CNS, and other microbial strains (including Escherichia coli.
Acinetobacter baumannii. Listeria spp.. Salmonella spp., and Serratia
marcescens). Each sample was purified prior to analysis. Figures 3.19 a-c
show the electropherograms obtained. The red peaks in each trace represent
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Figure 3.19 (a-c): Electropherograms showing GeneScan results of
fluorescent [Fj-triplex-PCR performed on various microbial species
Trace (a):

[F]-triplex-PCR of MRSA 28805

Trace (b):

[F]-triplex-PCR of MSSA 4245

Trace (c):

[F]-triplex-PCR of CNS 23714

(Red peaks = GeneScan 500 TAMRA standard and green peaks =TET-labelled
triplex-PCR products).
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Figure 3.19:
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nuc
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(b) MSSA 4245

(c) CNS 23714
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the GS 500 TAMRA size standard (see Appendix 2). Three green peaks
corresponding to the 3 MRSA specific targets confirm the identity of the clinical
isolates as MRSA (Figure 3.19 a). Two green peaks representing the S. aureus
specific genes, femA and nuc, were also detected for all MSSA, as shown for
the MSSA isolate in figure 3.19 (b). No peaks were detected for coagulase
negative staphylococci (Figure 3.19 c) and other microbial species (data not
shown) confirming the specificity of the assay design. Occasionally a single
green mecA peak was observed for CNS strains but the presence of this peak
was dependent upon the methicillin resistance status of the individual CNS
strain.
The three amplicons were sized automatically by the GeneScan software
by comparison with a GS 500 TAMRA standard. The PCR products were larger
than the expected target (i.e. nuc = 271 bp instead of 267 bp, femA = 504 bp
instead of 467 bp, and mecA = 610 bp instead of 604 bp). This size difference
was attributed to the inclusion of the fluorescent phosphoramidite dye TET in the
PCR products during amplification
It is evident form these results that the triplex-PCR targets can be
fluorescently labelled by inclusion of dye-labelled antisense primers in the PCR
reaction. The ABI PRISM™ 310 genetic analyser provides a sensitive, automated
system for detection of fluorescent amplicons generated during triplex-PCR.

3.6.2: Fluorescent RW3A fingerprinting:
rep-PCR fingerprinting of MRSA strains was performed using a 6-FAM-labelled
RW3A primer as described in section 2.2.5.3. All DNA fragments amplified
using this dye-labelled primer had a fluorescent label attached. Using the ABI
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Prism™ 310 genetic analyser, PCR-generated products that contained a 6-FAM
label were detected as blue peaks and were automatically sized by comparison
with a GS 2500 ROX (see Appendix 2) internal size standard (red peaks). Such
strategies, which combine rep-PCR with fluorescent detection of fluorophorelabelled amplicons have previously been termed FERP (fluorophore-enhanced
repetitive-PCR) (Versalovic et aj., 1994; Del Vecchio^^., 1995: see Section
1.7).
Prior to application of fluorescent RW3A fingerprinting to the CUH
hospital outbreak strains, a number of trials were performed to determine the
optimal GeneScan protocol for analysis of fluorescent fingerprints.

Trial 1: Varaition of sample injection time:
The electrokinetic injection time, as set in the GeneScan injection list (see
Section 2.2.5.3), was varied (injection times ranging from 5 sec to 20 sec were
performed) for analysis of the fluorescent fingerprint of strain 36197. This was
performed to identify an optimal injection time that would yield adequate
fluorescent signal for peak detection in the fingerprint. The results of this
comparison are shown in figure 3.20. It is evident from this figure that altering
the injection time from 5-20 seconds does not significantly change the
fluorescent fingerprint detected. It was concluded from this trial that injection
times of 5-20 seconds permitted efficient detection of fluorescent amplicons
generated using 6-FAM-labelled RW3A for fingerprinting of MRSA. Therefore in
all subsequent studies a 10 second injection time was utilised for GeneScan
analysis of fluorescent MRSA fingerprints.
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Figure 3.20: Effect of varying injection time (ranging from 5 to 20 sec) on
results of GeneScan analysis of the fluorescent 6-FAM labelled RW3A
fingerprinting of MRSA strain 36197.
Blue peaks correspond to 6-FAM labelled RW3A fingerprinting products which
were sized by comparison with the red peaks of the GeneScan 2500 ROX
labelled internal standard.
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Trial 2: Variation of sample volume:
The amount of sample prepared for GeneScan analysis (as described in
Section 2.2.5.3) can affect the quality of the final result obtained. Sufficient
sample must be analysed to generate sufficient fluorescence for an adequate
signal to noise ratio. The manufacturers of the ABI Prism™ 310 genetic analyser
recommend that the fluorescent signal be maintained between 150 and 4000
fluorescent units and that the appropriate volume of sample must be determined
to achieve optimal results.
To this end, the reaction volume of fluorescent RW3A-fingerprint of strain
36197 prepared for GeneScan analysis was altered. PCR volumes of 0.5 ^il, 1
^il, and 2 ^il were prepared and analysed as described in section 2.2.5.3. The
results of this analysis are shown in figure 3.21. This figure demonstrates that
the fluorescent fingerprint of MRSA strain 36197 was practically identical for
each sample volume tested. The background noise when using a 2 ^1 sample
volume was significantly increased as can be seen from the uneven sample
(blue) baseline (see Figure 3.21 c). Therefore, in all future GeneScan analyses
of MRSA strains 1 |il of the fluorescently labelled MRSA fingerprint was
analysed.

3.6.2.1: Fluorescent fingerprinting of non-MRSA Isolates using 6-FAM -labelled
RW3A:
The optimised fluorescent GeneScan rep-PCR strategy using 6-FAM RW3A was
applied to Escherichia coli. Acinetobacter baumanii and Pseudomonas
aeruginosa strains (which previously generated complex DNA profiles with the
unlabelled RW3A oligonucleotide). The resultant electropherograms are shown
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Figure 3.21 (a-c): Analysis of the fluorescent RW3A fingerprint of MRSA
strain 36197 using different PCR sample volumes.
Trace (a)

0.5^il

Trace (b)

1^il

Trace (c)

2^1

Blue peaks = 6-FAM labelled fingerprint products and red peaks represent the
GS 2500 ROX labelled fluorescent standard.
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Figure 3.21:
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in figure 3.22. Fluorescent amplicons were generated and detected for each
microbial strain using this technology. Comparison of the scans obtained
clearly show that different peaks were detected for these microbial genomes.
Generation of fluorescent labelled DNA fingerprints using RW3A for a wide
variety of pathogenic bacteria confirms the broad spectrum applicability of this
typing method but also reiterates the necessity to develop a combined detection
and typing scheme using GeneScan technology for MRSA strains.

3.6.2.2: FERP analysis of MRSA outbreak 2:
The genetic relatedness of MRSA strains in CUH outbreak 2 was assessed
using the optimised fluorescent RW3A fingerprinting assay. MRSA strains from
each fingerprint grouping according to the dendrogram were subjected to
GeneScan analysis and the resultant electropherograms are shown in figure
3.23.
It is evident from the GeneScan patterns obtained that some peaks are
conserved between the two strains of REP groups I and II (MRSA 32602 and
28805). These monomorphic fragments occurred in the range from 180-200 bp
and at 600 and 2,000 bp (conserved bands are indicated by purple arrows in
Figure 3.23). Common peaks represent conserved regions of the genomes of
MRSA strains in these REP groups, and may suggest that these assigned REP
groups are in fact subgroups of one main class (as suggested previously in
Section 3.52). The fluorescent fingerprint of strain 37866 (REP group III) is
significantly different (including many additional bands, indicated by the orange
arrows in Figure 3.23) and therefore confirm the existence of a third clustering of
strains within CUH outbreak 2.
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Figure 3.22 (a-d): GeneScan analysis of 6-FAM labelled RW3A fingerprint
profiles generated from various microbial genomes.
In each trace the blue peaks represent the 6-FAM labelled fingerprint amplicons
and the red peaks correspond to the GS ROX 2500 internal.
Trace (a) =

MRSA

Trace (b) =

Escherichia coli

Trace (c) =

Acinetobacter baumannii

Trace (d) =

Pseudomonas aeruginosa
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Figure 3.22:
(a)

MRSA

(b)

Escherichia coll

(c)

Acinetobacter baumannii

(d)

Pseudomonas aeruginosa
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Figure 3.23 (a-c): GeneScan traces of MRSA strains from CUH outbreak 2.
Blue peaks indicate FAM-labelled RW3A generated DNA fragments which were
sized directly by comparison with the ROX-labelled internal standard (red
peaks).

MRSA 32602 belongs to REP group I. MRSA 28805 is a member of REP group
II and MRSA 37866 was taken from the REP group III.).
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Figure 3.23:
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RW3A-REP group III; MRSA 37866
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The GeneScan ABI Prism™ 310 fluorescence detection system facilitates the
analysis of MRSA strain similarities. Accurate sizes of FAM-labelled fingerprint
products were obtained by comparison with a known internal standard. Results
obtained using this automated fluorescent detection strategy compare
favourably with conventional agarose gel electrophoresis. Increased sensitivity
of FERP has previously been discussed (Del Vecchio ^af., 1995) and therefore
it has been suggested that these fluorescent detection systems may provide a
more discriminating typing system.
The ABI Prism™ 310 genetic analyser is a reliable and convenient system
for fluorescent detection of fluorophore labelled PCR products. Using this
system each sample is capillary electrophoresed individually, this eliminates the
cumbersome preparation of polyacrylamide gels required for analogous
analysers (e.g. ABI Prism™ 373/377) and also once programmed this “walk
away” system can be left unattended. An additional advantage of GeneScan
technology is the possibility of developing multiplex assays using differentially
labelled primers (such as described in Section 3.6.3 below).

3.6.3: Combined detection and typing of MRSA strains using GeneScan
analysis:
Experimental methods which facilitate combined detection and typing of
bacterial strains have been previously described (Saulnier ^ aj., 1997;
Versalovic ^aj., 1994). Such strategies have been termed COGEDET
(combined gene detection and epidemiological typing). The objective of this
work was the development of an automated fluorescent system to permit the
simultaneous detection and typing of MRSA strains.
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The thermocyclic amplification profiles of the triplex-PCR assay for MRSA
detection and RW3A fingerprinting were deemed quite similar (see Section
2.2.4) therefore a combination of these two assays was attempted. As detection
of three specific MRSA genes and a DNA fingerprint in a single PCR reaction
would be quite complex, only the mecA and femA gene segments were
targeted. A definitive MRSA diagnosis could still be achieved using these two
targets (i.e. mecA amplification for methicillin-resistance and femA amplification
for S. aureus strains).
Oligonucleotide primers specific for the mecA and femA gene targets
were included in an RW3A fingerprinting experiment fortyping of MRSA strain
36197 (as described in Section 2.2.4.1). The products of this amplification were
initially analysed by electrophoresis in a 2% agarose gel and the results
obtained are shown in Figure 3.24) Lane 1 shows the RW3A fingerprint for
MRSA strain 36197 without addition of the MRSA specific primers. Inclusion of
the mecA and femA primers (duplex-primers) in the RW3A fingerprint, whilst
permitting amplification of the 2 specific gene targets, significantly alters the
banding pattern or fingerprint obtained for this strain (see Figure 3.24, lane 2). It
can be seen by comparison of lanes 1 and 2 in figure 3.24 that a number of
amplicons are lost or less intensely amplified when the duplex primers are
included in the RW3A-PCR amplification. This result suggests that the very
specific amplification of the mecA and femA gene targets interferes with the
somewhat less specific RW3A fingerprinting assay (as this is sampling the entire
genome and not distinct primer delineated amplification of gene fragments).
An alternative approach for combined detection and typing of MRSA was
assessed, whereby the RW3A fingerprinting reaction proceeded for 10
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Figure 3.24: Agarose gel showing results of tests performed on MRSA strain
36197 to develop a simultaneous detection and typing assay-COGEDET ) (see
Section 3.6.3).
Lane M: (t)X174/Haelll markers.
Lane 1: RW3A fingerprint
Lane 2: Combined duplex and RW3A-PCR
Lane 3: RW3A-PCR alone for 10 cycles followed by addition of specific
target primers.
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amplification cycles and then the duplex primers were added for the remaining
cycles. The results of this amplification system for strain 36197 is shown in
figure 3.24, lane 3. Comparison of lanes 1 (without duplex-primers) and 3
demonstrates that the RW3A fingerprint of this strain is maintained using this
strategy. Amplification of the mecA and femA gene targets was also evident in
lane 3. Therefore it can be concluded that this approach provides a suitable
system for MRSA detection and strain differentiation.
A significant limitation of utilising agarose gel electrophoresis for analysis
of COGEDET PCR products is that fingerprinting amplicons may be generated
which are of coincident size with the specific gene targets and thus
interpretation of this data may be complicated. This is seen in figure 3.24,
comparing lane 1 and 3 showing that a fingerprint amplicon of approximately
600 bp can be seen when RW3A fingerprinting is performed alone. The mecA
amplicon is of similar size (604 bp) and therefore difficulties arise in interpreting
the COGEDET results (Figure 3.24, lane 3). A similar observation was noted
also made by Saulnier^aj. (1997).
Inclusion of fluorescent labels on the oligonucleotide primer used for
COGEDET of MRSA (TET on the antisense mecA and femA primers and 6-FAM
on the RW3A primer) facilitated the detection of the dye-labelled PCR products
using GeneScan technology in an ABI Prism'" 310 genetic analyser. Figure
3.25 shows a comparison of RW3A fingerprinting (Figure 3.25 a) and COGEDET
analysis (Figure 3.25 b) of MRSA strain 36197. The red peaks represent the
internal lane standard (TAMRA 2500), the blue peaks are the 6-FAM labelled
RW3A amplicons and the green peaks correspond to the mecA and femA gene
products. It is evident from figure 3.25 (a) and (b) that the fluorescent fingerprint
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Figure 3.25 (a and b): GeneScan analysis of the products of an RW3A PCR
fingerprint of MRSA 36197 and analysis of the fluorescent products of a
COGEDET assay (for simultaneous detection of MRSA specific targets and
strain differentiation) performed on the same strain.
Trace (a):

RW3A PCR of MRSA 36197

Trace (b):

COGEDET assay of MRSA 36197

(Blue peaks = 6-FAM labelled RW3A fingerprint products, green peaks = TETlabelled duplex PCR products, and red peaks =TAMRA 2500 labelled GS
standard)
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generated for strain 36197 was identical even when the specific mecA and femA
primers were included in the amplification. In figure 3.25 (b) successful,
simultaneous detection and typing was obtained (i.e. 2 distinct green peaks for
the mecA and femA targets were observed in addition to the blue fingerprint
peaks).
COGEDET analysis was performed for a variety of bacteria including
MRSA, MSSA, CNS and other bacterial species. The results of this analysis are
shown in figure 3.26. These results show that although RW3A fingerprinting
occurs for a variety of microbial species, only S. aureus strains exhibited
amplification of the green femA peak (Figure 3.26 a and b). A mecA green peak
is only observed when microbial strains were resistant to methicillin (Figure 3.26
a).

These data suggests that a sensitive and specific automated COGEDET system
for MRSA detection and typing can be developed. Differential labelling of
detection and typing oligonucleotides primers produced a final results display
which was simple to interpret. The flexibility of this approach should in the future
permit the development of other sensitive, automated multi-target PCR-based
assays.
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Figure 3.26 (a-f): Fluorescent analysis using GeneScan technology of the
results of a COGEDET assay system applied to MRSA strains from CUH
outbreak 2. The results obtained for other microbial strains are shown as these
confirm the specificity of this assay system.
In each of the scans the red peaks correspond to the GeneScan 2500 TAMRA
internal standard the blue peaks are the 6-FAM labelled RW3A generated
fingerprint amplification products, and the green peaks represent the TETlabelled mecA or femA gene products.
Trace (a):

MRSA 25517: REP group I

Trace (b):

MRSA 27652: REP group II

Trace (c):

MSSA 4206

Trace (d):

CNS 9401

Trace (e):

Acinetobacter baumannii 21180

Trace (f):

Escherichia coli 58
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Figure 3.26:

(a) MRSA 25517: REP group I

(b) MRSA 27652: REP group II

w

(c) MSSA4206
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Fiqure3.26 contd.

(d) CNS 9401

(e) Acinetobacter baumannii 21180

(f) ETEC 58
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3.7: Comparison of the sensitivity of three PCR detection systems:
The priming efficiency of each individual PCR target will influence the limit of
various amplicon detection strategies. This observation is evident from previous
experiments (i.e. during triplex-PCR analysis amplification of the mecA and
femA gene targets produces a significantly stronger amplicon signal compared
to amplification of the nuc gene target (see Figures 3.3, 3.5, and 3.6). The aim of
these experiments was not to define a limit of detection using different detection
system but rather to compare the sensitivity and relative merits of some of the
available approaches.
The three systems compared were:
(i)

agarose gel electrophoresis

(ii)

“dot blot” analysis

(iii)

GeneScan analysis

To perform this comparative analysis, initially the DNA extracted from MRSA
strain 238 was serially diluted from 3 pg to 200 ng. Amplification of the mecA
gene target was achieved as described in section 2.2.4.2 using a range of DNA
concentrations in 50 ^il PCR reaction volumes. Digoxigenin labelling of the PCR
products, which forms the basis of the “dot blot” detection system, was
accomplished by inclusion in the PCR reaction of the modifed nucleotide DIGdUTP (Section 2.2.7.1). Use of a fluorophore-labelled reverse primer in the PCR
reaction generated fluorescent mecA amplicons which could be analysed using
GeneScan technology (Section 2.2.5.1). The products of each of these
amplification reactions then were analysed using the appropriate detection
formats. Results of this comparison are shown in figure 3.27.
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Figure 3.27 (a-c): Comparison of the sensitivity of three systems for
detection of a PCR generated mecA amplicon from a serially diluted DNA
sample (12 pg-200 ng). (The red arrows in 3.27 a and b indicate the last
positive sample detected using these systems)

a. Agarose gel electrophoresis:
Lane M, (j)X174/Haelll markers; lane 1,200 ng; lane 2, 50 ng; lane 3, 12.5 ng;
lane 4, 3.125 ng; lane 5, 781 pg; lane 6, 195; lane 7, 48 pg, lane 8, 12 pg.

b. “Dot blot’ analysis:
Dot 1,200 ng; dot 2, 50 ng; dot 3, 12.5 ng; dot 4, 3.125 ng; dot 5, 781 pg; dot 6,
195; dot 7, 48 pg, dot 8, 12 pg.

c. GeneScan analysis of TET-labelled mecA amplicon:
In each trace the green peak represents the TET-labelled mecA and the red
peaks correspond to a portion of the GS TAMRA 2500 standard adjacent to the
desired amplicon.
(At 12 pg, the “results dye scale” option of the ABI Prism™ 310 genetic analyser
was used to improve the sensitivity of peak detection and this is shown in two
traces designated a and b).
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Figure 3.27 c:
200 ng

50 ng

V

12.5 ng

195 pg

48 pg

Molecular weight

227

U

Agarose gel electrophoresis showed a clear mecA amplification product
for DNA concentrations ranging from 781 pg to 200 ng (Figure 3.27 a, lanes 16). Upon closer examination, PCR products could be detected in lanes 7 and 8,
representing 195 pg and 48 pg of DNA respectively. No mecA amplicon was
visible when 12 pg of DNA was subjected to PCR amplification and analysed by
this method.
The mecA PCR products amplified from DNA concentrations ranging from
781 pg-200 ng (Figure 3.27 b, dots 1-6) were readily detected by “dot blot”
analysis. Faintly positive dots were visible when lower concentrations of DNA
were analysed (Figure 3.27 b, dots 7 and 8), however below a concentration of
48 pg no dots were detectable.
GeneScan analysis permitted sensitive detection of mecA peaks when
using 48 pg-200 ng of DNA in the amplification reaction. However, using this
system, a green peak was detached for mecA at 610 bp even when 12 pg of
DNA was used for PCR amplification (Figure 3.27 c). At this DNA concentration,
the interpretation of the result data is highly subjective and necessitates a very
flat baseline fluorescence. Nevertheless, the GeneScan software permitted
enhancement of the peak detected when 12 pg of DNA was amplified. This was
achieved using the ‘Results Dye Scale” option in the software and is shown in
figure 3.27- 12 pg (i), therefore this system offers a highly sensitive detection
format.
The sensitivity of detection using these systems is comparable i.e. mecA
detection is possible using 48 pg of initial template DNA with each system.
GeneScan analysis only permitted detection of this amplicon when 12 pg of
DNA was amplified. It can be concluded that the fluorescence-based
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GeneScan system is more sensitive as only 1

of the PCR reaction mixture was

required for analysis compared with 10 [l\ using agarose gel electrophoresis
and “dot blot” analysis. Increased sensitivity using GeneScan analysis was also
reported by Del Vecchio

(1995) when analysing fluorescent fingerprints.

Each of these detection formats has its own merits. PCR products can be
analysed by agarose gel electrophoresis without purification. “Dot blot” analysis
requires a LiCI/ethanol precipitation to remove unincorporated digoxigenin (O’
Meara

1995). Samples for GeneScan analysis require prior purification

using a QIAquick kit to minimise the detection of non-specific fluorescent peaks
(Section 3.6.1).
The solid phase “dot blot” system provides a rapid, reliable, convenient,
“user-friendly” detection strategy which may be useful in a clinical diagnostic
setting. In addition, this system offers a highly specific non-isotopic detection
format (KesslerMai-, 1991). As discussed previously (Section 3.4), the
development of one-phase systems that combine amplification and detection
such as DIAPOPS (detection of immobilised amplified product in a one phase
system) may simplify DIG-based detection assays (such as “dot blots”) and
facilitate their incorporation into routine microbiological analysis (Ramussen ^
aj., 1994).

GeneScan detection of fluorescent amplicons using the ABI

Prism™ 310 genetic analyser provides a sensitive, “walk-away” automated
system capable of high-sample throughput and automatic analysis of results
(Cotter etaj., 1998). The results generated using this system are directly stored
in the dedicated computer and this permits retrospective analysis of results.
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3.8 : Characterisation of amplicons of interest from RW3A
fingerprints:

From analysis of the agarose gels showing the RW3A generated DNA
fingerprints of MRSA strains from CUH outbreaks 1 and 2 (see Figures 3.13 and
3.15), it was evident that a number of the amplified PCR products were
conserved between the organisms. The aim of these experiments was to
characterise some of these bands by DNA sequencing to determine if these
“putative” conserved bands were monomorphic (e.g. to determine if a 500 bp
PCR product amplified in a number of strains had the same DNA sequence). In
addition, these experiments would serve to determine the genomic origins of
these selected bands in order to evaluate their potential as strain-specific
probes.
Each of the selected bands were analysed similarly i.e. extracted from the
MRSA fingerprint, reamplified by RW3A-PCR and cloned into the pCR®2.1
vector prior to DNA sequencing using dye-primer chemistries (see Section
2.2.6). Table 3.10 below documents details of the bands selected for
characterisation using this method.

Table 3.10: Size and strain of origin of the DNA fragments
characterised in this study
Fragment name Approximate size (bp)
MRSA strain
M300a

300

26996

M300b

300

27842

M300C

300

32479

M600a

600

26996

M600b

600

27842

M800a

800

26996
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The steps involved in this strategy are shown in the figure 3.28 and in figure
3.29 that follows for the band designated M300a (s^ Table 3.10 above).
To increase the yield of the selected band (M300a), a 100 |xl RW3A-PCR
reaction mixture of strain 26996 was performed and the products of this reaction
were resolved in a 2% agarose gel (Figure 3.29 a). The M300a band was
excised from this gel using a clean, sharp scalpel. The extracted band was
reamplified using a modified RW3A-PCR (see Section 2.2.6). Figure 3.29 (b)
shows the reamplified M300a. This reamplification confirms that the band was
extracted as a single DNA amplicon from the gel (i.e. free fromi other DNA).
Furthermore Tag polymerase is known to generate 3'-A overhangs on PCR
products. This observation forms an essential feature for cloning into pCR®2.1
vector.
The reamplified M300a PCR product was cloned into the pCR®2.1 vector
(see Section 2.2.6.2) and then transformed into INVaF' cells. A rapid colony
screening procedure was performed to identify transformants containing the
required vector construct. Figure 3.29 (c) shows the results of this analysis.
From this figure it can be seen that the plasmids released after analysis of the
white colonies are of a larger molecular weight compared to those originating
from the blue colony (used as a negative control, i.e. pCR®2.1 vector without
insert). It can be concluded that this increase in molecular weight indicates that
these white colonies contain plasmids with the M300a insert.
These steps were performed for each of the amplicons from the RW3A
fingerprints chosen for characterisation and listed in table 3.10. A screened
white colony for each plasmid:insert combination was cultured in tryptic soya
broth and the plasmid construct isolated from the transformed microbial cells.
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Figure 3.28: Schematic view of the experimental strategy used for
characterisation of bands from RW3A fingerprints of MRSA strains.
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Figure 3.29:

a. 2% agarose gel showing resolution of a 100 |il volume of the RW3A
fingerprint of MRSA strain 26996. It can be seen from the figure that a band
designated M300a was excised from the gel (using a scalpel) for
characterisation.
Lane 1, 100 ^rl RW3A fingerprint of strain; lane N, negative; lane M grade V
molecular weight size standard.

b. Electrophoresis showing the reamplification of band M300a.
Lane M, Grade V molecular weight markers; lane 1, reamplified M300a.

c. Results of rapid colony screening protocol to identify a pCR®2.1 plasmid
which contains the M300a insert.
Lane M, grade III; lane 1-8, screened white colonies, lane 9, blue colony.
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blue colony

To confirm the presence of the insert in the vector a restriction digest using
EcoRI of the isolated plasmid DNA was performed. The results of this analysis
are shown in figure 3.30. This gel confirms that each of the isolated plasmids
contain the correct insert.
DNA sequencing of each of the plasmid inserts was performed in both
directions using the T7 promoter primer (forward) and the M13 reverse primer
(see Appendix 3 for the annealing sites of these primers on the pCR®2.1
plasmid vector). The sequencing data obtained from the ABI Prism™ 377
genetic analyser was of very high quality (with the exception of the forward read
of fragment M600b). Sequencing reads of many of these plasmid inserts were
greater than 550 bp and all reads demonstrated a very uniform peak intensity
(as would be expected when using the recently developed AmpliTaq DNA
polymerase, FS). Appendix 4 shows the electropherogram of the M13 reverse
DNA sequencing of insert M600a.
Analysis of the resulting sequencing data was performed using the
Sequencher™ 3.0 software. The results obtained for each insert using this
software are shown in figure 3.31 (a-e). Initially a contig assembly of the forward
and reverse sequencing reads for each plasmid insert was performed. This
assembly aligned the complementary DNA sequences of the forward and
reverse reads. The poor quality of the forward sequence data for M600b
prevented contig assembly for this insert and therefore only the reverse
sequence was analysed further (Figure 3.31 d). Contig assembly was also
attempted between the analysed sequences and from this it was determined
that fragments M300a and M300c had almost identical DNA sequence (Figure
3.31 a).
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Figure 3.30: EcoRI restriction of plasmids resolved in 1.5% agarose gel (used
to confirm correct plasmid:insert construct prior to sequencing).
Lane M, grade III and V molecular weight markers; lane S, grade V molecular
weight size standard; lane 1, pCR®2.1:M600a; lane 2, pCR®2.1 :M800a; lane 3,
pCR®2.1:M300a; lane 4, pCR®2.1:l\/l300b; lane 5, pCR®2.1:M300c; lane 6,
pCR®2.1:M600b.
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Figure 3.31 (a-e): Sequence data obtained from MRSA RW3A generated
IM

DNA fingerprint fragments using Sequencher 3.0 software.
(a)

Fragments M300a and M300c

(b)

Fragment M300b

(c)

Fragment M600a

(d)

Fragment M600b

(e)

Fragment M800a

For each fragment the following data is shown:
A contig assembly of the forward and reverse sequence reads (with the
exception of M600b for which only a high quality reverse sequence read was
obtained). The diagram key for contig assembly is shown below:

I I Hole in contig
Diagram Keu
Pn Single fragment
Multiple fragments same direction
Si Both strands
■I Both strands plus
j--|—f- ^ Start codon frame 1
=^=F.4_r-Stop codon frame 2

Bumps on
fragments
show motifs,
hollow
rectangles
show features

Also within the matched sequnces of M300a and M300c ambiguous bases
occur at a number of positions, and these are base coded:
R=

A or G

W=

AorT

Y=

CorT

The location of the RW3A priming site was identified in each contig sequence
and is shown underlined in red. A restriction map of each fragment sequence
(i.e. internal to the priming sites) was constructed.
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Figure 3.31
(a) M300a and M300c:
Contig assembly:
M300a, 17, 1 to 324
M300a, M13 rev, 1 to 332
M300C, 17, 1 to 332
M300C, M13 rev, 1 to 332

50

1 00

1 50

200

332

250

r?—rr

Sequence:
1

TCGCTCAAAA CAACGACACC GAAAAAAACT ACTAATCAAG

41

ATTTCGCACG GGGAAGAATC AATACCTATC CYGTACTRAT

81

TCYCTACTAA ACVvATGTTTA CATGATAATT TCCACCTATT

121

TAGACTTCAT ACATTAAAAA GACAATCTCT ATCATATCGC

161

TAATAGAAAT TGCCTTTTCG TATTGTCCTA ATAAATTGGT

201

ATCACTTACT GRTCTCAACA ATTAAGACTA TTTGATTTTA

241

TCTTTTAATA ACTTCTCAYA ACATTCATAA TCATATGGAT

281

CTTCAACTTT CTCGCCATTA ATAAATGCAG TTGGTGTCGT

321

TGTTTTGAGC GA

Restriction mao:
jRsal (74)
Hinfl(56)

Ndel (273)

rNlalll(104)

Mbol (277)

Mapping all cutsites.
Cutters : Hinfl, Mbol, Ndel NIalll & Rsal
Non-Cutters :

AccI, Apal, Aval, Avail, BamHl BanI, Bsp106, BstEII, BstNI, Ddel Dralll, FnulVR

Haell Haelll, Hhal, Hindi, Hpall, Neil, Ncol, NIalV, Nsil, PstI, Pvull, Sacll, Xhol & Xmalll
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Figure 3.31 contd.
(b) M300b:
Contiq assembly:
M300b, T7, 1 to 329
M300b, M13 rev, 1 to 329

1 00

50

200

1 50

250

329

+F

M-

i-------- i-

Sequence:
1

TCGCTCAAAA CAACGACACC TTGTGGAAAC GCAGCGCGAT

41

TAATTACTGT CTGCATATTT TCTAACCATG CATCTCTTTC

81

AAATTCAGTG TTTGTAAAAT CTATATGTCT TTTTCTTAGC

121

ATAGGMGTC CGTGTTCTTC GGTATAAATG TTTQGACAGC

161

CCAGAAACTG TGTTAAAAAC TGTTTTTGTT TACGACTTGT

201

TTCTGCAAAA TCTCCTGGAA ACAGGTGATT AAGTCGTTTA

241

TCTTTTTCTA CAAGGGTGTA AAAATAATCA ATCATATCGT

281

ATAACGCTTC TTTACCAATG ATGTCATATG GT GTCGTTGT

321

TTTGAGCG^

Restriction map:
.Drain (22)
^nulVH (32)
^lalll (70)

r

Isil (72)

fHhal (36)

(BstNI (215)

pdel (115)

Ndel (306)

Mapping all cutsites.
Cutters : BstNI, Dde| Dralll, FnulVH Hhal, Nde| NIalll & Nsil
Non-Cutters :

AccI, Alul, Aval, Avail, BamHI, BanI, BsplOO BstEII, Haell, Haelll, Hindi,

Hinfl, Hpall, Mbol, Neil, Ncol, NIalV, PstI, Pvull, Rsal, Sacll, Xhol& Xmalll
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Figure 3.31 contd.:
(c) M600a:
Contiq assembly:
M600a, 17, 1 to 598
M600a, M13 rev, 1 to 598

I
-»—W-

300

200

1 00

400

500

I II I I * I

I
9

598

m—9—

—e—

-w-

Sequence:
1

TCGCTCAAAA CAACGACACC AAAATGCATC ACAACAAGAA

41

ACTAATGATG CAGAACAAGA AGTTGATACT GAATTAAATC

81

AAQCGAAAAC AAATGTCGM CAATCATCAA CAAATGAATA

121

TGTTGATAAT GCAGTTAAAG AAGGAAAAGC TAAAATTAAT

161

GCAGTTAAAA CATTTAGTGA GTACAAAGAA GATGCTTTAG

201

CTAAAATTGA AGATGCATAT AATGCTAAAG TAAACGAAGC

241
281

GGATAACTCT AACGCTTCGA CTTCAAGTGA AATTGCTGAA
GCG^AACAAA AACTAGCTGA ATTAAAACAA ACTGCGGATC

321

AAAATGTTAA TCAAGCTACT TCTAAAGATG ACACTGAAGC

361

TCAAATTCAT AATGACTTAG ATAATATTAA CG^TTACACA

401

ATTCCAACGG GTAAAAAAGA ATCAGCTACG ACAGATTTAT

441

ATGCTTATGC AGATCAGAAG AAAAATAATA TTTCAGCTGA

481

CACTAAAGCA ACACAAGATG AAAAGCAACA AGCAATTAAG

521

CAAAGTTGAC CAAAATGTTT AGATTGCATT AGAAAGCATT

561

AATAATGGTG TGG^TAATGG TGTCGTTGTT TTGAGCGA

Restriction map:
fHinn (419)

Alul(296)
Alul(149)

Mbol (316)

rNsil (28)

rNsil (217)

rAluI (476)

rDdel (376)

pAluI(200)
Mbol (97)

Mbol (451)

Alul(359)

rRsal (182)

Alul (335)

■PvuII(476)

Alul (425)

Hindi (527)

Mapping all cutsites.
Cutters :

Alul, Ddel, Hindi, Hinfl, Mbol, Nsil, Pvull & Rsal

Non-Cutters:

Accl, Aval, Avail, BamHl, BanI, Bspl()6, BstEll, BstNl, Dralll, FnulVH, Haell,

Haelll, Hhal, Hpall, Neil, Ncol, Ndel NIalll, NIalV, Pstl, Sadi, Xhol & Xmalll
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Figure 3.31 contd.:
(d) M600b:
Reverse fragment:
M600b, M13 rev, 1 to 588

---------- P------P------ P-

-P-P-

PP P

W

?-

i--------Sequence:
1

GCAGAAQGTG AGG\TCCCGA TGCGGTAAAG GCTGGGCATG

41

GCCGCGQDGC AGATAACGTG GACCTGGGTT ACCAGCGCCA

81

GTTGG^CGAA GMGAACACC ATCGTGGTGA CGACATTGTT

121

CGCAATGGCA AACCTGATTT GT CTGTTCAA ACCCGCGATG

161

CCATACTCCT GCGTCACGM AAGAACAAAG TTCAGGGAAG

201

GTCCAGTCAT CTCGAGGCA3 TGCATGGTGG TGCGGATGAC

241

GTTGCATAAG AGQGCGAGGA CGTTGAAGAT CCACGAGAGG

281

CTQCGGCGTT TGGCACCCTG GGTCATTAGC AGGAGG^CCA

321

GGAGG^G^AT TGCAG^GGCA CCGAGCTGGG TGGCGAGQM

361

GATGGCGGTG CGa\CGGCOG TCAGCTTGAC ATACTCGATG

401

TCAATGGTGT TGAACTCCAT GGTGGATCCT TCGQ3GCCGA

441

TGAGTTCGAA GTCTGTTGAA G^TGTCGAAT GGTTTTGGTC

481

GAG4AGTCCC GGCACGGATT CTTCGACGGG QCCAAGATAT

521

GGTCCGCTGT CTTGCGGACr GCCGAAGTTG TTAATCCGGT

561

TGQCCCTGGT

GTCGTTGTTT TGAGCGA

Restriction map:
BamHI (12)
NIalV (14)

|NlalV (339)

pNlalll (40)

FnulVH (281)

BamHI (424)

Haelll (41)

FnulVH (284)

NIalV (426)

■FnulVH (42)
FnulVH (45)
•Sacll (45)

rXmalll (375)
[Haelll(377)
I i-Banl (292)

Hhal (49)

II

Xhol (211)

II

Avail (315)
I I

Haell (78)

I

I

NIalll (226)

Neil (489)
pHinfl (497)

|Alul (384)

l-NlalV (294)'

Avail (60)
Hhal (77)

^NlalV (435)

BanI (337)
Avail (200)
Aval (211)

■ ■

NIalV (510)

rNcol (417)
■[NIalll (421)
li

rAlul(345)

III

Haelll (436)

Haelll (511)
j-Avall (521)
rHaelll (563)

....... II III

Mapping all cutsites.

Alul, Aval, Avail, BamHI, BanI,FnulVH Haell, Haelll, Hhal.Hinfl, Neil, Ncol, NIalll,
NIalV, Sacll, Xhol & Xmalll
Non-Cutters ; AccI, Bsp106, BstXI, Ddel Drain, Hindi, Nde| Nsil, PstI, Pvull & Rsal

Cutters :
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Figure 3.30 contd.
(e) M800a;
Contia assembly:

M800a T7, 1 to 581

Sequence:
1

TCGCTCAAAA CAACGACACC GTCGAAACCA TCAACTGGTA

41

AATTAACAGT TGCTGCAAGC AATGGTGTCG CACAAATCAA

81

ACCAACAAAT AGTGGTTTAT TTACTACTGT ATACGACAAA

121

ACTGGTAAAG CAACTAATGA AGTTCAAAAA ACATTTGCTG

161

TATCTAAAAC AGCTACATTA GGTAATCTAA AATTCTATCT

201

TGTTCAGGTT ACAATTCTGG

241

AAGAAGGCGA TGTGGTTTAC AACACAGCTA AATCACCTGC

281

AGATGTAAAT CAATCATATT CAATCAATCC TGGTACGAAA

321

CTTTGTACAG TACCTTGGGG TACATCTAAA CAAGTTGCAG

361

GTAGTGTGTC TGGCTCTGGA ACCAAACATT TAAGGCTACA

401

AAGCAACAAC AAATTGATAA ATCGATTTAT TTATATGGCT

441

CTGTGAATGG TAAATCTGGT TGGGTAAGTA AAGCATATTT

481

AGTTGATACT GCTAAACCCA CGCCTACGCC AACACCTAAG

521

CCATCAACAC CTACAACTAT TAATAAATTA ACAGTTTTAT

taataaattt

GGTTGGGTTA

561

CATTAAACAG TGTTGCTCAG ATTAATGCTA AAAACAATGG

601

CTTATTCACT ACAGTTTATG AGAAAACTGG TAAGCCAACG

641

AAAGAAGTTC AAAAAACATT TGCTGTAACA AAAGAAGCAA

681

GTTTAGGTGG AAACAAATTC TACTTAGTTA AAGATTACAA

721

TAGTCCAACT TTAATTGGTT GGGTTAAACA AGGTGTCGTT

761

GlTILOASCfi. A
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Figure 3.31 contd.:
(e) M800a (contd):
Restriction mao:
pAlul (267)
BstNI (310)
Rsal (314)
Rsal (326)
FnulVH (53)

Rsai (331)
|-Alul (172)

AccI (110)

jRsal (341)
Pstl(281)

rBsp106(422)

Mapping ail cutsites.
Cutters : AccI, Alul, Bsp106, BstNI, FnulVK PstI & Rsal
Non-Cutters :

Aval, Avail, BamHl BanI, BstEII, Dralll, Hael| Haelll, Hhal, Hindi, Hinfl

Hpall, Mbol, Neil, Ncol, Ndel Nsil, Pvull,Sacll, Xhol & Xmalll
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The RW3A priming site on either end of the plasmid insert was located
using the ‘find sequence’ option in the Sequenchei^"^ 3.0 software. Construction
of restriction maps for each insert sequence (between RW3A priming sites) was
facilitated using the software. As M300a and M300c had almost identical DNA
sequnces, the results of these DNA fragments are presented togther in figure
3.31 a. In figure 3.31 (a-e), the contig assembly for each insert is shown. This
figure also includes the DNA sequence of each insert together with the
generated restriction map. The DNA sequences of these inserts were analysed
for the recognition sequences of 37 selected restriction endonucleases. The
number of endonuclease restriction sites identified were 5 (M300a and M300c),
8 (M300b), 11 (M800a), 17 (M600a) and 38 (M600b), ^ figure 3.31. Seven of
the 17 restriction sites on M600a were Aful recognition sequences (AGiCT) and
therefore this 558 bp sequence contains a significantly higher number of Alul
sites compared with the other inserts analysed. Within the 567 bp reverse read
of M600b, 38 restriction sites were located. It is evident that this insert
represents a ‘hot spot’ of restriction enzyme target sites, possibly reflecting
diverse evolutionary change.

Characterisation of a monomorphic DNA fragment (i.e. an amplicon that
appears in the same position in 3 DNA fingerprints) of approximately 300 bp
from three individual MRSA strains (26996, 27842, and 32479) was performed.
Computational analysis using the Sequencher™ 3.0 software demonstrated that
only M300a and M300c had near identical genomic sequences (there are only
six ambiguous nucleotide positions within these sequences, these are
highlighted in pink in Figure 3.31 a) . The DNA sequence of fragment M300b
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was substantially different (see Figure 3.31 b) and therefore contig assembly
with M300a and M300c was not permitted by the software programme. This
data confirms that although this fragment appeared monomorphic, only 2 of the
3 fragments characterised were identical. The M300b fragment represents
another RW3A targeted amplicon of coincident molecular weight. This result
has significant implications as it poses questions as to the accuracy of visual
interpretation of amplification profiles. It is also plausible that more than one
amplicon is present at 300 bp (which fails to be resolved by conventional
agarose gel electrophoresis) and this may explain the differences elucidated in
these so called ‘monomorphic’ fragments.
The DNA sequences of these inserts (with the exception of M600a for
which only the reverse sequence read was obtained), were edited for the RW3A
primer sequence. These inserts were then analysed for homologous
sequences in the NR (non-redundant) sequence database using the BLAST
(Basic Alignment Search Tool) computer programs yja the E-mail server.
BLAST searches employ algorithms developed by Altshuel Maj. (1994) and
Schuler ^a]. (1994) to facilitate fast and sensitive database searching. This
search revealed that M800a corresponds to a portion of the autolysin gene from
Staphylococcus aureus. A 96 % match occurred between nucleotides 378 and
764 of the M800a sequence and nucleotides 3244 and 3630 of the autolysin
gene.

The entire sequence was originally submitted to the database by Foster

(1995). Genbank database matches for the other inserts were not found. All
sequences were submitted to GenBank using the World Wide Web-based tool
Bankit (E-mail a66ress\gb-sub@ncbi.nlm.nih.go\/) and accession numbers
assigned (see Table 3.11).
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Appendix 5 shows the current GenBank record (retrieved using the assigned
accession number) for insert M800a.

Table 3.11: GenBank accession numbers for RW3A fingerprint
fragments characterised.
Fragment

Size (bp)

GenBank accession number

M300a/M300c

292

AF062375

M300b

289

AF062376

M600a

558

AF062373

M800a

731

AF062374
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3.9: Investigation of the ‘Accordion Effect’:
A number of the larger DNA fragments (> 1000 bp) amplified in RW3A
fingerprinting were selected for further characterisation by sequencing analysis
(as described in Section 2.2.6).
Upon reamplification, it was noted that the PCR reaction appeared to
‘collapse’ yielding many smaller amplicons in in addition the expected target and
this observation was termed the ‘Accordion Effect’. The resultant ‘collapsed’ PCR
products are shown in figure 3.32 (a). This experiment was repeated several
times, each culminating in a collapsing reaction. Fanning (1996, unpublished
work) made similar observations when studying tDNA fingerprinting of
Acinetobacter baumannii.
This phenomenum may be explained by the following hypothesis:
DNA fingerprinting of micro-organisms (whether by RAPD or rep-PCR) is thought
to sample the entire microbial genome and this feature forms the basis for
molecular epidemiological comparison(s) of bacterial strains by these methods.
Generation of additional bands after reamplification would logically suggest the
presence of internal RW3A priming sites in the larger RW3A derived amplicons. If
this is indeed the case, then it is tempting to speculate that RW3A fingerprinting
may not reflect the entire motif array of the template DNA but rather focusing on an
area of the organisms genome which is continually resampled internally (a
schematic representation of this hypothesis is shown in Figure 3.33), due possibly
to efficient priming within a suitable sequence context.
If the collapsing PCR reaction (‘Accordion Effect’) does occur due to internal
priming then it would see reasonable to suggest that the smallest of these
‘collapsed’ PCR products should be present in all amplicons generated during
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Figure 3.32: Agarose gels showing the steps involved in the investigation of the
“Accordion Effect”.

a. 2% agarose gel showing the “collapsed” PCR products resulting from
reamplification by RW3A-PCR of a band (>1000 bp) extracted and purified MRSA
fingerprints.
Lane M, grade III molecular weight size standard; lane 2, 2.5 kb fragment (A) from
RW3A fingerprint of strain 14281; lane 3, 2 kb fragment (B) from RW3A fingerprint
of strain 12175; lane 4, 1.3 kb fragment (C) of RW3A fingerprint of MRSA; lane 5,
1 kb fragment (D) from RW3A fingerprint of MRSA strain 12175.

b. DIG-labelling of 190 bp probe verified by agarose gel electrophoresis.
Lane M, grade V molecular weight size standards; lane 1, unlabelled 190 bp
probe; lane 2, DIG-labelled 190 bp probe.

c. Hybridisation of the 190 bp probe to nytran membrane containing collapsed
PCR products generated during reamplification.
Lane N, negative, lane 1, DIG-probe; lane 2, collapsed PCR products of D (see
above); lane 3, collapsed PCR products of C; lane 4, collapsed PCR products of B;
lane 5, collapsed PCR products of A; lane M, grade II molecular weight markers.
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Figure 3.32:

a.
M

1

2

3

4

C.

N

1

2

3

4

5

M
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Figure 3.33: Schematic view of the proposed “Accordion effect”.
An amplicon of >1000 bp was selected for characterisation by DNA sequencing.
This band was extracted from an RW3A fingerprint, gel purified and reamplified
using RW3A-PCR. Upon reamplification the expected fragment was not produced,
the PCR reaction appears to “collapse” and a number of smaller PCR products are
amplified, this observation was termed the “Accordion Effect”. It was postulated
that these amplicons are derived from internal priming of the amplicon (with the
RW3A primer) during reamplification (see Figure inset).
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Figure 3.33:
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▼
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R
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reamplification (Figure 3.32). In a direct attempt to test this hypothesis a DNA
probe assay was performed.
The ‘collapsed’ PCR products were denatured in the 2% agarose gel and
transferred to a nytran membrane using the TURBOBLOTTER™ system (see
Section 2.2.8.2). The smallest of these ‘collapsed” amplicons (which was
approximately 190 bp in size) was then extracted from a 2% agarose gel. This
product was reamplified incorporating digoxigenin, producing a DIG-labelled
probe (Figure 3.32 b). Lane 1 in figure 3.32 (b) shows the 190 bp fragment
reamplified without inclusion of the DIG-label and lane 2 shows the same fragment
containing the DIG-label. Incorporation of this DIG-label was verified by the
decreased mobility of the amplicon in this 2% agarose gel.
A hybridisation experiment was performed (as described in Section 2.2.8.3)
to determine if this DIG-labelled 190 bp DNA probe would anneal to the
“collapsed’ fragments on the nytran membrane). This strategy would also be used
to determine the extent of homology between the designated DNA probe and a
wide collection of bacteria (both Gram-positive and -negative) (see Section 3.9.1
below). Lane 1 in figure 3.32 (c) represents the assay control, containing the
assay 190 bp PCR fragment.. Lane 2-5 show the ‘collapsed’ PCR products and it
is evident from this this data that the 190 bp probe hybridised to each of these
amplicons.
This data obtained from this experiment would seem to support the
hypothesis outlined above. It appears that these RW3A fingerprints may not
represent the entire bacterial genome but may arise due to the continual internal
priming of a selected genomic region. This evidence should be considered by
researchers and molecular epidemiologists whe analysing the results of
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fingerprinting assays. Data originating from confined regions of the genome in
this way precludes wider genome sampling and limits the informational content of
the fingerprint. A similar theory was postulated at a recent IMBEM (International
meeting on bacteriological epidemiological markers) conference (Power 1997
unpublished observations; Power, 1996).

3.9.1: Investigation of the utility of the 190 bp fragment as an MRSA specific
probe:
As the 190 bp amplicon was present in each of the ‘collapsed’ PCR product, the
possibility of using this fragment as an MRSA specific probe was investigated. To
this end a hybridisation assay was performed to determine the specificity of this
putative MRSA probe. A wide variety of bacterial templates were analysed and
the results are shown in figure 3.34. Coloured dots (i.e. hybridisation) are visible
for 27 of the 28 MRSA strains analysed. The probe also hybridised to the DNA of
the 4 MSSA tested. From figure 3.34 it can be seen that hybridisation of this probe
to the other Gram-negative and Gram-positive bacteria did not occur. The single
MRSA strain to which the probe did not hybridise MRSA 665, was included in the
assay as an internal control of assay performance. As previously discussed (see
Section 3.3.2) this strain was re-defined as a CNS strain and therefore should not
have been included with the outbreak strains. This result indicates that this
190 bp probe is an S. aureus specific fragment present in both methicillin-resistant
and sensitive strains.
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Figure 3.34: Results of a DNA hybridisation experiment to evaluate the efficacy
of the 190 bp DIG probe as an MRSA specific probe. Initially a variety of bacterial
cultures were vacuumed onto the membrane. This membrane was then
hybridised with the DIG-probe. The hybridised DIG probe was then detected
using a typical “dot blot” procedure.

Row 1

Row 2

Row 3

A

MRSA 36197

MRSA 665

MRSA 8516

B

MRSA 10712

MRSA 14001

MRSA 10322

C

MRSA 18780

MRSA 36565

MRSA 13606

D

MRSA 10231

MRSA 10673

MRSA 14281

E

MRSA 14688

MRSA 8533

MRSA 238

F

MRSA 11678

MRSA 14364

MRSA 14627

G

MRSA 647

MRSA 7687

MRSA 12153

H

MRSA 11130

MRSA 13579

MRSA 20552

I

MRSA 13314

MRSA 11602

MRSA 12129

J

MRSA 12095
Row 4

Row 5

Row 6

A

Listeria spp. 374

CNS 1432

MSSA 4241

B

Listeria spp. 480

CNS 1479

MSSA 4280

C

Listeria spp. 341

CNS 1346

MSSA 42

D

Listeria spp. 550

CNS 9427

MSSA 4848

E

Acinetobacter spp. 37613

CNS 23714

ETEC 6

F

Acinetobacter spp. 162

Proteus spp. 19244

ETEC 27

G

Acinetobacter spp. 21373

Serratia spp. 19050

ETEC 3

H

Acinetobacter spp. 35187

Serratia spp. 19010

ETEC 56

I

Acinetobacter spp. 36010

ETEC 92

ETEC 8

J

ETEC 70
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Figure 3.34:
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Section 4
Conclusions and Future Directions

4.1 Conclusions:
(i) Triplex-PCR:
A one-tube triplex-PCR assay for MRSA detection was developed, wherein
three genes, the methicillin resistance gene (mecA). femA. and the extracellular
thermonuclease (nuc), were simultaneously amplified. The products of this PCR
assay were then analysed by conventional agarose gel electrophoresis. The
sensitivity and specificty of this strategy were confirmed by analysis of a wider
variety of microbial species. Using this system, direct detection of MRSA from
patients swabs was demonstrated.
Incorporation of DIG-dUTP in the PCR amplification facilitated
simultaneous amplification and DIG-labelling of the three gene targets. This
labelling enabled the use of solid phase detection formats i.e. ‘dot blots’ and
colour amplified PCR detection system (CAPS) for identification of MRSA. Also
fluorophore-labelling of the primers used for triplex PCR facilitated automated
analysis of results using GeneScan technology in the ABI Prism™ 310 genetic
analyser (see GeneScan analysis below).

(ii) RW3A fingerprinting:
Epidemiological evaluation of 2 MRSA outbreaks from CUH was performed
using a rep-PCR strategy with the RW3A primer. Discriminatory, strain-specific
profiles were obtained for each strain analysed. The results show that RW3A is
a suitable primer for MRSA strain differentaition.
Characterisation of monomorphic fragments from RW3A fingerprints
revealed that the DNA sequences of a coincidentally amplified band within the
fingerprints of 2 strains may not be identical. Also the difficulties encountered
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when attempting to characterise larger RW3A amplified fragments i.e.
“Accordion Effect” may indicate that PCR fingerprinting may not sample the
entire genome but reflect a resampling of a portion of the organisms DNA.
However these observations do not diminish the important role of PCR
fingerprinting, and in particular rep-PCR, in unravelling the complex molecular
epidemiology of this pathogen.

(iii) GeneScan analysis:
Fluorophore-labelling of the primers used for triplex-PCR and RW3A
fingerprinting facilitated GeneScan analysis using the ABI Prism™ 310 genetic
analyser of the PCR generated [F]-labelled amplicons. Accurate sizing of the
fluorescent amplicons was achieved by comparison with internal lane
standards. The sensitivity and specificity of these fluorescent detection systems
were demonstrated.
The use of GeneScan technology enabled the development of a multiplex-PCR
strategy termed COGEDET (combined gene detection and epidemiological
typing) for MRSA. Using this one-tube PCR system, the identity of an MRSA
strain was confirmed by the presence of 2 TET-labelled peaks (corresponding to
the mecA and femA gene targets) and strain differentiation was achieved by
RW3A fingerprinting.
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4.2 Future direction:
(i) Identification of a single, specific MRSA DNA target would facilitate the
development of a single dot/well solid phase detection system. This would
provide a more ‘user-friendly’ approach which could be integrated into a routine
microbiological laboratory.

(ii) The use of automated systems such as the ABI Prism™ 310 genetic analyser
for strain typing together with advances in computer software should provide the
means for the establishment of an electronic fingerprint database. It is hoped
that these databases will enable archiving of fingerprint data for retrospective
analysis and comparison of new isolates with those previously entered in the
database. Availability of this information through the World Wide Web (WWW)
would permit ‘on-line’ remote access to this valuable resource. This feature
would in turn aid the formulation of effective infection control policies.
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Appendix 1
DNA molecular weight size standards

Boehringer Mainnheim markers:

MW marker grade V

MW marker grade III
Fragment

No. of base pairs

Fragment

No. of base pairs

1

21226

1

587

2

5148, 4973

2

540

3

4268

3

504

4

3530

4

458, 434

5

2027

5

267

6

1904

6

234

7

1584

7

213

8

1375

8

192, 184

9

947

9

124, 123

10

831

10

104

11

564

11

89, 80

12

64, 57, 51, 18, 11

Promega marker:

(})X174/HaeHI marker
Fragment

No. of base pairs

1

1353

2

1078

3

872

4

603

5

310

6

281,271

7

234

8

194

9

118

Appendix 2
GeneScan molecular weight size standards

One of the following GeneScan size standards (either ROX or TAMRA
labelled) was included In each sample for analysis using the ABI Prism
genetic analyser.
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Appendix 3
Map of pCR 2.1® vector

A map of the pCR 2.1® vector and the sequence of the multiple cloning site
are shown below. The position at which the PCR product is ligated into the
vector is indicated. An EcoRI site flanks the Inserted PCR product on either
side.

/acZa ATG
Sad BarTH\
Hind I
Kpn I
Spe I
Ml3 Reverse Primer
I
I
I
I
I
CAG G^A ACA OCT Alfi AC C ATG ATT ACG CCA AQC TTG GTA CCG AGC TCG G^T CCA CTA
GTC CTT TGT CGA TAC TG G TAC TAA TGC GGT TCG AAC CAT GGC TCG AQC CTA GGT G^T

GTA ACG
CAT TGC

BsK I EcoR I
EcoR I
I
I
_____________________
I
GCCGOC AGT GTG CT6 GAA TTC GGC
GCC GVk TTC TGC
COGCGG TCA CAC GAC CTT AAG CCG ACBAflliiiilMl T T CGG CTT AAG ACG

EcoRV
I
AGA TAT
TCT ATA

Ava I
PaeR7 I
fis«l
Not\
Xriol
Nsi\Xba\
Apa\
.
III
II
I
CCATCA CAC TOG CGG CCG CTC GAG CAT GCA TCT AGA GOG CCC AAT TCG CCC TAT
GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AQC GGG ATA

T7 Promoter
CAAT TCA CTG GCC GTC GTT TTA C AA C 3T CGT GAC TGG GAA AAC
GTTA AGT GAC COG CAG CAA AAT G TT G CA GCA CTG ACC CTT TTG

Appendix 4
Electropherogram of reverse sequence read
of fragment M600a

Appendix 5
Current GenBank record for fragment M800a
(Accession number AF062374)

http;//www. ncbi.nlm.nih.gov/irx/cgi-bin/
birx_doc?newgenbank+102029

LOCUS
DEFINITION
ACCESSION
NID
KEYWORDS
SOURCE
ORGANISM

Document Reader

AF062374
731 bp
DNA
BCT
21-MAY-1998
Staphylococcus aureus strain W6652, unidentified sequence 2.
AF062374
g3142433

Staphylococcus aureus.
Staphylococcus aureus
Eubacteria; Firmicutes; Clostridium group firmicutes; Bacillaceae,
Staphylococcus.
REFERENCE
1
(bases 1 to 731)
AUTHORS
Cotter,L. and Fanning,S.
TITLE
Direct Submission
JOURNAL
Submitted (30-APR-1998) Biological Sciences, CIT, Bishopstown,
Cork, Ireland
FEATURES
Location/Qualifiers
source
1. .731
/organism= “Staphylococcus aureus“
/strain=“W6652“
/db_xref="taxon: 1280“
/note="fragment generated through RAPD fingerprinting"
BASE COUNT
271 a
126 c
126 g
208 t
ORIGIN
1 gtcgaaacca tcaactggta aattaacagt tgctgcaagc aatggtgtcg cacaaatcaa
61 accaacaaat agtggtttat ttactactgt atacgacaaa actggtaaag caactaatga
121 agttcaaaaa acatttgctg tatctaaaac agctacatta ggtaatctaa aattctatct
181 tgttcaggtt ace^*"
' aataaattt ggttgggtta aagaaggcga tgtggtttac
241 aacacagcta aatcacctgc agatgtaaat caatcatatt caatcaatcc tggtacgaaa
301 ctttgtacag taccttgggg tacatctaaa caagttgcag gtagtgtgtc tggctctgga
361 accaaacatt taaggctaca aagcaacaac aaattgataa atcgatttat ttatatggct
421 ctgtgaatgg taaatctggt tgggtaagta aagcatattt agttgatact gctaaaccca
481 cgcctacgcc aacacctaag ccatcaacac ctacaactat taataaatta acagttttat
541 cattaaacag tgttgctcag attaatgcta aaaacaatgg cttattcact acagtttatg
601 agaaaactgg taagccaacg aaagaagttc aaaaaacatt tgctgtaaca aaagaagcaa
661 gtttaggtgg aaacaaattc tacttagtta aagattacaa tagtccaact ttaattggtt
721 gggttaaaca a
//
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“Investigation of a methicillin-resistant Staphylococcus aureus
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J. Hasp. Infect. (1997) 36, 37-47
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